

Author Index for 1989

- Abbott, K. 28:279
Adinoff, B. 30:137
Adler, L. 27:1
Agam, G. 27:217
Ainsworth, B. 28:323
Aizenberg, D. 27:65
Akiskal, H.S. 30:21
Al-Sadir, J. 28:161
Albala, A.A. 27:161
Aldenhoff, J.B. 29:221
Alexson, J. 27:81
Alphs, L.D. 30:119
Altamura, C. 30:69
Altshuler, L. 27:193, 28:145
Amrung, S. 28:153
Ancrì, D. 29:409
Anderer, P. 29:387
Andersen, K.H. 30:77
Anderson, I.M. 29:161
Angeleri, F. 29:403
Angrist, B. 27:1
Angulo, L.N. 30:155
Araújo, M. 29:235
Arbisi, P.A. 28:323
Ardisson, J.-L. 28:263
Arora, R.C. 30:125
Aulich, A. 29:361, 29:363
- Baerwald, R. 29:341
Barchas, J.D. 30:111
Barocka, A. 29:187
Baron J.-C. 29:357
Barratt, E.S. 27:5
Barsi, J. 29:235
Bartko, J.J. 28:227
Bartzokis, G. 27:193, 28:117, 28:145
Baumann, N. 30:107
Bechter, K. 29:281
Beck, G. 29:187
Becker, H. 29:309
Becker, T. 29:285
Beckmann, H. 29:391, 29:463
Beersma, D.G.M. 28:47
Belkin, B.M. 29:113
Belugou, J.-L. 28:263
Benkert, O. 29:221, 30:83
Berga, S.L. 27:351
Berger, Y. 29:427
- Berglund, M. 27:49
Berlit, P. 29:459
Berman, S.R. 28:193
Besson, J.A.O. 29:291, 29:327, 29:447
Best, P.V. 29:447
Biggs, M.M. 27:127
Black, D.W. 30:243
Blue, L.D. 27:81
Bogerts, B. 29:255
Botsch, H. 29:335
Bouhuys, A.L. 28:47
Bourdel, M.-C. 29:409
Bovier, P. 30:103
Bracha, H.S. 30:275
Braden, W. 28:63
Bratenstein, P. 29:231
Brawanski, A. 29:307
Breier, A. 29:177
Brodie, J.D. 29:453
Broggini, G. 29:55
Brown, C.S. 27:5
Brown, G.M. 28:119
Brown, W.A. 28:315
Brunner, R.L. 30:223
Bryant, S.G. 27:5
Buchanan, R.W. 27:335, 30:119
Buehler, B. 29:459
Buller, R. 29:271
Burgess, J.W. 30:31
Burrows, G.D. 30:63
Buysse, D.J. 28:193
Byerley, W.F. 30:191
Bylund, D.B. 27:81
- Caillard, V. 29:357
Caligiuri, M.P. 30:275
Cameron, O.G. 28:25
Campanini, T. 28:89
Campbell, J.L. 27:5
Campbell, S.S. 27:23
Çamurcu, S. 29:151
Candito, M. 28:263
Capone, C. 29:425
Carpenter, W.T., Jr. 30:119
Carroll, B.J. 27:161
Carson, S.W. 30:217
Carstens, M.E. 27:101
Casacchia, M. 29:261

- Cassano, G.B. 30:21
 Cazzullo, C.L. 29:257
 Ceccoli, S. 29:261
 Chang, W.-H. 30:45
 Charles, G. 29:199
 Charney, D.S. 27:173
 Chen, T.-Y. 30:45
 Chicz-DeMet, A. 30:231
 Chiodera, P. 28:89
 Chris Heh, C.W. 30:313
 Christie, W. 29:375
 Classen, W. 29:267, 29:421
 Cleghorn, J.M. 28:119
 Coffman, J.A. 27:233
 Cogger, R.W. 28:117
 Coggiano, M.A. 30:259
 Cohen, B. 28:181
 Cohen, L.S. 28:345
 Coiro, V. 28:89
 Colter, N. 29:247
 Comaty, J. 28:97
 Conte, H.R. 27:71, 28:215
 Cook, B. 30:53
 Cooper, P.W. 29:137
 Cooper, T.B. 28:1
 Corchoran, C. 27:81
 Cordes, M. 29:341
 Cordovana, V. 29:265
 Cornblatt, B.A. 29:65
 Cornes, C. 27:225
 Cottraux, J.A. 27:31
 Courtney, P. 27:313
 Cowdry, R.W. 27:111
 Cowen, P.J. 29:161
 Cowley, D.S. 27:357
 Coryell, W.H. 30:243
 Costa, J. 30:313
 Crawford, J.R. 29:447
 Crook, W.S. 29:161
 Crow, T.J. 29:247
 Csernansky, J.G. 28:135, 30:111
 Cummings, J.L. 27:193, 28:145
 Cummings, K.L. 27:351
 Cummings, M.A. 27:351
 Curtis, G.C. 28:25
 Czece, É. 29:235

 D'Albenzio, L. 29:261
 Dager, S.R. 27:357
 Dains, K. 29:55

 Daniel, D.G. 27:55
 Daniels, S. 30:223
 Darcourt, G. 28:263
 Darko, D.F. 28:355
 Davidson, J. 29:327
 Davies, S.L. 29:87
 Davis, C.M. 28:153, 29:123, 30:45
 Davis, J.M. 28:73, 28:97
 Davous, P. 28:289
 Deering, W.M. 29:407
 Deisenhammer, E. 29:337, 29:443
 DeJong, J. 30:137
 de la Fuente, J.R. 30:155
 de Leon, M.J. 29:359
 de Maertelaere, V. 27:277
 Demer, J.L. 29:123
 DeMet, E. 30:231
 De Mol, J. 27:277
 Deng, H.-C. 30:45
 Denoroy, L. 27:31
 Depue, R.A. 28:323
 DeReuter, J. 29:55
 Derouesne, C. 29:409
 de Villiers, A.S. 27:101
 Devlin, M.J. 28:11
 Dieci, M. 29:257
 Diehl, B.J.M. 29:317
 Diekmann, V. 29:395
 Dierks, T. 29:399, 29:413, 29:417, 29:419,
 29:433, 29:435, 29:439, 29:449
 Dietz, H. 29:287, 29:309
 Dillon, D.J. 29:207
 Di Michele, V. 29:261
 Donner, A. 28:41
 Doran, A. 29:177
 Dressler, D. 29:457
 Drochner, R. 29:323
 Dubois, G. 30:107
 Duffy, F.H. 29:379
 Dumlao, M.S. 29:169
 Duncan, E. 27:1
 Duncan, W.C. 30:285
 Dunner, D.L. 27:357

 Easton, C. 28:161
 Ebmeier, K.P. 29:291, 29:327, 29:447
 Edell, W.S. 30:265
 Ehlers, C.L. 27:13, 30:165
 Ehrenheim, Ch. 29:283, 29:287
 Eilles, C. 29:449

- Eillies, C. 29:347
 Eiser, A.S. 27:359
 Elger, C.E. 29:369
 Emrich, D. 29:457
 Endicott, J. 27:183
 Ereshefsky, L. 30:45
 Erlenmeyer-Kimling, L. 29:65
 Esser, A.H. 28:279
 Etzel, B.A. 27:127
 Evans, N.T.S. 29:327

 Faienza, C. 29:425
 Faraone, S.V. 28:243, 28:315
 Farrell, M. 30:223
 Fasullo, S. 29:265
 Faull, K.F. 28:97, 30:111
 Faustman, W.O. 28:135
 Fava, M. 28:345
 Feather, J.N. 29:11
 Feenstra, A. 30:259
 Feer, H. 27:287
 Feinendegen, L.E. 29:361, 29:363
 Feitel, B. 28:279
 Feldmann, M. 29:457
 Felthous, A.R. 27:5
 Ferraro, T. 30:137
 Ferris, S.H. 29:359
 Fidone, G.S. 28:153
 Filipovic, S. 29:409
 Firnau, G. 28:119
 Fischer, C. 27:241
 Flügel, D. 29:231
 Flynn, J.M. 29:407
 Folts, D.J. 29:11
 Frackowiak, R.S.J. 29:353
 Frances, A. 28:31
 Frank, E. 27:225
 Frankel, F. 27:81
 Franssen, E. 29:359
 Freeman, W.J. 29:239
 Frey, M. 29:377
 Friberg, L. 29:319
 Friedhoff, A. 28:1
 Fristad, M.A. 29:215
 Frith, C.D. 29:247
 Fritze, J. 29:267, 29:419, 29:421
 Frlich, L. 29:347, 29:399, 29:449
 Frommberger, U. 29:271
 Fuenfgeld, E.W. 29:411
 Fuenfgeld, M. 29:335

 Futtersak, W. 29:55
 Fyer, A.J. 28:181, 28:171, 29:207
 Fyer, M. 27:183

 Gaab, M.R. 29:309
 Gaillard, J.-M. 30:103
 Galanter, M. 30:217
 Galaske, R.G. 29:343
 Gallyas, F. 29:463
 Galzin, A.-M. 28:289
 Garcia, M. 27:137
 Gardner, D.L. 27:111
 Garnett, E.W. 28:119
 Gartside, S.E. 29:161
 Garvey, M. 30:53
 Gaudel, G. 27:149
 Gay, N. 27:31
 Gay, T.L. 30:1
 Gebetsberger, B. 29:337
 Gemmell, H.G. 29:327, 29:447
 Gentsch, C. 27:287
 George, A.E. 29:359
 Georgi, P. 29:331
 Georgotas, A. 28:1
 Gerlach, L. 29:341
 Gershon, S. 29:169
 Gevedon, R.M. 27:5
 Giannini, A.J. 29:11
 Gibb, C. 30:95
 Giles, D.E. 27:127
 Gilleard, C.J. 27:313
 Giller, E.L., Jr. 30:265
 Gilles, C. 27:277
 Gillin, J.C. 27:23, 27:253, 27:351
 Giobbio, M. 29:257
 Giordano, P.L. 29:265
 Glass, R.M. 28:161
 Glassman, A.H. 28:11
 Glover, V. 30:95
 Gnudi, A. 28:89
 Goetz, R.G. 29:207
 Gold, M.S. 29:113
 Gold, P. 30:137
 Goldstein, J.M. 28:243
 Golshan, S. 27:351
 Gorman, J.M. 27:183, 28:171, 28:181, 29:207
 Gottesman, I.I. 29:37
 Govi, A. 28:89
 Graf von Keyserlingk, D. 29:461
 Greden, J.F. 27:359

- Griffin, M.L. 28:335
 Groezinger, B. 29:395
 Grot, L.J. 29:29
 Gruenberger, J. 29:387
 Gubarev, N. 29:303
 Gueguen, B. 29:409
 Guenther, W. 29:453
 Guercetti, G. 30:69
 Guidi, M. 29:403
 Gunreben, G. 29:307
 Gupta, K. 29:29
 Gur, R.C. 27:325
 Gur, R.E. 27:325
 Gurevich, D. 29:169

 Haas, S. 29:463
 Haier, R.J. 28:63
 Halbreich, U. 30:217
 Hale, A.S. 29:87
 Halmi, K.A. 29:105
 Halsband, U. 29:363
 Hanin, I. 29:45
 Harrington, A. 29:335
 Harris, W.R. 27:241
 Harrison, W.M. 27:183
 Haskett, R.F. 27:161
 Haubitz, I. 29:293
 Haviland, M.G. 27:351
 Hedde, J.-P. 29:323
 Heimann, H. 29:277
 Heinrichs, D.W. 27:199, 27:335
 Heinsen, H. 29:391, 29:463
 Heinsen, Y.L. 29:463
 Heintz, P. 29:283, 29:287
 Heiss, W.-D. 29:351
 Hemdal, P. 27:1
 Heninger, G.R. 27:173
 Hennerici, M. 29:363
 Henze, Th. 29:457
 Herholz, K. 29:351
 Hermesh, H. 27:65
 Hermle, L. 29:335
 Hernandez, J.M. 28:153
 Herrera, J. 28:307
 Herzog, H. 29:361, 29:363
 Herzog, S. 29:281
 Heun, R. 29:295
 Heuser, I. 29:221, 30:83
 Heyer, R. 29:343
 Hill, J.L. 29:1

 Hill, M.A. 27:193, 28:145
 Himle, J.A. 28:25
 Hinrichs, H. 29:431
 Hirsch, M. 28:345
 Hirschowitz, J. 29:55
 Hitzemann, B. 29:55
 Hitzemann, R. 29:55
 Hoell, K. 29:337, 29:443
 Hoke, M. 29:369
 Holl, K. 29:309
 Hollander, E. 28:171, 29:181, 29:207
 Horrobin, D.F. 27:313
 Horton, R.W. 29:87
 Hundeshagen, H. 29:283, 29:287, 29:367
 Huret, J.D. 29:357

 Ihl, R. 29:299, 29:347, 29:413, 29:417, 29:421,
 29:449
 Isenhardt, R. 30:313
 Imber, S. 27:225

 Jacobsen, F.M. 29:1
 Jaffe, J.H. 27:117
 Janicak, P.G. 28:97, 28:73
 Jann, M.W. 28:153, 30:45
 Janowsky, D.S. 27:23, 27:253
 Janz, D. 29:375
 Jauch, D. 27:199
 Javaid, J.I. 28:73, 28:97
 Javors, M.A. 27:241
 Jeste, D.V. 29:45
 Jin, Y. 30:313
 Joffe, R.T. 30:213
 Johnstone, E.C. 29:247
 Jones, S.B. 27:81
 Joseph, K.C. 28:255
 Joseph, R. 30:95
 Judd, F.K. 30:63
 Jutai, J.W. 27:207

 Kafka, M.S. 30:181
 Kaiya, H. 30:11
 Kaplan, R. 28:119
 Kappos, L. 29:293, 29:295
 Karege, F. 30:103
 Karp, L. 27:65
 Kaschka, W.P. 29:231
 Kasper, S. 28:227
 Kathol, R.G. 30:77
 Katona, C.L.E. 29:87

- Mathew, R.J. 27:55, 28:241
 Matsushima, E. 28:307
 Matuzas, W. 28:161
 Maurer, K. 29:239, 29:299, 29:347, 29:391,
 29:413, 29:417, 29:419, 29:421, 29:433,
 29:435, 29:439, 29:449, 29:461
 May, P.R.A. 27:193, 28:145
 Mays, W. 30:223
 Mazoyer, B.M. 29:357
 McAdam, D. 27:297
 McCue, R.E. 28:1
 McIntyre, I.M. 30:63
 McKenney, P.D. 30:119
 McLaughlin, J.A. 27:233
 McPhee, K. 28:25
 Meinig, G. 29:317
 Meixensberger, J. 29:307
 Mellow, A.M. 29:1
 Meltzer, H.L. 27:267
 Meltzer, H.Y. 30:125
 Mendelson, W.B. 30:285
 Mendlewicz, J. 27:277
 Meyer, G.J. 29:367
 Meyer, H.K. 29:317
 Miller, N.S. 29:113
 Mirin, S.M. 28:335
 Molchan, S.E. 29:1
 Monk, T.H. 27:89, 28:193
 Morrison, S.L. 29:137
 Morycz, R.K. 27:225
 Moser, E. 29:453
 Moses, J.A., Jr. 28:135
 Muhrin, Z. 29:303
 Mueller, E.A. 29:1
 Mueller, T. 29:419
 Mukherjee, S. 29:17
 Munitz, H. 27:65
 Murphy, D.L. 29:1

 Nagachandran, N. 28:1
 Nahmias, C. 28:119
 Nasrallah, H.A. 27:233
 Nathan, R.S. 30:165
 Nee, J. 27:183
 Negele-Anetsberger, J. 29:231
 Nelson, J. 30:231
 Nemati, M.N. 29:309
 Neufeld, M.Y. 29:427
 Newman, M.M. 29:105
 Newsholme, E.A. 29:161

 Newton, R. 29:327
 Niedermeier, T. 29:331
 Niemann, K. 29:461
 Noder, M. 29:187
 Norman, T.R. 30:63
 Noyes, R., Jr. 30:53, 30:243
 Nunes, E.V. 28:105
 Nutt, D.J. 28:351
 Oepen, G. 29:335
 Olson, S.C. 27:233
 Oltmanns, T.F. 27:199
 Opitz, H. 29:277
 Orpen, G. 30:305
 Owens, D.G.C. 29:247
 Oxenkrug, G.F. 29:169
 Öztaş, B. 29:151

 Pandey, G.N. 28:73
 Pantev, C. 29:369
 Papp, L.A. 28:171, 28:181, 29:207
 Parker, D.M. 29:447
 Parry, B.L. 30:285
 Parry-Billings, M. 29:161
 Pawlik, G. 29:351
 Paykel, E.S. 29:87
 Percudani, M. 30:69
 Perel, J.M. 27:225, 30:165
 Perisic, I. 29:399, 29:449
 Peron-Magnan, P. 29:357
 Perry, P.J. 30:77
 Peters, J.L. 27:297
 Petersen, D. 29:277, 29:285
 Petryshen, P. 28:41
 Petsch, R. 29:453
 Philipp, M. 29:221, 30:83
 Picard, S. 27:71
 Pickar, D. 27:111, 29:177
 Pirke, K.-M. 27:39
 Piscani, K. 29:55
 Placidi, G.F. 30:21
 Plancon, D. 29:409
 Plutchik, R. 27:71, 28:215
 Pogacnik, T. 29:313
 Poirier, M.-F. 28:289
 Pollack, M.H. 28:345
 Pollock, B.G. 30:165
 Porter, F.I. 29:123
 Potkin, S.G. 28:307, 30:313
 Prasad, A. 30:95
 Prati, G. 29:425

- Katz, J.L. 28:11
 Kaye, H. 29:137
 Kelley, J.S. 29:87
 Kelly, M.W. 30:243
 Kent, T.A. 27:5
 Kerry, S.M. 29:87
 Kharazmi, M. 28:307
 King, R.J. 30:111
 Kirby, J. 27:81
 Kirkpatrick, B. 27:199, 30:119
 Klahr, A.L. 29:113
 Klein, D.F. 28:105, 28:171, 28:181, 29:207
 Klose, U. 29:289
 Kluger, A. 29:359
 Knezevic, S. 29:303
 Koerner, R. 29:283
 Kojima, T. 28:307
 Kopp, N. 27:31
 Kopp, U. 29:45
 Korczyn, A.D. 29:427
 Korn, M. 27:71
 Kornhuber, H.H. 29:395
 Koschorke, S. 29:273
 Kovasznay, B. 29:55
 Krajewski, K. 29:123
 Krebs, B. 28:263
 Kretschmar, K. 29:221
 Krieg, J.-C. 27:39
 Kripke, D.F. 27:23, 27:253, 27:351
 Kruesi, M.J.P. 28:115
 Kruse, J. 29:29
 Kumor, K.M. 27:117
 Künkel, K. 29:431
 Kunz, U. 29:283, 29:287
 Kupfer, D.J. 27:127, 27:13, 27:225, 28:193, 30:165
 Kutcher, S.P. 29:137, 30:213
 Kuwert, T. 29:361, 29:363
- LaGrone, H. 29:55
 Lajos, J. 29:235
 Lamour, Y. 28:289
 Lanczik, M. 29:347, 29:421
 Lange, H.W. 29:361
 Langen, K.-J. 29:361
 Langer, S.Z. 28:289
 Lauer, C. 27:39
 Lawlor, B.A. 29:1
 Lawson, W.B. 29:45
 Leblhuber, F. 29:337, 29:443
 Lefebvre, C. 29:375
 Lehmann, D. 29:385
 Lehnertz, K. 29:369
 Leibing, U. 29:395
- Lejoyeux, M. 30:107
 Lempérière, T. 30:107
 Lenzenweger, M.F. 29:65
 Leon, A. 28:323
 Lichtsteiner, M. 27:287
 Liebowitz, M.R. 28:171, 28:181, 29:207
 Linkie, D.M. 28:11
 Linnoila, M. 27:297, 30:137
 Lista, A.L. 30:253
 Little, K.Y. 30:1
 Littlewood, J. 30:95
 Livne, A. 27:217
 Lohr, J.B. 30:275
 Lohr, N.E. 27:161
 Lombard, C.J. 27:101
 Loo, H. 29:357
 Lucas, P.B. 27:111
 Luetkenhoener, B. 29:369
 Lung, F.-W. 30:45
- Maas, J.W. 27:241
 MacDonald, C. 30:213
 Macedo, C.A. 27:241
 Machowski, R. 29:199
 MacLaughlin, R.A. 28:345
 Mahajan, S. 29:55
 Maier, W. 29:221, 30:83
 Maier-Hauff, K. 29:341
 Mallard, J.R. 29:327
 Malloy, P. 28:63
 Maloney, M.J. 30:223
 Mamelak, M. 29:137
 Manku, M.S. 27:313
 Mann, K. 29:277
 Mann, U. 29:293
 Marazziti, D. 30:21
 Marchesi, C. 28:89
 Marienhagen, J. 29:231
 Markow, T.A. 29:37
 Marks, G. 27:137
 Markut, H. 29:443
 Marshall, L.E. 28:295
 Martin, P. 27:149
 Martinez, J.M. 28:171
 Martinot, J.L. 29:357
 Massol, J. 27:149
- Preskorn, S.H. 29:215
 Pringuey, D. 28:263
 Prohovnik, I. 27:49, 29:301
 Puehringer, W. 29:337
- Quitkin, F.M. 28:105
- Rasmussen, S. 28:63

- Rea, M.M. 28:31
 Reed, M.K. 29:429
 Rees, J. 29:395
 Reich, J. 30:145
 Reimherr, F.W. 30:191
 Reischies, F.M. 29:323
 Reisecker, F. 29:337, 29:443
 Resnick, S.M. 27:325
 Reynolds, C.F. III 27:13, 27:225, 28:193
 Rice, D.M. 30:313
 Richards, A.L. 30:45
 Riederer, P. 29:187, 29:391
 Rihmer, Z. 29:235
 Ringelstein, E.B. 29:273
 Risberg, J. 27:49, 29:297, 29:303
 Risch, S.C. 27:23, 27:253
 Roeda, D. 29:327
 Roffwarg, H.P. 27:127
 Rogeness, G.A. 27:241
 Rohrbach, E. 29:295
 Roose, S.P. 28:11
 Rose, F.C. 30:95
 Rose, R.M. 27:5
 Rosen, J. 27:297
 Rosenbaum, J.F. 28:345
 Ross, D. 28:171
 Rossi, A. 29:261
 Roth, S.D. 29:17
 Rotrosen, J. 27:1
 Rott, R. 29:281
 Roudier, M. 28:289
 Roy, A. 29:177, 30:137, 30:181
 Rubino, M.A. 29:265
 Rubinow, D. 30:137
 Rupprecht, C. 29:187
 Rupprecht, M. 29:187
 Rupprecht, R. 29:187, 29:417, 29:435
 Rush, A.J. 27:127
 Russell, V.A. 27:101
 Ryckaert, P. 27:277
 Rzesacz, E. 29:309
 Sacchetti, E. 29:257
 Sack, D.A. 30:285
 Sacks, W. 28:279
 Saklad, S.R. 30:45
 Saletu, B. 29:387
 Salin-Pascual, R.J. 30:155
 Salvati, E. 28:263
 Sandberg, D. 27:183
 Sandler, M. 30:95
 Sandman, C.A. 30:313
 Sandyk, R. 29:17
 Sangdahl, C. 30:231
 Sani, E. 29:425
 Sauer, H. 29:331
 Scarpino, O. 29:403
 Scharff, G. 29:463
 Scherb, W. 29:395
 Schiazza, G. 29:261
 Schittecatte, M. 29:199
 Schlecht, A. 29:231
 Schlegel, S. 29:221, 29:271, 30:83
 Schnabel, M. 29:377
 Schneider, R. 29:273
 Schnur, D.B. 29:17
 Schober, O. 29:343, 29:367
 Schroeder, J. 29:331
 Schrot, G. 29:277, 29:289
 Schüler, P. 29:377
 Schüttler, R. 29:281
 Schwarzkopf, S.B. 27:233
 Searson, J.A. 27:101
 Seggie, J. 30:305
 Seidel, J.W. 29:367
 Serafetinides, E.A. 28:117
 Sharma, R. 28:97
 Sharp, P.F. 29:327, 29:447
 Shekim, W.O. 27:81
 Sherer, M.A. 27:117
 Sherman, A.D. 30:77
 Shimazono, Y. 28:307
 Shipley, J.E. 27:359
 Shrout, P.E. 30:201
 Siegel, B. 29:169
 Simon, G. 29:431
 Sitaram, N. 28:255
 Skodol, A.E. 30:201
 Slotnick, V. 27:1
 Smith, F.W. 29:291, 29:327, 29:447
 Snow, W.G. 29:137
 Sofic, E. 29:187
 Solomon, C.M. 28:31
 Soubrié, P. 27:149
 Souetrê, E. 28:263
 Southwick, S.M. 30:265
 Spilich, G. 29:303
 Spooont, M.R. 28:323
 Sramek, J. 30:313
 Staedt, D. 29:293, 29:295
 Stein, M.K. 33:231
 Steinberg, R. 29:453
 Steiner, M. 30:305
 Steinhausel, H. 29:443
 Steinmetz, H. 29:363
 Stolke, D. 29:287
 Stoppe, G. 29:367

- Stratta, P. 29:261
 Strauss, M.E. 27:199
 Streck, P. 29:453
 Sullivan, B.S. 29:11
 Summerfelt, A. 27:199
 Sunderland, T. 29:1
 Sweeney, J.A. 28:31
 Syrota, A. 29:357
 Szalai, J.P. 29:137
 Szechtman, B. 28:119
 Szechtman, H. 28:119
 Szelies, B. 29:351
- Taljaard, J.J.F. 27:101
 Tampieri, E. 28:89
 Tandon, R. 27:359
 Targum, S.D. 28:295
 Tartaro, A. 29:261
 Teitlebaum, L. 29:55
 Tesar, G.E. 28:345
 Theodorou, A.E. 29:87
 Thornton, J. 27:225
 Tissot, R. 30:103
 Tollefson, G. 30:53
 Tommasi, M. 27:31
 Tran, C. 30:231
 Trenkler, E. 29:337
 Trenkler, J. 29:443
 Tsuang, M.T. 28:243
 Turpin, J.-C. 30:107
- Uematsu, M. 30:11
 Uhlenhuth, E.H. 28:161
 Ullrich, O.W. 29:307
 Ulrich, I. 29:123
 Ulrich, P. 29:317
 Uy, J. 27:183
- Vaddadi, K.S. 27:313
 Valvassori, G. 29:257
 van den Hoofdakker, R.H. 28:47
 Vande Wiele, R. 28:11
 van Kammen, D.P. 27:297
 van Kammen, W.B. 27:297
 van Praag, H.M. 27:71, 28:215
 Van Toller, S. 29:429
 van Zyl, A.M. 27:101
 Varga, M. 29:235
 Vieth, J. 29:377
- Villani, D. 29:425
 Vita, A. 29:257
 Volkow, N.D. 29:123
 Vore, M. 30:1
 Voth, E. 29:457
 Vucinic, G. 29:303
- Walsh, B.T. 28:11
 Walsh, V. 28:31
 Waltrip, R.W. II 27:199
 Wannenmacher, W. 29:303
 Ward, M.F. 30:191
 Wasel, J. 29:461
 Wehr, T.A. 30:285
 Weiss, R.D. 28:335
 Weller, E.B. 29:215
 Weller, R.A. 29:215
 Wense, A.V.D. 29:293
 Westphal, K.P. 29:395
 Wetzel, E. 29:459
 White, P.A. 28:135
 Wiedemann, K. 30:83
 Wienhard, K. 29:351
 Wiethoelter, H. 29:285
 Wildhagen, K. 29:367
 Wilhelm, K.R. 29:331
 Williamson, P.C. 29:137
 Willinsky, R.A. 29:137
 Wilmotte, J. 29:199
 Wilson, W.H. 27:55, 28:241
 Wirshing, W. 27:193, 28:145
 Wolf, A.P. 29:359
 Wolkowitz, O.M. 29:177
 Woods, S.W. 27:173
 Wright, L. 28:11
 Wright, N. 30:305
 Wyatt, R.J. 29:45, 30:259
- Yao, J.K. 27:297
 Yaylayan, S.A. 29:215
 Yeh, C.-M. 30:217
 Yehuda, R. 30:265
 Yerevanian, B.I. 29:29
 Young, A.S. 28:315
- Zacher, A. 29:433
 Zborowski, L. 29:29
 Zhang, Y. 27:267
 Zis, A.P. 27:161

Subject Index for 1989

Abnormal Involuntary Movement Scale

- electromechanical measures, observer ratings, tardive dyskinesia, 27:193
- observer ratings, electromechanical measures, tardive dyskinesia, 27:193
- tardive dyskinesia, electromechanical measures, observer ratings, 27:193

Acetazolamide

- anxiety, carbon dioxide, cerebral blood flow, 28:241
- carbon dioxide, anxiety, cerebral blood flow, 28:241
- cerebral blood flow, anxiety, carbon dioxide, 28:241
- pyruvate dehydrogenase, schizophrenia, thiamine, 28:279
- schizophrenia, pyruvate dehydrogenase, thiamine, 28:279
- thiamine, pyruvate dehydrogenase, schizophrenia, 28:279

Activity

- menstrual cycle, premenstrual syndrome, sleep, temperature, 30:285
- premenstrual syndrome, sleep, temperature, 30:285
- sleep, menstrual cycle, premenstrual syndrome, temperature, 30:285
- temperature, menstrual cycle, premenstrual syndrome, sleep, 30:285

Acute Panic Inventory

- affective disorder, lactate, panic, 27:357
- carbon dioxide inhalation, panic, premenstrual dysphoria, 27:183
- lactate, affective disorder, panic, 27:357
- lactate, panic disorder, somatic symptoms, 29:207
- panic, affective disorder, 27:357
- panic, carbon dioxide inhalation, 27:183
- panic disorder, lactate, somatic symptoms, 29:207
- panic, lactate, 27:357
- panic, premenstrual dysphoria, 27:183
- premenstrual dysphoria, carbon dioxide inhalation, panic, 27:183
- somatic symptoms, lactate, panic disorder, 29:207

Adenosine

- caffeine, panic disorder, posttraumatic stress disorder, taste test, 30:231
- panic disorder, caffeine, posttraumatic stress disorder, taste test, 30:231
- posttraumatic stress disorder, caffeine, panic disorder, taste test, 30:231
- taste test, caffeine, panic disorder, posttraumatic stress disorder, 30:231

Adenosine monophosphate. See cyclic adenosine monophosphate

Adolescence

- affective disorder, cortisol, 27:101
- affective disorder, 3-methoxy-4-hydroxyphenylglycol, 27:101
- affective disorder, norepinephrine, 27:101
- cortisol, affective disorder, 27:101
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:101
- cortisol, norepinephrine, 27:101
- 3-methoxy-4-hydroxyphenylglycol, affective disorder, 27:101
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:101
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:101
- norepinephrine, affective disorder, 27:101
- norepinephrine, cortisol, 27:101
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:101

Affective disorder

- Acute Panic Inventory, lactate, 27:357
- adolescents, cortisol, 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:101
- Albert Einstein College of Medicine Suicide Intent Scale, 27:71
- age of onset, 3-methoxy-4-hydroxyphenylglycol, 30:103
- Alzheimer's disease, clonidine, growth hormone, 27:277
- Alzheimer's disease, EEG mapping, evoked potentials, 29:403
- ankyrin, bipolar subtype, lithium, red blood cell membrane, 27:267

Affective Disorder continued

- antidepressants, clonidine binding in platelets, 28:73
- antidepressants, diagnostic criteria, 30:83
- antidepressants, geriatric depression, 28:1
- antidepressants, lithium, 28:73
- antidepressants, nortriptyline, 28:1
- antidepressants, phenelzine, 28:1
- antidepressants, schizophrenia, 28:73
- antidepressants, treatment response, 30:83
- antisocial personality disorder, borderline, 30:265
- antisocial personality disorder, monoamine oxidase, 30:265
- antisocial personality disorder, 30:265
- attention, continuous performance test, laterality, schizophrenia, 29:65
- bipolar depression, circadian rhythm, sleep, temperature, 27:23
- bipolar subtype, ankyrin, lithium, red blood cell membrane, 27:267
- borderline personality disorder, platelet monoamine oxidase, 30:265
- Center for Epidemiologic Studies Depression Scale, Mexican-Americans, 27:137
- cerebral blood flow, SPECT, 29:323, 29:331
- children, cholesterol, 29:215
- children, dexamethasone suppression test, 29:215
- children, glucose, 29:215
- children, potassium, 29:215
- children, sodium, 29:215
- cholesterol, children, 29:215
- cholesterol, dexamethasone suppression test, 29:215
- cholesterol, glucose, 29:215
- cholesterol, potassium, 29:215
- cholesterol, sodium, 29:215
- circadian rhythms, bipolar depression, 27:23
- circadian rhythms, cortisol, 28:263
- circadian rhythms, global vigor and affect, 27:89
- circadian rhythms, melatonin, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, sleep, temperature, 27:23, 28:263
- circadian rhythms, thyroid stimulating hormone, 28:263
- circadian rhythms, Visual Analogue Scale, 27:89
- circannual rhythms, dexamethasone suppression test, 29:87

Affective Disorder continued

- circannual rhythms, platelet imipramine binding, 29:87, 30:21
- clomipramine, interview behavior, 28:47
- clomipramine, sleep, 30:165
- clomipramine, sleep deprivation, 28:47
- clonidine, Alzheimer's disease, 27:277
- clonidine, binding in platelets, lithium, 28:73
- clonidine, binding in platelets, schizophrenia, 28:73
- clonidine, growth hormone, 27:277, 29:199
- clonidine, lithium, 28:73
- clonidine, schizophrenia, 28:73
- cluster analysis, seasonal affective disorder, 28:227
- cocaine, comorbidity, 28:105, 28:335
- cocaine, substance abuse, 28:105, 28:335
- comorbidity, cocaine, substance abuse, 28:105, 28:335
- computed tomography, psychotic symptoms, 29:221
- computed tomography, symptomatology, 29:271
- computed tomography, ventricle-brain ratio, 29:271
- continuous performance test, attention, laterality, schizophrenia, 29:65
- cortisol, adolescents, 27:101
- cortisol, circadian rhythms, 28:263
- cortisol, cyclic adenosine monophosphate, 30:181
- cortisol, dexamethasone suppression test, 27:161, 29:187
- cortisol, dihydroergocryptine, 30:181
- cortisol, dopamine, 29:187
- cortisol, epinephrine, 29:187
- cortisol, melatonin, 28:263
- cortisol, 3-methoxy-4-hydroxy-phenylglycol, 27:101
- cortisol, norepinephrine, 27:101, 28:263, 29:187
- cortisol, prostaglandin, 30:181
- cortisol, temperature, 28:263
- cortisol, thyroid stimulating hormone, 28:263
- cyclic adenosine monophosphate, 30:181
- dexamethasone suppression test, children, 29:215
- dexamethasone suppression test, cholesterol, 29:215
- dexamethasone suppression test, circannual rhythms, 29:87
- dexamethasone suppression test, cortisol, 27:161, 29:187

Affective Disorder continued

- dexamethasone suppression test, dopamine, 29:187
- dexamethasone suppression test, epinephrine, 29:187
- dexamethasone suppression test, glucose, 29:215
- dexamethasone suppression test, homovanillic acid, 29:177
- dexamethasone suppression test, imipramine binding, 29:87
- dexamethasone suppression test, norepinephrine, 29:187
- dexamethasone suppression test, potassium, 29:215
- dexamethasone suppression test, sodium, 29:215
- diagnostic criteria, antidepressants, 30:83
- diagnostic criteria, treatment response, 30:83
- diagnostic specificity, imipramine binding, 30:21
- dihydroergocryptine binding, 30:181
- dopamine, cortisol, 29:187
- dopamine, dexamethasone suppression test, 29:187
- dopamine, epinephrine, 29:187
- dopamine, norepinephrine, 29:187
- EEG mapping, Alzheimer's disease, 29:403
- EEG mapping, evoked potentials, 29:403
- elderly subjects, EEG mapping, 29:403
- elderly subjects, evoked potentials, 29:403
- epinephrine, cortisol, 29:187
- epinephrine, dexamethasone suppression test, 29:187
- epinephrine, dopamine, 29:187
- epinephrine, norepinephrine, 29:187
- evoked potentials, Alzheimer's disease, 29:403
- evoked potentials, EEG mapping, 29:403
- evoked potentials, elderly subjects, 29:403
- fluoxetine, Hamilton Rating Scale for Depression, 30:191
- fluoxetine, imipramine, 30:191
- fluoxetine, placebo washout, 30:191
- generalized anxiety disorder, norepinephrine, 30:253
- generalized anxiety disorder, time sampling, 30:253
- geriatric depression, antidepressants, 28:1
- geriatric depression, maintenance pharmacotherapy, 27:225
- geriatric depression, nortriptyline, 27:225, 28:1

Affective Disorder continued

- geriatric depression, phenelzine, 28:1
- geriatric depression, sleep, 27:13
- geriatric depression, survival analysis, 27:225
- global vigor and affect, circadian rhythm, 27:89
- global vigor and affect, Visual Analogue Scale, 27:89
- glucose, children, 29:215
- glucose, cholesterol, 29:215
- glucose, dexamethasone suppression test, 29:215
- glucose, potassium, 29:215
- glucose, sodium, 29:215
- growth hormone, Alzheimer's disease, 27:277
- growth hormone, clonidine, 27:277, 29:199
- Hamilton Rating Scale for Depression, fluoxetine, 30:191
- Hamilton Rating Scale for Depression, imipramine, 30:191
- Hamilton Rating Scale for Depression, placebo washout, 30:191
- homovanillic acid, dexamethasone suppression test, 29:177
- 5-hydroxyindolacetic acid, 30:181
- imipramine, fluoxetine, 30:191
- imipramine, Hamilton Rating Scale for Depression, 30:191
- imipramine, placebo washout, 30:191
- imipramine binding, circannual rhythms, 29:87, 30:21
- imipramine binding, diagnostic specificity, 30:21
- imipramine binding, dexamethasone suppression test, 29:87
- immune function, mania, 29:235
- interview behavior, clomipramine, 28:47
- interview behavior, sleep deprivation, 28:47
- lactate, Acute Panic Inventory, 27:357
- laterality, attention, continuous performance test, 29:65
- laterality, schizophrenia, 29:65
- life events, mania, 30:213
- life events, Psychiatric Epidemiology Research Interview, 30:213
- life events, stressors, 30:213
- light, melatonin, 27:351
- light therapy, seasonal affective disorder, 29:29
- lithium, ankyrin, 27:267
- lithium, antidepressants, 28:73
- lithium, bipolar subtype, 27:267

Affective Disorder continued

- lithium, clonidine binding in platelets, 28:73
- lithium, red blood cell membrane, 27:267
- lithium, schizophrenia, 28:73
- maintenance pharmacotherapy, geriatric depression, 27:225
- maintenance pharmacotherapy, nortriptyline, 27:225
- maintenance pharmacotherapy, survival analysis, 27:225
- mania, immune function, 29:235
- mania, life events, 30:213
- mania, stressors, 30:213
- melatonin, circadian rhythms, 28:263
- melatonin, light, 27:351
- melatonin, temperature, 28:263
- 3-methoxy-4-hydroxyphenylglycol, adolescents, 27:101
- 3-methoxy-4-hydroxyphenylglycol, age of onset, 30:103
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:101
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:101
- Mexican-Americans, Center for Epidemiologic Studies Depression Scale, 27:137
- monoamine oxidase, borderline personality disorder, 30:265
- monoamine oxidase, antisocial personality disorder, 30:265
- naps, sleep deprivation, 27:253
- neuroleptics, schizophrenia, 28:315
- neuroleptics, tardive dyskinesia, 28:315
- norepinephrine, adolescents, 27:101
- norepinephrine, circadian rhythms, 28:263
- norepinephrine, cortisol, 27:101, 28:263, 29:187
- norepinephrine, dexamethasone suppression test, 29:187
- norepinephrine, dopamine, 29:187
- norepinephrine, epinephrine, 29:187
- norepinephrine, generalized anxiety disorder, 30:253
- norepinephrine, melatonin, 28:263
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:101
- norepinephrine, temperature, 28:263
- norepinephrine, thyroid stimulating hormone, 28:263
- norepinephrine, time sampling, 30:253

Affective Disorder continued

- nortriptyline, geriatric depression, 27:225, 28:1
- nortriptyline, maintenance pharmacotherapy, 27:225
- nortriptyline, phenelzine, 28:1
- nortriptyline, survival analysis, 27:225
- panic, Acute Panic Inventory, 27:357
- panic, lactate, 27:357
- personality disorder, antisocial personality disorder, 30:265
- personality disorder, borderline, 30:265
- personality disorder, monoamine oxidase, 30:265
- phenelzine, geriatric depression, 28:1
- phenelzine, nortriptyline, 28:1
- Pittsburgh Sleep Quality Index, 28:193
- placebo washout, fluoxetine, 30:191
- placebo washout, imipramine, 30:191
- placebo washout, Hamilton Rating Scale for Depression, 30:191
- potassium, children, 29:215
- potassium, cholesterol, 29:215
- potassium, dexamethasone suppression test, 29:215
- potassium, glucose, 29:215
- potassium, sodium, 29:215
- prostaglandin, 30:181
- Psychiatric Epidemiology Research Interview, life events, 30:213
- psychotic symptoms, computed tomography, 29:221
- red blood cell membrane, ankyrin, 27:267
- red blood cell membrane, bipolar subtype, 27:267
- red blood cell membrane, lithium, 27:267
- relatives of unipolars, REM latency, sleep, 27:127
- schizophrenia, antidepressants, 28:73
- schizophrenia, attention, 29:65
- schizophrenia, clonidine binding in platelets, 28:73
- schizophrenia, continuous performance test, 29:65
- schizophrenia, laterality, 29:65
- schizophrenia, lithium, 28:73
- schizophrenia, neuroleptics, 28:315
- schizophrenia, tardive dyskinesia, 28:315
- seasonal affective disorder, cluster analysis, 28:227
- seasonal affective disorder, light therapy, 29:29
- seasonal affective disorder, temperature, 28:323

Affective Disorder continued

- serotonin uptake, 30:181
- single photon emission computed tomography, cerebral blood flow, 29:323, 29:331
- sleep, bipolar depression, 27:23
- sleep, circadian rhythm, 27:23
- sleep, clomipramine, 30:165
- sleep deprivation, clomipramine, 28:47
- sleep deprivation, interview behavior, 28:47
- sleep deprivation, naps, 27:253
- sleep deprivation, thyroid stimulating hormone, 29:231
- sleep deprivation, triiodothyronine, 29:231
- sleep, geriatric depression, 27:13
- sleep, Pittsburgh Sleep Quality Index, 28:193
- sleep, relatives of unipolars, 27:127
- sleep, REM latency, 27:127
- sleep, temperature, 27:23
- sodium, children, 29:215
- statistics, cluster analysis, 28:227
- statistics, seasonal affective disorder, 28:227
- stressors, life events, 30:213
- stressors, mania, 30:213
- substance abuse, cocaine, 28:105, 28:335
- substance abuse, comorbidity, 28:105, 28:335
- suicide, Albert Einstein College of Medicine Suicide Intent Scale, 27:71
- survival analysis, nortriptyline, 27:225
- survival analysis, geriatric depression, 27:225
- survival analysis, maintenance pharmacotherapy, 27:225
- symptomatology, computed tomography, 29:271
- symptomatology, ventricle-brain ratio, 29:271
- tardive dyskinesia, neuroleptics, 28:315
- tardive dyskinesia, schizophrenia, 28:315
- temperature, bipolar depression, 27:23
- temperature, circadian rhythms, 27:23, 28:263
- temperature, cortisol, 28:263
- temperature, melatonin, 28:263
- temperature, norepinephrine, 28:263
- temperature, seasonal affective disorder, 28:323
- temperature, sleep, 27:23
- temperature, thyroid stimulating hormone, 28:263

Affective Disorder continued

- thyroid stimulating hormone, circadian rhythms, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, melatonin, 28:263
- thyroid stimulating hormone, norepinephrine, 28:263
- thyroid stimulating hormone, sleep deprivation, 29:231
- thyroid stimulating hormone, temperature, 28:263
- thyroid stimulating hormone, triiodothyronine, 29:231
- time sampling, norepinephrine, 30:253
- treatment response, antidepressants, 30:83
- treatment response, diagnostic criteria, 30:83
- triiodothyronine, sleep deprivation, 29:231
- triiodothyronine, thyroid stimulating hormone, 29:231
- ventricle-brain ratio, computed tomography, 29:271
- ventricle-brain ratio, symptomatology, 29:271
- Visual Analogue Scale, circadian rhythms, 27:89
- Visual Analogue Scale, global vigor and affect, 27:89

Age

- chlorophenylpiperazine, 29:1
- cortisol, 29:1
- mental retardation, social group formation, 30:31
- prolactin, 29:1
- serotonin, 29:1
- social group formation, mental retardation, 30:31

Agoraphobia. See Panic disorder**Aggression.** See also Violence

- impulsivity, serotonin, 27:5
- serotonin, impulsivity, 27:5

Akathisia

- beta blocker, posttraumatic stress disorder, 27:1
- beta blocker, schizophrenia, 27:1
- neuroleptic side effect, propranolol, 27:1
- posttraumatic stress disorder, beta blocker, 27:1
- posttraumatic stress disorder, schizophrenia, 27:1
- propranolol, neuroleptic side effects, 27:1
- schizophrenia, beta blocker, 27:1

Akathisia continued

schizophrenia, posttraumatic stress disorder, 27:1

Alcoholism

blackout, cerebral blood flow, 27:49
 cerebral blood flow, blackout, 27:49
 cocaine, comorbidity, 29:113
 cocaine, genetics, 29:113
 comorbidity, cocaine, 29:113
 comorbidity, genetics, 29:113
 comorbidity, substance abuse, 29:113
 computed tomography, cerebrospinal fluid volumetry, 29:277
 computed tomography, growth hormone, 28:89
 computed tomography, magnetic resonance imaging, 29:277
 computed tomography, prolactin, 28:89
 computed tomography, thyroid stimulating hormone, 28:89
 computed tomography, thyrotropin releasing hormone test, 28:89
 cortisol, dexamethasone suppression test, 30:217
 cortisol, liver function, 30:217
 cerebrospinal fluid volumetry, computed tomography, 29:277
 cerebrospinal fluid volumetry, magnetic resonance imaging, 29:277
 dexamethasone suppression test, cortisol, 30:217
 dexamethasone suppression test, liver function, 30:217
 genetics, cocaine, 29:113
 genetics, comorbidity, 29:113
 genetics, substance abuse, 29:113
 growth hormone, computed tomography, 28:89
 growth hormone, prolactin, 28:89
 growth hormone, thyroid stimulating hormone, 28:89
 growth hormone, thyrotropin releasing hormone test, 28:89
 lithium, prolactin, 29:55
 lithium, red blood cells, 29:55
 liver function, cortisol, 30:217
 liver function, dexamethasone suppression test, 30:217
 magnetic resonance imaging, computed tomography, 29:277
 magnetic resonance imaging, cerebrospinal fluid volumetry, 29:277
 prolactin, computed tomography, 28:89
 prolactin, growth hormone, 28:89

Alcoholism, continued

prolactin, lithium, 29:55
 prolactin, red blood cells, 29:55
 prolactin, thyroid stimulating hormone, 28:89
 prolactin, thyrotropin releasing hormone test, 28:89
 red blood cells, lithium, 29:55
 red blood cells, prolactin, 29:55
 substance abuse, cocaine, 29:113
 substance abuse, comorbidity, 29:113
 substance abuse, genetics, 29:113
 thyroid stimulating hormone, computed tomography, 28:89
 thyroid stimulating hormone, growth hormone, 28:89
 thyroid stimulating hormone, prolactin, 28:89
 thyrotropin releasing hormone test, computed tomography, 28:89
 thyrotropin releasing hormone test, growth hormone, 28:89
 thyrotropin releasing hormone test, prolactin, 28:89

Albert Einstein College of Medicine Suicide Intent Scale

affective disorders, suicide, 27:71
 suicide, affective disorders, 27:71

Alprazolam

diazepam, 3-methoxy-4-hydroxyphenylglycol, 30:53
 diazepam, panic disorder, 30:53
 diazepam, treatment response, 30:53
 3-methoxy-4-hydroxyphenylglycol, panic disorder, 30:53
 3-methoxy-4-hydroxyphenylglycol, treatment response, 30:53
 panic disorder, 3-methoxy-4-hydroxyphenylglycol, 30:53
 panic disorder, treatment response, 30:53
 treatment response, diazepam, 30:53
 treatment response, panic disorder, 30:53

Alzheimer's disease. See also Dementia

affective disorder, clonidine, 27:277
 affective disorder, growth hormone, 27:277
 affective disorder, EEG mapping, 29:403
 affective disorders, elderly subjects, 29:403
 affective disorders, evoked potentials, 29:403
 cerebral blood flow, magnetic resonance imaging, 29:447
 cerebral blood flow, parietotemporal deficit, 29:301
 cerebral blood flow, pyritinol, 29:303

Alzheimer's disease continued

cerebral blood flow, single photon emission computed tomography, 29:347
 clonidine, affective disorder, 27:277
 clonidine, growth hormone, 27:277
 cognitive impairment, EEG mapping, 29:409
 computed tomography, dementia, 29:445
 computed tomography, positron emission tomography, 29:359
 computed tomography, single photon emission computed tomography, 29:445
 computed tomography, white matter, 29:359
 cortisol, dexamethasone suppression test, 29:169
 cortisol, gender, 29:169
 dementia, computed tomography, 29:445
 dementia, single photon emission computed tomography, 29:445
 deoxyglucose, positron emission tomography, 29:351
 dexamethasone suppression test, cortisol, 29:169
 dexamethasone suppression test, gender, 29:169
 disease severity, EEG mapping, 29:399
 EEG mapping, affective disorders, 29:403
 EEG mapping, cognitive impairment, 29:409
 EEG mapping, disease severity, 29:399
 EEG mapping, elderly subjects, 29:403
 EEG mapping, evoked potentials, 29:403
 EEG mapping, phosphatidylserine, 29:411
 EEG mapping, single photon emission computed tomography, 29:449
 elderly subjects, affective disorders, 29:403
 elderly subjects, EEG mapping, 29:403
 elderly subjects, evoked potentials, 29:403
 evoked potentials, affective disorders, 29:403
 evoked potentials, EEG mapping, 29:403
 evoked potentials, elderly subjects, 29:403
 gallyas impregnation, neuropathology, 29:463
 gender, cortisol, 29:169
 gender, dexamethasone suppression test, 29:169
 growth hormone, affective disorder, 27:277
 growth hormone, clonidine, 27:277
 imipramine binding, platelet, 28:289
 magnetic resonance imaging, cerebral blood flow, 29:447
 neuropathology, gallyas impregnation, 29:463

Alzheimer's disease continued

parietotemporal deficit, cerebral blood flow, 29:301
 phosphatidylserine, EEG mapping, 29:411
 platelet, imipramine binding, 28:289
 positron emission tomography, computed tomography, 29:359
 positron emission tomography, deoxyglucose, 29:351
 pyritinol, cerebral blood flow, 29:303
 single photon emission computed tomography, cerebral blood flow, 29:347
 single photon emission computed tomography, computed tomography, 29:445
 single photon emission computed tomography, dementia, 29:445
 single photon emission computed tomography, EEG mapping, 29:449
 white matter, computed tomography, 29:359

Amantadine

bromocriptine, cocaine, 29:11
 bromocriptine, substance abuse, 29:11
 bromocriptine, withdrawal, 29:11
 cocaine, bromocriptine, 29:11
 cocaine, withdrawal, 29:11
 substance abuse, bromocriptine, 29:11
 substance abuse, withdrawal, 29:11
 withdrawal, bromocriptine, 29:11
 withdrawal, cocaine, 29:11

Ankyrin

affective disorder, bipolar, 27:267
 affective disorder, lithium, 27:267
 affective disorder, red blood cell membrane, 27:267
 bipolar affective disorder, 27:267
 bipolar, lithium, 27:267
 bipolar, red blood cell membrane, 27:267
 lithium, affective disorder, 27:267
 lithium, bipolar, 27:267
 lithium, red blood cell membrane, 27:267
 red blood cell membrane, affective disorder, 27:267
 red blood cell membrane, bipolar, 27:267
 red blood cell membrane, lithium, 27:267

Anorexia nervosa. See Eating disorders**Anticonvulsants**

neuroleptics, plasma concentration, 28:153
 plasma concentration, neuroleptics, 28:153

Antidepressants

affective disorder, diagnostic criteria, 30:83
 affective disorder, schizophrenia, 28:73
 affective disorder, treatment response, 30:83

Antidepressants continued

- clonidine binding in platelets, affective disorder, 28:73
- clonidine binding in platelets, schizophrenia, 28:73
- clonidine, lithium, 28:73
- diagnostic criteria, affective disorder, 30:83
- diagnostic criteria, treatment response, 30:83
- food intake, learned helplessness, 27:149
- food intake, rats, 27:149
- food intake, triiodothyronine, 27:149
- geriatric depression, nortriptyline, 28:1
- geriatric depression, phenelzine, 28:1
- learned helplessness, food intake, 27:149
- learned helplessness, rats, 27:149
- learned helplessness, triiodothyronine, 27:149
- lithium, affective disorder, 28:73
- lithium, clonidine binding in platelets, 28:73
- lithium, schizophrenia, 28:73
- nortriptyline, affective disorder, 28:1
- nortriptyline, geriatric depression, 28:1
- phenelzine, affective disorder, 28:1
- phenelzine, geriatric depression, 28:1
- rats, food intake, 27:149
- rats, learned helplessness, 27:149
- rats, triiodothyronine, 27:149
- schizophrenia, affective disorder, 28:73
- schizophrenia, clonidine binding in platelets, 28:73
- schizophrenia, lithium, 28:73
- treatment response, affective disorders, 30:83
- treatment response, diagnostic criteria, 30:83
- triiodothyronine, food intake, 27:149
- triiodothyronine, learned helplessness, 27:149
- triiodothyronine, rats, 27:149

Anxiety

- acetazolamide, cerebral blood flow, 28:241
- carbon dioxide, cerebral blood flow, 28:241
- cerebral blood flow, acetazolamide, 28:241
- cerebral blood flow, carbon dioxide, 28:241
- depressed mood, headache, 30:95
- depressed mood, migraine, 30:95
- depressed mood, monoamine oxidase, 30:95
- depressed mood, obsessive-compulsive disorder, 27:65

Anxiety continued

- depressed mood, pseudocholinesterase, 27:65
- depressed mood, tribulin, 30:95
- fenfluramine, panic disorder, 28:295
- fenfluramine, serotonin, 28:295
- headache, depressed mood, 30:95
- headache, monoamine oxidase, 30:95
- headache, tribulin, 30:95
- migraine, depressed mood, 30:95
- migraine, monoamine oxidase, 30:95
- migraine, tribulin, 30:95
- monoamine oxidase, depressed mood, 30:95
- monoamine oxidase, headache, 30:95
- monoamine oxidase, migraine, 30:95
- monoamine oxidase, tribulin, 30:95
- obsessive-compulsive disorder, depressed mood, 27:65
- obsessive-compulsive disorder, pseudocholinesterase, 27:65
- panic disorder, fenfluramine, 28:295
- panic disorder, serotonin, 28:295
- pseudocholinesterase, depressed mood, 27:65
- pseudocholinesterase, obsessive-compulsive disorder, 27:65
- serotonin, fenfluramine, 28:295
- serotonin, panic disorder, 28:295
- tribulin, depressed mood, 30:95
- tribulin, headache, 30:95
- tribulin, migraine, 30:95
- tribulin, monoamine oxidase, 30:95

Arylsulfatase A

- metachromatic leucodystrophy, schizophrenia, 30:107
- schizophrenia, metachromatic leucodystrophy, 30:107

Attention

- affective disorder, continuous performance test, 29:65
- affective disorder, laterality, 29:65
- affective disorder, schizophrenia, 29:65
- clinical stabilization, eye movements, 28:31
- clinical stabilization, schizophrenia, 28:31
- college students, Perceptual Aberration-Magical Ideation, 27:207
- college students, Physical Anhedonia, 27:207
- college students, psychosis proneness, 27:207
- college students, risk factors, 27:207
- computed tomography, laterality, 29:267
- computed tomography, schizophrenia, 29:267

Attention continued

- computed tomography, ventricle-brain ratio, 29:267
- continuous performance test, affective disorder, 29:65
- continuous performance test, laterality, 29:65
- continuous performance test, schizophrenia, 29:65
- eye movements, clinical stabilization, 28:31
- eye movements, schizophrenia, 28:31
- laterality, affective disorder, 29:65
- laterality, computed tomography, 29:267
- laterality, continuous performance test, 29:65
- laterality, schizophrenia, 29:65, 29:267
- laterality, ventricle-brain ratio, 29:267
- Perceptual Aberration-Magical Ideation Scale, psychosis, 27:207
- Physical Anhedonia Scale, college students, 27:207
- Physical Anhedonia Scale, psychosis proneness, 27:207
- Physical Anhedonia Scale, risk factors, 27:207
- psychosis proneness, college students, 27:207
- psychosis proneness, Perceptual Aberration-Magical Ideation Scale, psychosis proneness, Physical Anhedonia Scale, 27:207
- psychosis proneness, risk factors, 27:207
- risk factors, college students, 27:207
- risk factors, Perceptual Aberration-Magical Ideation Scale, 27:207
- risk factors, Physical Anhedonia Scale, 27:207
- risk factors, psychosis proneness, 27:207
- schizophrenia, affective disorder, 29:65
- schizophrenia, clinical stabilization, 28:31
- schizophrenia, computed tomography, 29:267
- schizophrenia, continuous performance test, 29:65
- schizophrenia, eye movements, 28:31
- schizophrenia, laterality, 29:65, 29:267
- schizophrenia, ventricle-brain ratio, 29:267
- ventricle-brain ratio, computed tomography, 29:267
- ventricle-brain ratio, laterality, 29:267
- ventricle-brain ratio, schizophrenia, 29:267

Attention deficit disorder

- catecholamines, conduct disorder, 27:241
- conduct disorder, catecholamines, 27:241

Attention deficit disorder continued

- conduct disorder, dopamine-beta-hydroxylase, 27:241
- conduct disorder, 3-methoxy-4-hydroxyphenylglycol, 27:241
- conduct disorder, norepinephrine, 27:241
- dopamine-beta-hydroxylase, conduct disorder, 27:241
- dopamine-beta-hydroxylase, norepinephrine, 27:241
- 3-methoxy-4-hydroxyphenylglycol, conduct disorder, 27:241
- norepinephrine, conduct disorder, 27:241
- norepinephrine, dopamine-beta-hydroxylase, 27:241

Beta blockers

- akathisia, posttraumatic stress disorder, 27:1
- akathisia, schizophrenia, 27:1
- posttraumatic stress disorder, akathisia, 27:1
- schizophrenia, akathisia, 27:1

Beta-hydroxybutyric acid

- computed tomography, cortisol, 27:39
- computed tomography, eating disorders, 27:39
- computed tomography, triiodothyronine, 27:39
- computed tomography, ventricle-brain ratio, 27:39
- cortisol, computed tomography, 27:39
- cortisol, eating disorders, 27:39
- cortisol, triiodothyronine, 27:39
- cortisol, ventricle-brain ratio, 27:39
- eating disorders, computed tomography, 27:39
- eating disorders, cortisol, 27:39
- eating disorders, triiodothyronine, 27:39
- eating disorders, ventricle-brain ratio, 27:39
- triiodothyronine, computed tomography, 27:39
- triiodothyronine, cortisol, 27:39
- triiodothyronine, eating disorders, 27:39
- triiodothyronine, ventricle-brain ratio, 27:39
- ventricle-brain ratio, computed tomography, 27:39
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, eating disorders, 27:39
- ventricle-brain ratio, triiodothyronine, 27:39

Blood-brain barrier

- electroconvulsive seizure, hypoglycemia, 29:151

Blood-brain barrier continued

hypoglycemia, electroconvulsive seizure, 29:151

rats, electroconvulsive seizure, 29:151

Blood pressure

cocaine, haloperidol, 27:117

cocaine, heart rate, 27:117

cocaine, subjective effects, 27:117

cortisol, generalized anxiety disorder, 27:173

cortisol, heart rate, 27:173

cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:173

cortisol, norepinephrine, 27:173

cortisol, yohimbine, 27:173

eating disorders, heart rate, 30:223

eating disorders, stressors, 30:223

eating disorders, Type A behavior, 30:223

generalized anxiety disorder, cortisol, 27:173

generalized anxiety disorder, heart rate, 27:173

generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173

generalized anxiety disorder,

norepinephrine, 27:173

generalized anxiety disorder, yohimbine, 27:173

haloperidol, cocaine, 27:117

haloperidol, heart rate, 27:117

haloperidol, subjective effects, 27:117

haloperidol, substance abuse, 27:117

heart rate, cocaine, 27:117

heart rate, cortisol, 27:173

heart rate, eating disorders, 30:223

heart rate, generalized anxiety disorder, 27:173

heart rate, haloperidol, 27:117

heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173

heart rate, norepinephrine, 27:173

heart rate, premenstrual dysphoria, 27:183

heart rate, stressors, 30:223

heart rate, subjective effects, 27:117

heart rate, substance abuse, 27:117

heart rate, Type A behavior, 30:223

heart rate, yohimbine, 27:173

3-methoxy-4-hydroxyphenylglycol, cortisol, 27:173

3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173

3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173

3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:173

Blood pressure continued

3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173

norepinephrine, cortisol, 27:173

norepinephrine, generalized anxiety disorder, 27:173

norepinephrine, heart rate, 27:173

norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:173

norepinephrine, yohimbine, 27:173

premenstrual dysphoria, heart rate, 27:183

stressors, eating disorders, 30:223

stressors, heart rate, 30:223

stressors, Type A behavior, 30:223

subjective effects, cocaine, 27:117

subjective effects, haloperidol, 27:117

subjective effects, heart rate, 27:117

subjective effects, substance abuse, 27:117

substance abuse, cocaine, 27:117

substance abuse, haloperidol, 27:117

substance abuse, heart rate, 27:117

substance abuse, subjective effects, 27:117

Type A behavior, eating disorders, 30:223

Type A behavior, heart rate, 30:223

Type A behavior, stressors, 30:223

yohimbine, cortisol, 27:173

yohimbine, generalized anxiety disorder, 27:173

yohimbine, heart rate, 27:173

yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173

yohimbine, norepinephrine, 27:173

Borderline personality disorder. See also Personality disorder

computed tomography, 27:111

third ventricle size, gender differences, 27:111

Borna disease

magnetic resonance imaging,

psychiatric patients, 29:281

psychiatric patients, magnetic resonance imaging, 29:281

Brain imaging. See also Cerebral blood flow, Computed tomography, EEG topography, Magnetic resonance imaging,

Magnetoencephalography, Positron

emission tomography, Single photon emission computed tomography

acetazolamide, anxiety, 28:241

affective disorder, Alzheimer's disease, 29:403

affective disorder, computed tomography, 29:221, 29:271

affective disorder, evoked potentials, 29:403

affective disorder, psychotic symptoms, 29:221

Brain imaging continued

affective disorder, single photon emission computed tomography, 29:323, 29:331
 affective disorder, symptomatology, 29:271
 affective disorder, ventricle-brain ratio, 29:271
 alcoholism, blackout, 27:49
 alcoholism, cerebral blood flow, 27:49
 alcoholism, cerebrospinal fluid volumetry, 29:277
 alcoholism, computed tomography, 28:89
 alcoholism, magnetic resonance imaging, 29:277
 algorithm, spatial interpolation, 29:431
 Alzheimer's disease, affective disorders, 29:403
 Alzheimer's disease, cerebral blood flow, 29:447
 Alzheimer's disease, cognitive impairment, 29:409
 Alzheimer's disease, computed tomography, 29:359
 Alzheimer's disease, dementia, 29:445
 Alzheimer's disease, deoxyglucose, 29:351
 Alzheimer's disease, disease severity, 29:399
 Alzheimer's disease, elderly subjects, 29:403
 Alzheimer's disease, evoked potentials, 29:403
 Alzheimer's disease, magnetic resonance imaging, 29:447
 Alzheimer's disease, parietotemporal deficit, 29:301
 Alzheimer's disease, positron emission tomography, 29:359
 Alzheimer's disease, pyritinol, 29:303
 Alzheimer's disease, single photon emission computed tomography, 29:347, 29:445, 29:449
 Alzheimer's disease, white matter, 29:359
 anxiety, acetazolamide, 28:241
 anxiety, carbon dioxide, 28:241
 arachnoid cyst, evoked potentials, 29:421
 arachnoid cyst, P300, 29:421
 arachnoid cyst, schizophrenia, 29:421
 atherosclerosis, operative therapy, 29:309
 attention, laterality, 29:267
 attention, schizophrenia, 29:267
 attention, ventricle-brain ratio, 29:267
 auditory and visual paradigm, evoked potential, 29:439

Brain imaging continued

auditory and visual paradigm, P300, 29:439
 auditory and visual paradigm, semantic tasks, 29:439
 autogenic training, beta reduction, 29:433
 autogenic training, hypnosis, 29:317
 autogenic training, laterality, 29:317
 beta-hydroxybutyric acid, computed tomography, 27:39
 beta-hydroxybutyric acid, ventricle-brain ratio, 27:39
 beta reduction, autogenic training, 29:433
 blackout, alcoholism, 27:49
 blackout, cerebral blood flow, 27:49
 borderline personality disorder, computed tomography, 27:111
 Borna disease, magnetic resonance imaging, 29:281
 brain atlas, computed tomography, 29:461
 brain atlas, EEG mapping, 29:461
 brain tumors, SPECT, 29:341
 bromospiperone, dopamine receptors, 29:357
 bromospiperone, schizophrenia, 29:357
 carbon dioxide, anxiety, 28:241
 cerebral blood flow, alcoholism, 27:49
 cerebral blood flow, Alzheimer's disease, 29:447
 cerebral blood flow, blackout, 27:49
 cerebral blood flow, corpus callosum, 29:453
 cerebral blood flow, gender, 27:55
 cerebral blood flow, laterality, 27:325
 cerebral blood flow, positron emission tomography, 27:325
 cerebral blood flow, schizophrenia, 27:325, 29:453
 cerebral blood flow, sex role orientation, 27:55
 cerebral blood flow, single photon emission computed tomography, 29:319
 cerebral ischemia, single photon emission computed tomography, 29:457
 cerebrospinal fluid flow, magnetic resonance imaging, 29:289
 cerebrospinal fluid flow, normal pressure hydrocephalus, 29:289
 cerebrospinal fluid volumetry, alcoholism, 29:277
 cerebrospinal fluid volumetry, computed tomography, 29:277
 cerebrospinal fluid volumetry, magnetic resonance imaging, 29:277

Brain imaging continued

- clonidine, evoked potentials, 28:255
- clonidine, P300, 28:255
- cognitive function, electroencephalography, 29:385
- cognitive function, pyritinol, 29:387
- cognitive impairment, Alzheimer's disease, 29:409
- computed tomography, affective disorder, 29:221, 29:271
- computed tomography, alcoholism, 28:89, 29:277
- computed tomography, Alzheimer's disease, 29:359
- computed tomography, beta-hydroxybutyric acid, 27:39
- computed tomography, borderline personality disorder, 27:111
- computed tomography, brain atlas, 29:461
- computed tomography, cerebrospinal fluid volumetry, 29:277
- computed tomography, cortisol, 27:39
- computed tomography, diencephalic lesions, 29:285
- computed tomography, eating disorders, 27:39
- computed tomography, electroencephalogram, 29:137
- computed tomography, electroencephalographic focus, 29:459
- computed tomography, frontal lobe, 29:137
- computed tomography, laterality, 29:247
- computed tomography, limbic system, 29:255
- computed tomography, lupus erythematosus, 29:367
- computed tomography, magnetic resonance imaging, 29:277, 29:363, 29:367
- computed tomography, positron emission tomography, 29:363, 29:367
- computed tomography, psychotic symptoms, 29:221
- computed tomography, schizophrenia, 29:137, 29:247, 29:255, 29:257, 29:265
- computed tomography, seizures, 29:459
- computed tomography, single photon emission computed tomography, 29:457, 29:459
- computed tomography, symptomatology, 29:271
- computed tomography, thalamic infarction, 29:363

Brain imaging continued

- computed tomography, ventricle-brain ratio, 27:39, 29:257, 29:265, 29:271
- computed tomography, white matter, 29:359
- computed tomography, Wisconsin Card Sort Test, 29:137
- computerized brains, historical background, 29:239
- corpus callosum, cerebral blood flow, 29:453
- corpus callosum, magnetic resonance imaging, 29:453
- corpus callosum, schizophrenia, 29:453
- cortisol, ventricle-brain ratio, 27:39
- dementia, Alzheimer's disease, 29:445
- dementia, deoxyglucose, 29:353
- dementia, evoked potentials, 29:391
- dementia, P300, 29:391
- dementia, schizophrenia, 29:391
- dementia, single photon emission computed tomography, 29:327, 29:445
- dementia, xenon inhalation, 29:297
- deoxyglucose, Alzheimer's disease, 29:351
- deoxyglucose, dementia, 29:353
- diencephalic lesions, computed tomography, 29:285
- diencephalic lesions, magnetic resonance imaging, 29:285
- disease severity, Alzheimer's disease, 29:399
- dopamine receptors, bromospiperone, 29:357
- dopamine receptors, schizophrenia, 29:357
- dyseidetic children, dyslexia, 29:407
- dyslexia, dyseidetic children, 29:407
- eating disorders, computed tomography, 27:39
- eating disorders, ventricle-brain ratio, 27:39
- EEG focus, computed tomography, 29:459
- EEG focus, magnetic resonance imaging, 29:459
- EEG focus, seizures, 29:459
- EEG focus, single photon emission computed tomography, 29:459
- EEG mapping, brain atlas, 29:461
- elderly subjects, affective disorders, 29:403
- elderly subjects, Alzheimer's disease, 29:403
- elderly subjects, evoked potentials, 29:403
- electroencephalogram, brain imaging, 29:137
- electroencephalogram, cognitive functions, 29:385

Brain imaging continued

electroencephalogram, computed tomography, 29:137
 electroencephalogram, evoked potentials, 29:379
 electroencephalogram, frontal lobe, 29:137
 electroencephalogram, schizophrenia, 29:137
 electroencephalogram, Wisconsin Card Sort Test, 29:137
 embolic mechanisms, stroke, 29:273
 evoked potentials, affective disorders, 29:403
 evoked potentials, Alzheimer's disease, 29:403
 evoked potentials, arachnoid cyst, 29:421
 evoked potentials, auditory and visual paradigm, 29:439
 evoked potentials, clonidine, 28:255
 evoked potentials, dementia, 29:391
 evoked potentials, elderly subjects, 29:403
 evoked potentials, electroencephalography, 29:379
 evoked potentials, frontal lobe, 28:63
 evoked potentials, obsessive-compulsive disorder, 28:63
 evoked potentials, P300, 28:63, 28:255, 29:391, 29:413, 29:421, 29:439
 evoked potentials, pyritinol, 29:413
 evoked potentials, schizophrenia, 29:391, 29:421
 evoked potentials, semantic tasks, 29:439
 frontal lobe, electroencephalogram, 29:137
 frontal lobe, evoked potentials, 28:63
 frontal lobe, head injury, 29:313
 frontal lobe, obsessive-compulsive disorder, 28:63
 frontal lobe, P300, 28:63
 frontal lobe reduction, schizophrenia, 29:331
 frontal lobe reduction, single photon emission computed tomography, 29:331
 frontal lobe, schizophrenia, 29:137
 frontal lobe size, magnetic resonance imaging, 30:11
 frontal lobe size, negative symptoms, 30:11
 frontal lobe size, sagittal morphology, 30:11
 frontal lobe size, schizophrenia, 30:11
 frontal lobe, Wisconsin Card Sort Test, 29:137
 frontal lobes, parietal lobes, 28:119
 frontal lobes, positron emission tomography, 28:119

Brain imaging continued

frontal lobes, schizophrenia, 28:119
 gender, cerebral blood flow, 27:55
 gender, sex role orientation, 27:55
 Gilles de la Tourette syndrome, normal comparison, 29:427
 head injury, frontal lobe, 29:313
 historical background, computerized brains, 29:239
 Huntington's chorea, psychiatric symptoms, 29:361
 hypnosis, laterality, 29:317
 intracranial pressure, low pressure hydrocephalus, 29:307
 K complex, sleep, 29:435
 laterality, attention, 29:267
 laterality, autogenic training, 29:317
 laterality, cerebral blood flow, 27:325
 laterality, computed tomography, 29:247
 laterality, hypnosis, 29:317
 laterality, positron emission tomography, 27:325
 laterality, schizophrenia, 27:325, 29:247, 29:267
 laterality, ventricle-brain ratio, 29:267
 limbic system, computed tomography, 29:255
 limbic system, schizophrenia, 29:255
 low pressure hydrocephalus, intracranial pressure, 29:307
 lupus erythematosus, computed tomography, 29:367
 lupus erythematosus, magnetic resonance imaging, 29:367
 lupus erythematosus, positron emission tomography, 29:367
 magnetic resonance imaging, alcoholism, 29:277
 magnetic resonance imaging, Alzheimer's disease, 29:447
 magnetic resonance imaging, Borna disease, 29:281
 magnetic resonance imaging, cerebrospinal fluid flow, 29:289
 magnetic resonance imaging, cerebrospinal fluid volumetry, 29:277
 magnetic resonance imaging, computed tomography, 29:277, 29:363, 29:367
 magnetic resonance imaging, corpus callosum, 29:453
 magnetic resonance imaging, diencephalic lesions, 29:285
 magnetic resonance imaging, EEG focus, 29:459

Brain imaging continued

- magnetic resonance imaging, frontal lobe size, 30:11
- magnetic resonance imaging, lupus erythematosus, 29:367
- magnetic resonance imaging, negative symptoms, 30:11
- magnetic resonance imaging, normal pressure hydrocephalus, 29:287, 29:289
- magnetic resonance imaging, pituitary tumors, 29:283
- magnetic resonance imaging, positron emission tomography, 29:363, 29:367
- magnetic resonance imaging, psychiatric patients, 29:281
- magnetic resonance imaging, sagittal morphology, 30:11
- magnetic resonance imaging, schizophrenia, 29:261, 29:265, 29:453, 30:11
- magnetic resonance imaging, seizures, 29:459
- magnetic resonance imaging, single photon emission computed tomography, 29:459
- magnetic resonance imaging, subcaudate tractotomy lesions, 29:291
- magnetic resonance imaging, temporal lobe, 29:261
- magnetic resonance imaging, thalamic infarction, 29:363
- magnetic resonance imaging, ventricle-brain ratio, 29:265
- multiple sclerosis, neuropsychology, 29:293
- multiple sclerosis, optic neuritis, 29:295
- negative symptoms, frontal lobe size, 30:11
- negative symptoms, magnetic resonance imaging, 30:11
- negative symptoms, sagittal morphology, 30:11
- negative symptoms, schizophrenia, 30:11
- neuropsychology, multiple sclerosis, 29:293
- normal comparison, Gilles de la Tourette syndrome, 29:427
- normal pressure hydrocephalus, cerebrospinal fluid flow, 29:289
- normal pressure hydrocephalus, magnetic resonance imaging, 29:287, 29:289
- normal volunteers, phosphatidylserine, 29:417
- obsessive-compulsive disorder, evoked potentials, 28:63
- obsessive-compulsive disorder, frontal lobe, 28:63

Brain imaging continued

- obsessive-compulsive disorder, P300, 28:63
- olfactory stimulation, trigeminal stimulants, 29:429
- operative therapy, atherosclerosis, 29:309
- optic neuritis, multiple sclerosis, 29:295
- P300, arachnoid cyst, 29:421
- P300, auditory and visual paradigm, 29:439
- P300, clonidine, 28:255
- P300, dementia, 29:391
- P300, frontal lobe, 28:63
- P300, obsessive-compulsive disorder, 28:63
- P300, pyritinol, 29:413
- P300, schizophrenia, 29:391, 29:421
- P300, semantic tasks, 29:439
- parietal lobes, frontal lobes, 28:119
- parietal lobes, positron emission tomography, 28:119
- parietal lobes, schizophrenia, 28:119
- parietotemporal deficit, Alzheimer's disease, 29:301
- phosphatidylserine, Alzheimer's disease, 29:411
- phosphatidylserine, normal volunteers, 29:417
- pituitary tumors, magnetic resonance imaging, 29:283
- positron emission tomography, Alzheimer's disease, 29:359
- positron emission tomography, cerebral blood flow, 27:325
- positron emission tomography, computed tomography, 29:363, 29:367
- positron emission tomography, frontal lobes, 28:119
- positron emission tomography, laterality, 27:325
- positron emission tomography, lupus erythematosus, 29:367
- positron emission tomography, magnetic resonance imaging, 29:363, 29:367
- positron emission tomography, parietal lobes, 28:119
- positron emission tomography, schizophrenia, 27:325, 28:119
- positron emission tomography, thalamic infarction, 29:363
- positron emission tomography, white matter, 29:359
- prolactin, computed tomography, 28:89
- psychiatric patients, Borna disease, 29:281
- psychiatric patients, magnetic resonance imaging, 29:281

Brain imaging continued

psychiatric symptoms, Huntington's chorea, 29:361
 psychotic symptoms, affective disorder, 29:221
 psychotic symptoms, computed tomography, 29:221
 pyritinol, Alzheimer's disease, 29:303
 pyritinol, cognitive function, 29:387
 pyritinol, evoked potentials, 29:413
 pyritinol, P300, 29:413
 Rett syndrome, theta activity, 29:425
 sagittal morphology, frontal lobe size, 30:11
 sagittal morphology, magnetic resonance imaging, 30:11
 sagittal morphology, negative symptoms, 30:11
 sagittal morphology, schizophrenia, 30:11
 Scale for the Assessment of Negative Symptoms, schizophrenia, 29:137
 schizophrenia, arachnoid cyst, 29:421
 schizophrenia, attention, 29:267
 schizophrenia, bromospiperone, 29:357
 schizophrenia, cerebral blood flow, 27:325, 29:453
 schizophrenia, computed tomography, 29:137, 29:247, 29:255, 29:257, 29:265
 schizophrenia, corpus callosum, 29:453
 schizophrenia, dementia, 29:391
 schizophrenia, dopamine receptors, 29:357
 schizophrenia, electroencephalogram, 29:137
 schizophrenia, evoked potentials, 29:391, 29:421
 schizophrenia, frontal lobe, 28:119, 29:137, 29:331, 30:11
 schizophrenia, laterality, 27:325, 29:247, 29:267
 schizophrenia, limbic system, 29:255
 schizophrenia, magnetic resonance imaging, 29:261, 29:265, 29:453, 30:11
 schizophrenia, negative symptoms, 30:11
 schizophrenia, P300, 29:391, 29:421
 schizophrenia, parietal lobes, 28:119
 schizophrenia, positron emission tomography, 27:325, 28:119
 schizophrenia, sagittal morphology, 30:11
 schizophrenia, Scale for the Assessment of Negative Symptoms, 29:137
 schizophrenia, single photon emission computed tomography, 29:331
 schizophrenia, temporal lobe, 29:261
 schizophrenia, temporal lobe beta, 29:419

Brain imaging continued

schizophrenia, ventricle-brain ratio, 29:257, 29:265, 29:267
 schizophrenia, Wisconsin Card Sort Test, 29:137
 seizures, computed tomography, 29:459
 seizures, EEG focus, 29:459
 seizures, magnetic resonance imaging, 29:459
 seizures, single photon emission computed tomography, 29:459
 semantic tasks, auditory and visual paradigm, 29:439
 semantic tasks, evoked potential, 29:439
 semantic tasks, P300, 29:439
 sex role orientation, cerebral blood flow, 27:55
 sex role orientation, gender, 27:55
 single photon emission computed tomography, affective disorder, 29:331, 29:323
 single photon emission computed tomography, Alzheimer's disease, 29:347, 29:445, 29:449
 single photon emission computed tomography, brain tumors, 29:341
 single photon emission computed tomography, cerebral blood flow, 29:319
 single photon emission computed tomography, cerebral ischemia, 29:457
 single photon emission computed tomography, computed tomography, 29:457, 29:459
 single photon emission computed tomography, dementia, 29:327, 29:445
 single photon emission computed tomography, EEG focus, 29:459
 single photon emission computed tomography, frontal lobe reduction, 29:331
 single photon emission computed tomography, magnetic resonance imaging, 29:459
 single photon emission computed tomography, schizophrenia, 29:331
 single photon emission computed tomography, seizures, 29:459
 sleep, K complex, 29:435
 spatial interpolation, algorithm, 29:431
 stroke, embolic mechanisms, 29:273
 subcaudate tractotomy lesions, brain imaging, 29:291
 subcaudate tractotomy lesions, magnetic resonance imaging, 29:291

Brain imaging continued

- symptomatology, affective disorders, 29:271
- symptomatology, computed tomography, 29:271
- symptomatology, ventricle-brain ratio, 29:271
- temporal lobe beta, schizophrenia, 29:419
- temporal lobe, magnetic resonance imaging, 29:261
- temporal lobe, schizophrenia, 29:261
- thalamic infarction, computed tomography, 29:363
- thalamic infarction, magnetic resonance imaging, 29:363
- thalamic infarction, positron emission tomography, 29:363
- theta activity, Rett syndrome, 29:425
- thyroid stimulating hormone, computed tomography, 28:89
- thyrotropin releasing hormone test, computed tomography, 28:89
- trigeminal stimulants, olfactory stimulation, 29:429
- triiodothyronine, computed tomography, 27:39
- triiodothyronine, ventricle-brain ratio, 27:39
- ventricle-brain ratio, affective disorders, 29:271
- ventricle-brain ratio, attention, 29:267
- ventricle-brain ratio, beta-hydroxybutyric acid, 27:39
- ventricle-brain ratio, computed tomography, 27:39, 29:257, 29:265, 29:271
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, eating disorders, 27:39
- ventricle-brain ratio, laterality, 29:267
- ventricle-brain ratio, magnetic resonance imaging, 29:265
- ventricle-brain ratio, schizophrenia, 29:257, 29:265, 29:267
- ventricle-brain ratio, symptomatology, 29:271
- ventricle-brain ratio, triiodothyronine, 27:39
- white matter, Alzheimer's disease, 29:359
- white matter, computed tomography, 29:359
- white matter, positron emission tomography, 29:359
- Wisconsin Card Sort Test, computed tomography, 29:137

Brain imaging continued

- Wisconsin Card Sort Test, electroencephalogram, 29:137
- Wisconsin Card Sort Test, frontal lobe, 29:137
- Wisconsin Card Sort Test, schizophrenia, 29:137
- xenon inhalation, dementia, 29:297

Brief Psychiatric Rating Scale

- Minnesota Multiphasic Personality Inventory, 28:135,
- schizoaffective disorder, schizophrenia, 28:135
- schizophrenia, Minnesota Multiphasic Personality Inventory, 28:135

Bromocriptine

- amantadine, cocaine withdrawal, 29:11
- cocaine withdrawal, 29:11
- withdrawal, cocaine, 29:11

Bulimia. See Eating disorders**Butaclamol**

- dopamine, lymphocytes, 30:259
- dopamine, spiperone binding, 30:259
- lymphocytes, dopamine, 30:259
- lymphocytes, spiperone binding, 30:259
- spiperone binding, dopamine, 30:259
- spiperone binding, lymphocytes, 30:259

Caffeine

- adenosine, panic disorder, 30:231
- adenosine, posttraumatic stress disorder, 30:231
- adenosine, taste test, 30:231
- panic disorder, adenosine, 30:231
- panic disorder, taste test, 30:231
- posttraumatic stress disorder, adenosine, 30:231
- posttraumatic stress disorder, taste test, 30:231
- taste test, panic disorder, 30:231
- taste test, posttraumatic stress disorder, 30:231

Cyclic adenosine monophosphate

- affective disorder, cortisol, 30:181
- affective disorder, dihydroergocryptine binding, 30:181
- affective disorder, 5-hydroxyindolacetic acid, 30:181
- affective disorder, prostaglandin, 30:181
- affective disorder, serotonin uptake, 30:181
- cortisol, affective disorder, 30:181
- dihydroergocryptine binding, affective disorder, 30:181
- 5-hydroxyindolacetic acid, affective disorders, 30:181

Cyclic adenosine monophosphate

continued

prostaglandin, affective disorders, 30:181

serotonin uptake, affective disorders,
30:181**Carbon dioxide**

acetazolamide, anxiety, 28:241

Acute Panic Inventory, premenstrual
dysphoria, 27:183

anxiety, cerebral blood flow, 28:241

cerebral blood flow, acetazolamide, 28:241

cerebral blood flow, anxiety, 28:241

panic, premenstrual dysphoria, 27:183

premenstrual dysphoria, Acute Panic
Inventory, 27:183

premenstrual dysphoria, panic, 27:183

Cardiovascular function. See Blood
pressure, Heart rate**Center for Epidemiological Studies****Depression Scale**affective disorder, Mexican-Americans,
27:137**Cerebral blood flow**

acetazolamide, anxiety, 28:241

acetazolamide, carbon dioxide, 28:241

affective disorder, single photon emission
computed tomography, 29:331 29:323

alcoholism, blackout, 27:49

Alzheimer's disease, magnetic resonance
imaging, 29:447Alzheimer's disease, parietotemporal
deficit, 29:301

Alzheimer's disease, pyritinol, 29:303

Alzheimer's disease, single photon
emission computed tomography, 29:347

anxiety, acetazolamide, 28:241

anxiety, carbon dioxide, 28:241

atherosclerosis, operative therapy, 29:309

autogenic training, hypnosis, 29:317

autogenic training, laterality, 29:317

blackout, alcoholism, 27:49

brain tumors, single photon emission
computed tomography, 29:341

carbon dioxide, acetazolamide, 28:241

carbon dioxide, anxiety, 28:241

computed tomography, single photon
emission computed tomography, 29:457corpus callosum, magnetic resonance
imaging, 29:453

corpus callosum, schizophrenia, 29:453

dementia, single photon emission
computed tomography, 29:327

dementia, xenon inhalation, 29:297

frontal lobe, head injury, 29:313

Cerebral blood flow continuedfrontal lobe reduction, schizophrenia,
29:331frontal lobe reduction, single photon
emission computed tomography, 29:331

gender, sex role orientation, 27:55

head injury, frontal lobe, 29:313

hypnosis, autogenic training, 29:317

hypnosis, laterality, 29:317

intracranial pressure, low pressure
hydrocephalus, 29:307

laterality, autogenic training, 29:317

laterality, hypnosis, 29:317

laterality, positron emission tomography,
27:325

laterality, schizophrenia, 27:325

low pressure hydrocephalus, intracranial
pressure, 29:307magnetic resonance imaging, Alzheimer's
disease, 29:447magnetic resonance imaging, corpus
callosum, 29:453magnetic resonance imaging,
schizophrenia, 29:453

operative therapy, atherosclerosis, 29:309

parietotemporal deficit, Alzheimer's
disease, 29:301positron emission tomography, laterality,
27:325positron emission tomography,
schizophrenia, 27:325

pyritinol, Alzheimer's disease, 29:303

schizophrenia, corpus callosum, 29:453

schizophrenia, frontal lobe reduction,
29:331

schizophrenia, laterality, 27:325

schizophrenia, magnetic resonance
imaging, 29:453schizophrenia, positron emission
tomography, 27:325schizophrenia, single photon emission
computed tomography, 29:331

sex role orientation, gender, 27:55

single photon emission computed
tomography, affective disorder, 29:323,
29:331, 29:323single photon emission computed
tomography, Alzheimer's disease, 29:347single photon emission computed
tomography, brain tumors, 29:341single photon emission computed
tomography, computed tomography,
29:457

Cerebral blood flow continued

- single photon emission computed tomography, dementia, 29:327
- single photon emission computed tomography, frontal lobe reduction, 29:331
- single photon emission computed tomography, schizophrenia, 29:331
- xenon inhalation, dementia, 29:297

m-Chlorophenylpiperazine

- age, 29:1
- cortisol, 29:1
- prolactin, 29:1
- serotonin, 29:1

Cholesterol

- affective disorder, children, 29:215
- children, affective disorder, 29:215
- dexamethasone suppression test, 29:215
- glucose, 29:215
- potassium, 29:215
- sodium, 29:215

Choline

- neuroleptics, red blood cells, schizophrenia, tardive dyskinesia, 29:45
- red blood cells, neuroleptics, schizophrenia, tardive dyskinesia, 29:45
- schizophrenia, neuroleptics, red blood cells, tardive dyskinesia, 29:45
- tardive dyskinesia, neuroleptics, red blood cells, schizophrenia, 29:45

Circadian rhythms

- affective disorder, bipolar depression, 27:23
- affective disorder, cortisol, 28:263
- affective disorder, global vigor and affect, 27:89
- affective disorder, melatonin, 28:263
- affective disorder, norepinephrine, 28:263
- affective disorder, sleep, 27:23
- affective disorder, temperature, 27:23, 28:263
- affective disorder, thyroid stimulating hormone, 28:263
- affective disorder, Visual Analogue Scale, 27:89
- bipolar depression, sleep, 27:23
- bipolar depression, temperature, 27:23
- cortisol, affective disorder, 28:263
- cortisol, melatonin, 28:263
- cortisol, norepinephrine, 28:263
- cortisol, temperature, 28:263
- cortisol, thyroid stimulating hormone, 28:263
- global vigor and affect, affective disorder, 27:89

Circadian rhythms continued

- global vigor and affect, Visual Analogue Scale, 27:89
- melatonin, affective disorder, 28:263
- melatonin, cortisol, 28:263
- melatonin, norepinephrine, 28:263
- melatonin, temperature, 28:263
- melatonin, thyroid stimulating hormone, 28:263
- norepinephrine, affective disorder, 28:263
- norepinephrine, cortisol, 28:263
- norepinephrine, melatonin, 28:263
- norepinephrine, temperature, 28:263
- norepinephrine, thyroid stimulating hormone, 28:263
- sleep, affective disorder, 27:23
- sleep, bipolar depression, 27:23
- sleep, temperature, 27:23
- temperature, affective disorder, 27:23, 28:263
- temperature, bipolar depression, 27:23
- temperature, cortisol, 28:263
- temperature, melatonin, 28:263
- temperature, norepinephrine, 28:263
- temperature, sleep, 27:23
- temperature, thyroid stimulating hormone, 28:263
- thyroid stimulating hormone, affective disorder, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, melatonin, 28:263
- thyroid stimulating hormone, norepinephrine, 28:263
- thyroid stimulating hormone, temperature, 28:263
- Visual Analogue Scale, affective disorder, 27:89
- Visual Analogue Scale, global vigor and affect, 27:89

Circannual rhythms

- affective disorder, dexamethasone suppression test, 29:87
- affective disorder, imipramine binding, 29:87, 30:21
- dexamethasone suppression test, affective disorder, 29:87
- dexamethasone suppression test, imipramine binding, 29:87
- imipramine binding, affective disorder, 29:87, 30:21
- imipramine binding, dexamethasone suppression test, 29:87
- serotonin, platelet uptake, 27:5

Clenbuterol

- clomipramine, food restriction, rats, 27:149
- desipramine, food restriction, rats, 27:149
- food restriction, clomipramine, desipramine, indalpine, nialamide, rats, 27:149
- indalpine, food restriction, rats, 27:149
- nialamide, food restriction, rats, 27:149

Clomipramine

- affective disorder, interview behavior, 28:47
- affective disorders, sleep, 30:165
- affective disorder, sleep deprivation, 28:47
- clenbuterol, food restriction, rats, 27:149
- desipramine, food restriction, rats, 27:149
- food restriction, rats, 27:149
- indalpine, food restriction, rats, 27:149
- interview behavior, affective disorder, 28:47
- interview behavior, sleep deprivation, 28:47
- nialamide, food restriction, rats, 27:149
- sleep, affective disorder, 30:165
- sleep deprivation, affective disorder, 28:47
- sleep deprivation, interview behavior, 28:47

Clonidine

- affective disorder, Alzheimer's disease, 27:277
- affective disorder, antidepressants, 28:73
- affective disorder, growth hormone, 27:277
- affective disorder, growth hormone, 29:199
- affective disorder, lithium, 28:73
- affective disorder, schizophrenia, 28:73
- Alzheimer's disease, affective disorder, 27:277
- Alzheimer's disease, growth hormone, 27:277
- antidepressants, affective disorder, 28:73
- antidepressants, lithium, 28:73
- antidepressants, schizophrenia, 28:73
- binding in platelets, 28:73
- evoked potentials, 28:255
- growth hormone, affective disorder, 27:277, 29:199
- growth hormone, Alzheimer's disease, 27:277
- growth hormone, 3-methoxy-4-hydroxyphenylglycol, 27:297
- growth hormone, norepinephrine, 27:297
- growth hormone, schizophrenia, 27:297
- growth hormone, treatment response prediction, 27:297
- lithium, affective disorder, 28:73

Clonidine continued

- lithium, antidepressants, 28:73
- lithium, schizophrenia, 28:73
- 3-methoxy-4-hydroxyphenylglycol, growth hormone, 27:297
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:297
- 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 27:297
- 3-methoxy-4-hydroxyphenylglycol, treatment response prediction, 27:297
- norepinephrine, growth hormone, 27:297
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:297
- norepinephrine, schizophrenia, 27:297
- norepinephrine, treatment response prediction, 27:297
- P300, evoked potentials, 28:255
- schizophrenia, affective disorder, 28:73
- schizophrenia, antidepressants, 28:73
- schizophrenia, growth hormone, 27:297
- schizophrenia, lithium, 28:73
- schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 27:297
- schizophrenia, norepinephrine, 27:297
- schizophrenia, treatment response prediction, 27:297
- treatment response prediction, growth hormone, 27:297
- treatment response prediction, 3-methoxy-4-hydroxyphenylglycol, 27:297
- treatment response prediction, norepinephrine, 27:297
- treatment response prediction, schizophrenia, 27:297

Cocaine

- affective disorder, comorbidity, 28:105, 28:335
- alcoholism, comorbidity, 29:113
- alcoholism, genetics, 29:113
- amantadine, bromocriptine, 29:11
- amantadine, withdrawal, 29:11
- blood pressure, haloperidol, 27:117
- blood pressure, heart rate, 27:117
- blood pressure, subjective effects, 27:117
- blood pressure, substance abuse, 27:117
- bromocriptine, amantadine, 29:11
- bromocriptine, withdrawal, 29:11
- comorbidity, affective disorder, 28:105, 28:335
- comorbidity, alcoholism, 29:113
- comorbidity, genetics, 29:113
- eye movements, 3-methoxy-4-hydroxyphenylglycol, 29:123
- genetics, alcoholism, 29:113

Cocaine continued

- genetics, comorbidity, 29:113
- haloperidol, blood pressure, 27:117
- haloperidol, heart rate, 27:117
- haloperidol, subjective effects, 27:117
- heart rate, blood pressure, 27:117
- heart rate, haloperidol, 27:117
- heart rate, subjective effects, 27:117
- 3-methoxy-4-hydroxyphenylglycol, eye movements, 29:123
- subjective effects, blood pressure, 27:117
- subjective effects, haloperidol, 27:117
- subjective effects, heart rate, 27:117
- withdrawal, amantadine, 29:11
- withdrawal, bromocriptine, 29:11

Computed tomography

- affective disorder, psychotic symptoms, 29:221
- affective disorder, symptomatology, 29:271
- affective disorder, ventricle-brain ratio, 29:271
- alcoholism, cerebrospinal fluid volumetry, 29:277
- alcoholism, growth hormone, 28:89
- alcoholism, magnetic resonance imaging, 29:277
- Alzheimer's disease, dementia, 29:445
- Alzheimer's disease, positron emission tomography, 29:359
- Alzheimer's disease, single photon emission computed tomography, 29:445
- Alzheimer's disease, white matter, 29:359
- attention, laterality, 29:267
- attention, schizophrenia, 29:267
- attention, ventricle-brain ratio, 29:267
- beta-hydroxybutyric acid, ventricle-brain ratio, 27:39
- borderline personality disorder, 27:111
- brain atlas, EEG mapping, 29:461
- bulimia nervosa, 27:39
- cerebral ischemia, single photon emission computed tomography, 29:457
- cortisol, ventricle-brain ratio, 27:39
- cerebrospinal fluid volumetry, alcoholism, 29:277
- cerebrospinal fluid volumetry, magnetic resonance imaging, 29:277
- dementia, Alzheimer's disease, 29:445
- dementia, single photon emission computed tomography, 29:445
- diencephalic lesions, magnetic resonance imaging, 29:285
- eating disorders, ventricle-brain ratio, 27:39

Computed tomography continued

- EEG focus, magnetic resonance imaging, 29:459
- EEG focus, seizures, 29:459
- EEG focus, single photon emission computed tomography, 29:459
- EEG mapping, brain atlas, 29:461
- electroencephalogram, frontal lobe, 29:137
- electroencephalogram, schizophrenia, 29:137
- electroencephalogram, Wisconsin Card Sort Test, 29:137
- embolic mechanisms, stroke, 29:273
- frontal lobe, electroencephalogram, 29:137
- frontal lobe, schizophrenia, 29:137
- frontal lobe, Wisconsin Card Sort Test, 29:137
- laterality, attention, 29:267
- laterality, schizophrenia, 29:247, 29:267
- laterality, ventricle-brain ratio, 29:267
- limbic system, schizophrenia, 29:255
- lupus erythematosus, magnetic resonance imaging, 29:367
- lupus erythematosus, positron emission tomography, 29:367
- magnetic resonance imaging, alcoholism, 29:277
- magnetic resonance imaging, cerebrospinal fluid volumetry, 29:277
- magnetic resonance imaging, diencephalic lesions, 29:285
- magnetic resonance imaging, EEG focus, 29:459
- magnetic resonance imaging, lupus erythematosus, 29:367
- magnetic resonance imaging, positron emission tomography, 29:363, 29:367
- magnetic resonance imaging, schizophrenia, 29:265
- magnetic resonance imaging, seizures, 29:459
- magnetic resonance imaging, single photon emission computed tomography, 29:459
- magnetic resonance imaging, thalamic infarction, 29:363
- magnetic resonance imaging, ventricle-brain ratio, 29:265
- positron emission tomography, Alzheimer's disease, 29:359
- positron emission tomography, lupus erythematosus, 29:367
- positron emission tomography, magnetic resonance imaging, 29:363, 29:367
- positron emission tomography, thalamic infarction, 29:363

Computed tomography continued

- positron emission tomography, white matter, 29:359
- psychotic symptoms, affective disorder, 29:221
- schizophrenia, attention, 29:267
- schizophrenia, electroencephalogram, 29:137
- schizophrenia, frontal lobe, 29:137
- schizophrenia, laterality, 29:247, 29:267
- schizophrenia, limbic system, 29:255
- schizophrenia, magnetic resonance imaging, 29:265
- schizophrenia, ventricle-brain ratio, 29:257, 29:265, 29:267
- schizophrenia, Wisconsin Card Sort Test, 29:137
- seizures, EEG focus, 29:459
- seizures, magnetic resonance imaging, 29:459
- seizures, single photon emission computed tomography, 29:459
- single photon emission computed tomography, Alzheimer's disease, 29:445
- single photon emission computed tomography, cerebral ischemia, 29:457
- single photon emission computed tomography, dementia, 29:445
- single photon emission computed tomography, EEG focus, 29:459
- single photon emission computed tomography, magnetic resonance imaging, 29:459
- single photon emission computed tomography, seizures, 29:459
- stroke, embolic mechanisms, 29:273
- symptomatology, affective disorders, 29:271
- symptomatology, ventricle-brain ratio, 29:271
- thalamic infarction, magnetic resonance imaging, 29:363
- thalamic infarction, positron emission tomography, 29:363
- third ventricle size, borderline personality disorder, 27:111
- triiodothyronine, ventricle-brain ratio, 27:39
- ventricle-brain ratio, affective disorders, 29:271
- ventricle-brain ratio, attention, 29:267
- ventricle-brain ratio, beta-hydroxybutyric acid, 27:39
- ventricle-brain ratio, borderline personality disorder, 27:111

Computed tomography continued

- ventricle-brain ratio, bulimia nervosa, 27:39
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, eating disorders, 27:39
- ventricle-brain ratio, laterality, 29:267
- ventricle-brain ratio, magnetic resonance imaging, 29:265
- ventricle-brain ratio, schizophrenia, 29:257, 29:265, 29:267
- ventricle-brain ratio, symptomatology, 29:271
- ventricle-brain ratio, triiodothyronine, 27:39
- Wisconsin Card Sort Test, electroencephalogram, 29:137
- Wisconsin Card Sort Test, frontal lobe, 29:137
- Wisconsin Card Sort Test, schizophrenia, 29:137
- white matter, Alzheimer's disease, 29:359
- white matter, positron emission tomography, 29:359

Conduct disorder. See also Attention deficit disorder

- attention deficit disorder, catecholamines, 27:241
- attention deficit disorder, dopamine-beta-hydroxylase, 27:241
- attention deficit disorder, 3-methoxy-4-hydroxyphenylglycol, 27:241
- attention deficit disorder, norepinephrine, 27:241
- case report, 5-hydroxyindolacetic acid, 28:115
- case report, cruelty to animals, 28:115
- catecholamines, attention deficit disorder, 27:241
- catecholamines, dopamine-beta-hydroxylase, 27:241
- catecholamines, norepinephrine, 27:241
- cruelty to animals, 5-hydroxyindolacetic acid, 28:115
- cruelty to animals, case report, 28:115
- dopamine-beta-hydroxylase, attention deficit disorder, 27:241
- dopamine-beta-hydroxylase, catecholamines, 27:241
- dopamine-beta-hydroxylase, norepinephrine, 27:241
- 5-hydroxyindole acetic acid, case report, 28:115
- 5-hydroxyindole acetic acid, cruelty to animals, 28:115

Conduct disorder continued

- 3-methoxy-4-hydroxyphenylglycol, attention deficit disorder, 27:241
- norepinephrine, attention deficit disorder, 27:241
- norepinephrine, catecholamines, 27:241
- norepinephrine, dopamine-beta-hydroxylase, 27:241

Continuous performance test

- affective disorder, attention, 29:65
- affective disorder, laterality, 29:65
- affective disorder, schizophrenia, 29:65
- laterality, affective disorder, 29:65
- laterality, attention, 29:65
- laterality, schizophrenia, 29:65
- schizophrenia, attention, 29:65
- schizophrenia, laterality, 29:65

Corticotropin releasing hormone

- gamma-aminobutyric acid, gambling, 30:137
- gamma-aminobutyric acid, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gamma-aminobutyric acid, neuropeptides, 30:137
- gamma-aminobutyric acid, norepinephrine, 30:137
- gambling, gamma-aminobutyric acid, 30:137
- gambling, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gambling, neuropeptides, 30:137
- gambling, norepinephrine, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gambling, 30:137
- 3-methoxy-4-hydroxyphenylglycol, neuropeptides, 30:137
- neuropeptides, gamma-aminobutyric acid, 30:137
- neuropeptides, gambling, 30:137
- neuropeptides, 3-methoxy-4-hydroxyphenylglycol, 30:137
- neuropeptides, norepinephrine, 30:137
- norepinephrine, gambling, 30:137

Cortisol

- adolescents, affective disorder, 27:101
- adolescents, 3-methoxy-4-hydroxyphenylglycol, 27:101
- adolescents, norepinephrine, 27:101
- affective disorder, adolescents, 27:101
- affective disorder, dexamethasone suppression test, 27:161, 29:187
- affective disorder, dopamine, 29:187
- affective disorder, epinephrine, 29:187
- affective disorder, 3-methoxy-4-hydroxyphenylglycol, 27:101

Cortisol continued

- affective disorder, norepinephrine, 27:101, 29:187
- affective disorders, circadian rhythms, 28:263
- affective disorders, cyclic adenosine monophosphate, 30:181
- affective disorders, dihydroergocryptine, 30:181
- affective disorders, melatonin, 28:263
- affective disorders, norepinephrine, 28:263
- affective disorders, prostaglandin, 30:181
- affective disorders, temperature, 28:263
- affective disorders, thyroid stimulating hormone, 28:263
- age, chlorophenylpiperazine, 29:1
- age, prolactin, 29:1
- age, serotonin, 29:1
- alcoholism, dexamethasone suppression test, 30:217
- alcoholism, liver function, 30:217
- Alzheimer's disease, dexamethasone suppression test, 29:169
- Alzheimer's disease, gender, 29:169
- beta-hydroxybutyric acid, computed tomography, 27:39
- beta-hydroxybutyric acid, eating disorders, 27:39
- beta-hydroxybutyric acid, triiodothyronine, 27:39
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, heart rate, 27:173
- blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173
- blood pressure, norepinephrine, 27:173
- blood pressure, yohimbine, 27:173
- chlorophenylpiperazine, age, 29:1
- chlorophenylpiperazine, prolactin, 29:1
- chlorophenylpiperazine, serotonin, 29:1
- circadian rhythms, affective disorders, 28:263
- circadian rhythms, melatonin, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, temperature, 28:263
- circadian rhythms, thyroid stimulating hormone, 28:263
- computed tomography, beta-hydroxybutyric acid, 27:39
- computed tomography, eating disorders, 27:39
- computed tomography, triiodothyronine, 27:39
- computed tomography, ventricle-brain ratio, 27:39

Cortisol continued

cyclic adenosine monophosphate, affective disorders, dihydroergocryptine, prostaglandin, 30:181
 dehydroepiandrosterone, panic disorder, 28:345
 dexamethasone suppression test, affective disorder, 27:161, 29:187
 dexamethasone suppression test, alcoholism, 30:217
 dexamethasone suppression test, Alzheimer's disease, 29:169
 dexamethasone suppression test, dopamine, 29:187
 dexamethasone suppression test, epinephrine, 29:187
 dexamethasone suppression test, gender, 29:169
 dexamethasone suppression test, liver function, 30:217
 dexamethasone suppression test, negative symptoms, 30:69
 dexamethasone suppression test, norepinephrine, 29:187
 dexamethasone suppression test, obsessive-compulsive 30:243,
 dexamethasone suppression test, panic disorder, 30:243
 dexamethasone suppression test, schizophrenia, 30:69
 dihydroergocryptine, affective disorders, 30:181
 dihydroergocryptine, cyclic adenosine monophosphate, 30:181
 dihydroergocryptine, prostaglandin, 30:181
 dopamine, affective disorder, 29:187
 dopamine, dexamethasone suppression test, 29:187
 dopamine, epinephrine, 29:187
 dopamine, norepinephrine, 29:187
 eating disorders, beta-hydroxybutyric acid, 27:39
 eating disorders, computed tomography, 27:39
 eating disorders, estradiol, 29:105
 eating disorders, osteoporosis, 29:105
 eating disorders, triiodothyronine, 27:39
 eating disorders, ventricle-brain ratio, 27:39
 epinephrine, affective disorder, 29:187
 epinephrine, dexamethasone suppression test, 29:187
 epinephrine, dopamine, 29:187
 epinephrine, norepinephrine, 29:187
 estradiol, eating disorders, 29:105

Cortisol continued

estradiol, osteoporosis, 29:105
 gender, Alzheimer's disease, 29:169
 gender, dexamethasone suppression test, 29:169
 generalized anxiety disorder, blood pressure, 27:173
 generalized anxiety disorder, heart rate, 27:173
 generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173
 generalized anxiety disorder, norepinephrine, 27:173
 generalized anxiety disorder, yohimbine, 27:173
 growth hormone, panic disorder, 28:351
 growth hormone, prolactin, 28:351
 growth hormone, syncope, 28:351
 heart rate, blood pressure, 27:173
 heart rate, generalized anxiety disorder, 27:173
 heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173
 heart rate, norepinephrine, 27:173
 heart rate, yohimbine, 27:173
 liver function, alcoholism, 30:217
 liver function, dexamethasone suppression test, 30:217
 melatonin, affective disorders, 28:263
 melatonin, circadian rhythms, 28:263
 melatonin, norepinephrine, 28:263
 melatonin, temperature, 28:263
 melatonin, thyroid stimulating hormone, 28:263
 3-methoxy-4-hydroxyphenylglycol, adolescents, 27:101
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 27:101
 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173
 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173
 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:101, 27:173
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173
 negative symptoms, dexamethasone suppression test, 30:69
 negative symptoms, schizophrenia, 30:69
 norepinephrine, adolescents, 27:101
 norepinephrine, affective disorder, 27:101, 28:263, 29:187
 norepinephrine, blood pressure, 27:173

Cortisol continued

norepinephrine, circadian rhythms, 28:263
 norepinephrine, dexamethasone suppression test, 29:187
 norepinephrine, dopamine, 29:187
 norepinephrine, epinephrine, 29:187
 norepinephrine, generalized anxiety disorder, 27:173
 norepinephrine, heart rate, 27:173
 norepinephrine, melatonin, 28:263
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:101, 27:173
 norepinephrine, temperature, 28:263
 norepinephrine, thyroid stimulating hormone, 28:263
 norepinephrine, yohimbine, 27:173
 obsessive-compulsive disorder, dexamethasone suppression test, 30:243
 osteoporosis, eating disorders, 29:105
 osteoporosis, estradiol, 29:105
 panic disorder, dehydroepiandrosterone, 28:345
 panic disorder, dexamethasone suppression test, 30:243
 panic disorder, growth hormone, 28:351
 panic disorder, prolactin, 28:351
 panic disorder, syncope, 28:351
 prolactin, age, 29:1
 prolactin, chlorophenylpiperazine, 29:1
 prolactin, growth hormone, 28:351
 prolactin, panic disorder, 28:351
 prolactin, serotonin, 29:1
 prolactin, syncope, 28:351
 prostaglandin, affective disorders, 30:181
 prostaglandin, cyclic adenosine monophosphate, 30:181
 prostaglandin, dihydroergocryptine, 30:181
 schizophrenia, dexamethasone suppression test, 30:69
 schizophrenia, negative symptoms, 30:69
 serotonin, age, 29:1
 serotonin, chlorophenylpiperazine, 29:1
 serotonin, prolactin, 29:1
 syncope, growth hormone, 28:351
 syncope, panic disorder, 28:351
 syncope, prolactin, 28:351
 temperature, affective disorder, 28:263
 temperature, circadian rhythms, 28:263
 temperature, melatonin, 28:263
 temperature, norepinephrine, 28:263
 temperature, thyroid stimulating hormone, 28:263
 thyroid stimulating hormone, affective disorder, 28:263

Cortisol continued

thyroid stimulating hormone, circadian rhythms, 28:263
 thyroid stimulating hormone, melatonin, 28:263
 thyroid stimulating hormone, norepinephrine, 28:263
 thyroid stimulating hormone, temperature, 28:263
 triiodothyronine, beta-hydroxybutyric acid, 27:39
 triiodothyronine, computed tomography, 27:39
 triiodothyronine, eating disorders, 27:39
 triiodothyronine, ventricle-brain ratio, 27:39
 ventricle-brain ratio, beta-hydroxybutyric acid, 27:39
 ventricle-brain ratio, computed tomography, 27:39
 ventricle-brain ratio, eating disorders, 27:39
 ventricle-brain ratio, triiodothyronine, 27:39
 yohimbine, blood pressure, 27:173
 yohimbine, generalized anxiety disorder, 27:173
 yohimbine, heart rate, 27:173
 yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173
 yohimbine, norepinephrine, 27:173

Dehydroepiandrosterone-sulfate

panic disorder, cortisol, 28:345

Dementia. See also Alzheimer's disease

Alzheimer's disease, computed tomography, 29:445
 Alzheimer's disease, single photon emission computed tomography, 29:445
 cerebral blood flow, single photon emission computed tomography, 29:327
 cerebral blood flow, xenon inhalation, 29:297
 computed tomography, Alzheimer's disease, 29:445
 computed tomography, single photon emission computed tomography, 29:445
 deoxyglucose, positron emission tomography, 29:353
 EEG mapping, evoked potentials, 29:391
 EEG mapping, P300, 29:391
 EEG mapping, schizophrenia, 29:391
 evoked potentials, EEG mapping, 29:391
 evoked potentials, P300, 29:391
 evoked potentials, schizophrenia, 29:391

Dementia continued

- P300, EEG mapping, 29:391
- P300, evoked potentials, 29:391
- P300, schizophrenia, 29:391
- positron emission tomography, deoxy-glucose, 29:353
- schizophrenia, EEG mapping, 29:391
- schizophrenia, evoked potentials, 29:391
- schizophrenia, P300, 29:391
- single photon emission computed tomography, Alzheimer's disease, 29:445
- single photon emission computed tomography, cerebral blood flow, 29:327
- single photon emission computed tomography, computed tomography, 29:445
- xenon inhalation, cerebral blood flow, 29:297

Dermatoglyphics

- genetics, schizophrenia, 29:37
- schizophrenia, genetics, 29:37
- schizophrenia, twins, 29:37
- twins, schizophrenia, 29:37

Desipramine

- clenbuterol, food restriction, rats, 27:149
- clomipramine, food restriction, rats, 27:149
- food restriction, rats, 27:149
- frontal lobe, imipramine binding, 30:125
- frontal lobe, serotonin, 30:125
- frontal lobe, suicide, 30:125
- imipramine binding, frontal lobe, 30:125
- imipramine binding, serotonin, 30:125
- imipramine binding, suicide, 30:125
- indalpine, food restriction, rats, 27:149
- nialamide, food restriction, rats, 27:149
- serotonin, frontal lobe, 30:125
- serotonin, imipramine binding, 30:125
- serotonin, suicide, 30:125
- suicide, frontal lobe, 30:125
- suicide, imipramine binding, 30:125

Dexamethasone suppression test

- affective disorder, children, 29:215
- affective disorder, cholesterol, 29:215
- affective disorder, circannual rhythms, 29:87
- affective disorder, cortisol, 27:161, 29:187
- affective disorder, dopamine, 29:187
- affective disorder, epinephrine, 29:187
- affective disorder, glucose, 29:215
- affective disorder, homovanillic acid, 29:177
- affective disorder, imipramine binding, 29:87
- affective disorder, norepinephrine, 29:187

Dexamethasone suppression test continued

- affective disorder, potassium, 29:215
- affective disorder, sodium, 29:215
- alcoholism, cortisol, 30:217
- alcoholism, liver function, 30:217
- Alzheimer's disease, cortisol, 29:169
- Alzheimer's disease, gender, 29:169
- children, affective disorder, 29:215
- children, cholesterol, 29:215
- children, glucose, 29:215
- children, potassium, 29:215
- children, sodium, 29:215
- cholesterol, affective disorder, 29:215
- cholesterol, children, 29:215
- cholesterol, glucose, 29:215
- circannual rhythms, affective disorder, 29:87
- circannual rhythms, imipramine binding, 29:87
- cortisol, affective disorder, 27:161, 29:187
- cortisol, alcoholism, 30:217
- cortisol, Alzheimer's disease, 29:169
- cortisol, dopamine, 29:187
- cortisol, epinephrine, 29:187
- cortisol, gender, 29:169
- cortisol, liver function, 30:217
- cortisol, negative symptoms, 30:69
- cortisol, norepinephrine, 29:187
- cortisol, obsessive-compulsive disorder, 30:243
- cortisol, panic disorder, 30:243
- cortisol, schizophrenia, 30:69
- dopamine, affective disorder, 29:187
- dopamine, cortisol, 29:187
- dopamine, epinephrine, 29:187
- dopamine, norepinephrine, 29:187
- epinephrine, affective disorder, 29:187
- epinephrine, cortisol, 29:187
- epinephrine, dopamine, 29:187
- epinephrine, norepinephrine, 29:187
- gender, Alzheimer's disease, 29:169
- gender, cortisol, 29:169
- glucose, affective disorder, 29:215
- glucose, children, 29:215
- glucose, cholesterol, 29:215
- homovanillic acid, affective disorder, 29:177
- imipramine binding, affective disorder, 29:87
- imipramine binding, circannual rhythms, 29:87
- liver function, alcoholism, 30:217
- liver function, cortisol, 30:217
- negative symptoms, cortisol, 30:69

Dexamethasone suppression test continued

- negative symptoms, schizophrenia, 30:69
- norepinephrine, affective disorder, 29:187
- norepinephrine, cortisol, 29:187
- norepinephrine, dopamine, 29:187
- obsessive-compulsive disorder, cortisol, 30:243
- panic disorder, cortisol, 30:243
- potassium, affective disorder, 29:215
- potassium, children, 29:215
- potassium, cholesterol, 29:215
- potassium, glucose, 29:215
- schizophrenia, cortisol, 30:69
- schizophrenia, negative symptoms, 30:69
- sodium, affective disorder, 29:215
- sodium, children, 29:215

Diabetes

- glucose tolerance, haloperidol, 29:17
- glucose tolerance, schizophrenia, 29:17
- glucose tolerance, tardive dyskinesia, 29:17
- haloperidol, glucose tolerance, 29:17
- haloperidol, schizophrenia, 29:17
- haloperidol, tardive dyskinesia, 29:17
- schizophrenia, glucose tolerance, 29:17
- schizophrenia, haloperidol, 29:17
- schizophrenia, tardive dyskinesia, 29:17
- tardive dyskinesia, glucose tolerance, 29:17
- tardive dyskinesia, haloperidol, 29:17
- tardive dyskinesia, schizophrenia, 29:17

Diagnostic criteria

- affective disorders, antidepressants, 30:83
- affective disorders, treatment response, 30:83
- antidepressants, affective disorders, 30:83
- antidepressants, treatment response, 30:83
- Axis IV, DSM-III, 30:201
- Axis IV, stressors, 30:201
- DSM-III, Axis IV, 30:201
- DSM-III, stressors, 30:201
- personality disorder, self-defeating, 30:145
- self-defeating personality disorder, 30:145
- stressors, Axis IV, 30:201
- stressors, DSM-III, 30:201
- treatment response, affective disorders, 30:83
- treatment response, antidepressants, 30:83

Diazepam

- alprazolam, 3-methoxy-4-hydroxyphenylglycol, 30:53
- alprazolam, panic disorder, 30:53
- alprazolam, treatment response, 30:53
- 3-methoxy-4-hydroxyphenylglycol, panic disorder, 30:53

Diazepam continued

- 3-methoxy-4-hydroxyphenylglycol, treatment response, 30:53
- panic disorder, 3-methoxy-4-hydroxyphenylglycol, 30:53
- panic disorder, treatment response, 30:53
- treatment response, 3-methoxy-4-hydroxyphenylglycol, 30:53
- treatment response, panic disorder, 30:53

Dihydroergocryptine

- affective disorders, cyclic adenosine monophosphate, 30:181
- affective disorders, cortisol, 30:181
- affective disorders, 5-hydroxyindolacetic acid, 30:181
- affective disorders, prostaglandin, 30:181
- affective disorders, serotonin uptake, 30:181
- cortisol, affective disorders, 30:181
- cortisol, cyclic adenosine monophosphate, 30:181
- cortisol, prostaglandin, 30:181
- cyclic adenosine monophosphate, affective disorders, 30:181
- cyclic adenosine monophosphate, cortisol, 30:181
- cyclic adenosine monophosphate, 5-hydroxyindolacetic acid, 30:181
- cyclic adenosine monophosphate, prostaglandin, 30:181
- cyclic adenosine monophosphate, serotonin uptake, 30:181
- 5-hydroxyindolacetic acid, affective disorders, 30:181
- 5-hydroxyindolacetic acid, cyclic adenosine monophosphate, 30:181
- 5-hydroxyindolacetic acid, serotonin uptake, 30:181
- prostaglandin, affective disorders, 30:181
- prostaglandin, cyclic adenosine monophosphate, 30:181
- prostaglandin, cortisol, 30:181
- serotonin uptake, affective disorders, 30:181
- serotonin uptake, cyclic adenosine monophosphate, 30:181
- serotonin uptake, 5-hydroxyindolacetic acid, 30:181

Dopamine

- affective disorder, cortisol, 29:187
- affective disorder, dexamethasone suppression test, 29:187
- affective disorder, epinephrine, 29:187
- affective disorder, norepinephrine, 29:187

Dopamine continued

attention deficit disorder, catecholamines, 27:241
 attention deficit disorder, conduct disorder, 27:241
 attention deficit disorder, norepinephrine, 27:241
 bromospiperone, positron emission tomography, 29:357
 bromospiperone, schizophrenia, 29:357
 butaclamol, lymphocytes, 30:259
 butaclamol, spiperone binding, 30:259
 catecholamines, attention deficit disorder, 27:241
 catecholamines, conduct disorder, 27:241
 catecholamines, norepinephrine, 27:241
 conduct disorder, attention deficit disorder, 27:241
 conduct disorder, catecholamines, 27:241
 conduct disorder, norepinephrine, 27:241
 cortisol, affective disorder, 29:187
 cortisol, dexamethasone suppression test, 29:187
 cortisol, epinephrine, 29:187
 cortisol, norepinephrine, 29:187
 dexamethasone suppression test, affective disorder, 29:187
 dexamethasone suppression test, cortisol, 29:187
 dexamethasone suppression test, epinephrine, 29:187
 dexamethasone suppression test, norepinephrine, 29:187
 epinephrine, affective disorder, 29:187
 epinephrine, cortisol, 29:187
 epinephrine, dexamethasone suppression test, 29:187
 epinephrine, norepinephrine, 29:187
 locus ceruleus, paranoid subtype, 27:31
 locus ceruleus, post-mortem study, 27:31
 locus ceruleus, schizophrenia, 27:31
 lymphocytes, butaclamol, 30:259
 lymphocytes, spiperone binding, 30:259
 norepinephrine, affective disorder, 29:187
 norepinephrine, attention deficit disorder, 27:241
 norepinephrine, catecholamines, 27:241
 norepinephrine, conduct disorder, 27:241
 norepinephrine, cortisol, 29:187
 norepinephrine, epinephrine, 29:187
 paranoid subtype, locus ceruleus, 27:31
 paranoid subtype, post-mortem study, 27:31
 paranoid subtype, schizophrenia, 27:31

Dopamine continued

positron emission tomography, bromospiperone, 29:357
 positron emission tomography, schizophrenia, 29:357
 post-mortem study, locus ceruleus, 27:31
 post-mortem study, paranoid subtype, 27:31
 post-mortem study, schizophrenia, 27:31
 schizophrenia, bromospiperone, 29:357
 schizophrenia, locus ceruleus, 27:31
 schizophrenia, paranoid subtype, 27:31
 schizophrenia, positron emission tomography, 29:357
 schizophrenia, post-mortem study, 27:31
 spiperone binding, butaclamol, 30:259
 spiperone binding, lymphocytes, 30:259

DSM-III

Axis IV, diagnostic criteria, 30:201
 Axis IV, stressors, 30:201
 diagnostic criteria, Axis IV, 30:201
 diagnostic criteria, stressors, 30:201
 life events, Psychiatric Epidemiology Research Interview, 30:201
 Psychiatric Epidemiology Research Interview, life events, 30:201
 stressors, Axis IV, 30:201
 stressors, diagnostic criteria, 30:201

Dyslexia

dyseidetic children, EEG mapping, 29:407
 EEG mapping, dyseidetic children, 29:407

Eating disorders

beta-hydroxybutyric acid, computed tomography, 27:39
 beta-hydroxybutyric acid, cortisol, 27:39
 beta-hydroxybutyric acid, triiodothyronine, 27:39
 beta-hydroxybutyric acid, ventricle-brain ratio, 27:39
 blood pressure, heart rate, 30:223
 blood pressure, stressors, 30:223
 blood pressure, Type A behavior, 30:223
 cocaine, comorbidity, 28:105
 comorbidity, cocaine, 28:105
 computed tomography, beta-hydroxybutyric acid, 27:39
 computed tomography, cortisol, 27:39
 computed tomography, triiodothyronine, 27:39
 computed tomography, ventricle-brain ratio, 27:39
 cortisol, beta-hydroxybutyric acid, 27:39
 cortisol, computed tomography, 27:39
 cortisol, estradiol, 29:105

Eating disorders continued

- cortisol, osteoporosis, 29:105
- cortisol, triiodothyronine, 27:39
- cortisol, ventricle-brain ratio, 27:39
- estradiol, cortisol, 29:105
- estradiol, osteoporosis, 29:105
- follicle stimulating hormone, luteinizing hormone, 28:11
- gonadotropin releasing hormone, luteinizing hormone, 28:11
- gonadotropin releasing hormone, menstrual cycle, 28:11
- heart rate, blood pressure, 30:223
- heart rate, stressors, 30:223
- heart rate, Type A behavior, 30:223
- imipramine binding, platelet, 30:21
- luteinizing hormone, follicle stimulating hormone, 28:11
- luteinizing hormone, gonadotropin releasing hormone, 28:11
- luteinizing hormone, menstrual cycle, 28:11
- menstrual cycle, gonadotropin releasing hormone, 28:11
- menstrual cycle, luteinizing hormone, 28:11
- osteoporosis, cortisol, 29:105
- osteoporosis, estradiol, 29:105
- stressors, blood pressure, 30:223
- stressors, heart rate, 30:223
- stressors, Type A behavior, 30:223
- triiodothyronine, beta-hydroxybutyric acid, 27:39
- triiodothyronine, computed tomography, 27:39
- triiodothyronine, cortisol, 27:39
- triiodothyronine, ventricle-brain ratio, 27:39
- Type A behavior, blood pressure, 30:223
- Type A behavior, heart rate, 30:223
- Type A behavior, stressors, 30:223
- ventricle-brain ratio, beta-hydroxybutyric acid, 27:39
- ventricle-brain ratio, computed tomography, 27:39
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, triiodothyronine, 27:39

Electroencephalogram

- alpha, photic driving, 30:313
- alpha, schizophrenia, 30:313
- brain electrical activity mapping, cognitive functions, 29:385

Electroencephalogram continued

- brain electrical activity mapping, evoked potentials, 29:379
- cognitive functions, brain electrical activity mapping, 29:385
- computed tomography, frontal lobe, 29:137
- computed tomography, schizophrenia, 29:137
- computed tomography, Wisconsin Card Sort Test, 29:137
- evoked potentials, brain electrical activity mapping, 29:379
- frontal lobe, computed tomography, 29:137
- frontal lobe, schizophrenia, 29:137
- frontal lobe, Wisconsin Card Sort Test, 29:137
- neuroleptics, schizophrenia, 29:395
- photic driving, schizophrenia, 30:313
- schizophrenia, alpha, 30:313
- schizophrenia, computed tomography, 29:137
- schizophrenia, frontal lobe, 29:137
- schizophrenia, neuroleptics, 29:395
- schizophrenia, photic driving, 30:313
- schizophrenia, thalamus, 30:313
- schizophrenia, Wisconsin Card Sort Test, 29:137
- thalamus, alpha, 30:313
- thalamus, schizophrenia, 30:313
- Wisconsin Card Sort Test, computed tomography, 29:137
- Wisconsin Card Sort Test, frontal lobe, 29:137
- Wisconsin Card Sort Test, schizophrenia, 29:137

Electroencephalographic (EEG) topography

- affective disorders, Alzheimer's disease, 29:403
- affective disorders, evoked potentials, 29:403
- algorithm, spatial interpolation, 29:431
- Alzheimer's disease, affective disorders, 29:403
- Alzheimer's disease, cognitive impairment, 29:409
- Alzheimer's disease, disease severity, 29:399
- Alzheimer's disease, evoked potentials, 29:403
- Alzheimer's disease, phosphatidylserine, 29:411

Electroencephalographic (EEG)**topography continued**

Alzheimer's disease, single photon emission computed tomography, 29:449
 arachnoid cyst, evoked potentials, P300, 29:421
 arachnoid cyst, schizophrenia, 29:421
 auditory and visual paradigm, evoked potentials, P300, 29:439
 auditory and visual paradigm, semantic tasks, 29:439
 autogenic training, beta reduction, 29:433
 beta reduction, autogenic training, 29:433
 brain atlas, computed tomography, 29:461
 cognitive function, electroencephalography, 29:385
 cognitive function, pyritinol, 29:387
 cognitive impairment, Alzheimer's disease, 29:409
 computed tomography, brain atlas, 29:461
 dementia, evoked potentials, P300, 29:391
 dementia, schizophrenia, 29:391
 disease severity, Alzheimer's disease, 29:399
 dyseidetic children, dyslexia, 29:407
 dyslexia, dyseidetic children, 29:407
 elderly subjects, affective disorders, 29:403
 elderly subjects, Alzheimer's disease, 29:403
 elderly subjects, evoked potentials, 29:403
 electroencephalography, cognitive function, 29:385
 electroencephalography, evoked potentials, 29:379
 evoked potentials, affective disorders, 29:403
 evoked potentials, Alzheimer's disease, 29:403
 evoked potentials, arachnoid cyst, 29:421
 evoked potentials, auditory and visual paradigm, 29:439
 evoked potentials, dementia, 29:391
 evoked potentials, elderly subjects, 29:403
 evoked potentials, electroencephalography, 29:379
 evoked potentials, P300, 29:391, 29:413, 29:421, 29:439
 evoked potentials, pyritinol, 29:413
 evoked potentials, schizophrenia, 29:391, 29:421
 evoked potentials, semantic tasks, 29:439
 Gilles de la Tourette syndrome, normal comparison, 29:427
 K complex, sleep, 29:435

Electroencephalographic (EEG)**topography continued**

normal volunteers, phosphatidylserine, 29:417
 normal comparison, Gilles de la Tourette syndrome, 29:427
 olfactory stimulation, trigeminal stimulants, 29:429
 P300, arachnoid cyst, 29:421
 P300, auditory and visual paradigm, 29:439
 P300, dementia, 29:391
 P300, evoked potentials, 29:391, 29:413, 29:421, 29:439
 P300, pyritinol, 29:413
 P300, schizophrenia, 29:391, 29:421
 P300, semantic tasks, 29:439
 phosphatidylserine, Alzheimer's disease, 29:411
 phosphatidylserine, normal volunteers, 29:417
 pyritinol, cognitive function, 29:387
 pyritinol, evoked potentials, P300, 29:413
 Rett syndrome, theta activity, 29:425
 Scale for the Assessment of Negative Symptoms, schizophrenia, 29:137
 schizophrenia, arachnoid cyst, 29:421
 schizophrenia, dementia, 29:391
 schizophrenia, evoked potentials, 29:391, 29:421
 schizophrenia, P300, 29:391, 29:421
 schizophrenia, temporal lobe beta, 29:419
 schizophrenia, Scale for the Assessment of Negative Symptoms, 29:137
 semantic tasks, auditory and visual paradigm, 29:439
 semantic tasks, evoked potential, 29:439
 semantic tasks, P300, 29:439
 sleep, K complex, 29:435
 spatial interpolation, algorithm, 29:431
 single photon emission computed tomography, Alzheimer's disease, 29:449
 temporal lobe beta, schizophrenia, 29:419
 theta activity, Rett syndrome, 29:425
 trigeminal stimulants, olfactory stimulation, 29:429

Electroconvulsive therapy

blood-brain barrier, hypoglycemia, rats, 29:151
 hypoglycemia, blood-brain barrier, rats, 29:151

Epinephrine

affective disorder, cortisol, 29:187
 affective disorder, dexamethasone suppression test, 29:187

Epinephrine continued

- affective disorder, dopamine, 29:187
- affective disorder, norepinephrine, 29:187
- cortisol, affective disorder, 29:187
- cortisol, dexamethasone suppression test, 29:187
- cortisol, dopamine, 29:187
- cortisol, norepinephrine, 29:187
- dexamethasone suppression test, affective disorder, 29:187
- dexamethasone suppression test, cortisol, 29:187
- dexamethasone suppression test, norepinephrine, 29:187
- dopamine, affective disorder, 29:187
- dopamine, dexamethasone suppression test, 29:187
- dopamine, norepinephrine, 29:187
- norepinephrine, affective disorder, 29:187
- norepinephrine, cortisol, 29:187
- norepinephrine, dexamethasone suppression test, 29:187

Essential fatty acids

- linoleic acid, tardive dyskinesia, 27:313
- tardive dyskinesia, linoleic acid, 27:313

Estradiol

- cortisol, eating disorders, 29:105
- cortisol, osteoporosis, 29:105
- eating disorders, cortisol, 29:105
- osteoporosis, eating disorders, 29:105

Evoked potentials

- affective disorders, Alzheimer's disease, 29:403
- affective disorders, EEG mapping, 29:403
- affective disorders, elderly subjects, 29:403
- Alzheimer's disease, affective disorders, 29:403
- Alzheimer's disease, EEG mapping, 29:403
- Alzheimer's disease, elderly subjects, 29:403
- arachnoid cyst, EEG mapping, 29:421
- arachnoid cyst, P300, 29:421
- arachnoid cyst, schizophrenia, 29:421
- auditory and visual paradigm, EEG mapping, 29:439
- auditory and visual paradigm, P300, 29:439
- auditory and visual paradigm, semantic tasks, 29:439
- auditory stimuli, magnetoencephalography, 29:369
- brain electrical activity mapping, electroencephalography, 29:379
- clonidine, P300, 28:255
- dementia, EEG mapping, 29:391

Evoked potentials continued

- dementia, P300, 29:391
- dementia, schizophrenia, 29:391
- EEG mapping, affective disorder, 29:403
- EEG mapping, Alzheimer's disease, 29:403
- EEG mapping, arachnoid cyst, 29:421
- EEG mapping, auditory and visual paradigm, 29:439
- EEG mapping, dementia, 29:391
- EEG mapping, elderly subjects, 29:403
- EEG mapping, P300, 29:391, 29:413, 29:421, 29:439
- EEG mapping, pyritinol, 29:413
- EEG mapping, schizophrenia, 29:391, 29:421
- EEG mapping, semantic tasks, 29:439
- elderly subjects, affective disorders, 29:403
- elderly subjects, Alzheimer's disease, 29:403
- elderly subjects, EEG mapping, 29:403
- electroencephalography, brain electrical activity mapping, 29:379
- frontal lobe, obsessive-compulsive disorder, 28:63
- frontal lobe, P300, 28:63
- magnetoencephalography, auditory stimuli, 29:369
- obsessive-compulsive disorder, frontal lobe, 28:63
- obsessive-compulsive disorder, P300, 28:63
- P300, arachnoid cyst, 29:421
- P300, auditory and visual paradigm, 29:439
- P300, clonidine, 28:255
- P300, dementia, 29:391
- P300, EEG mapping, 29:391, 29:413, 29:421, 29:439
- P300, frontal lobe, 28:63
- P300, obsessive-compulsive disorder, 28:63
- P300, pyritinol, 29:413
- P300, schizophrenia, 29:391, 29:421
- P300, semantic tasks, 29:439
- pyritinol, EEG mapping, 29:413
- pyritinol, P300, 29:413
- schizophrenia, arachnoid cyst, 29:421
- schizophrenia, dementia, 29:391
- schizophrenia, EEG mapping, 29:391, 29:421
- schizophrenia, P300, 29:391, 29:421
- schizophrenia, tardive dyskinesia, 28:117
- semantic tasks, auditory and visual paradigm, 29:439
- semantic tasks, EEG mapping, 29:439
- semantic tasks, P300, 29:439
- tardive dyskinesia, schizophrenia, 28:117

Eye movements

- attention, clinical stabilization, 28:31
- attention, schizophrenia, 28:31
- clinical stabilization, schizophrenia, 28:31
- cocaine, 3-methoxy-4-hydroxyphenylglycol, 29:123
- 3-methoxy-4-hydroxyphenylglycol, cocaine, 29:123
- 3-methoxy-4-hydroxyphenylglycol, substance abuse, 29:123
- neuroleptics, schizophrenia, 28:307
- schizophrenia, attention, 28:31
- schizophrenia, clinical stabilization, 28:31
- schizophrenia, neuroleptics, 28:307
- substance abuse, 3-methoxy-4-hydroxyphenylglycol, 29:123

Fenfluramine

- anxiety, serotonin, 28:295
- panic disorder, anxiety, 28:295
- panic disorder, serotonin, 28:295
- serotonin, panic disorder, 28:295

Fluoxetine

- affective disorder, Hamilton Rating Scale for Depression, 30:191
- affective disorder, imipramine, 30:191
- affective disorder, placebo washout, 30:191
- Hamilton Rating Scale for Depression, imipramine, 30:191
- Hamilton Rating Scale for Depression, placebo washout, 30:191
- imipramine, placebo washout, 30:191
- placebo washout, affective disorder, 30:191
- placebo washout, imipramine, 30:191

Follicle stimulating hormone

- eating disorders, luteinizing hormone, 28:11
- luteinizing hormone, eating disorders, 28:11

Food intake

- antidepressants, learned helplessness, 27:149
- antidepressants, rats, 27:149
- antidepressants, triiodothyronine, 27:149
- learned helplessness, antidepressants, 27:149
- learned helplessness, triiodothyronine, 27:149
- triiodothyronine, antidepressants, 27:149
- triiodothyronine, learned helplessness, 27:149
- triiodothyronine, rats, 27:149

Frontal lobe

- cerebral blood flow, head injury, 29:313
- cerebral blood flow, schizophrenia, 29:331
- cerebral blood flow, single photon emission computed tomography, 29:331

Frontal lobe continued

- computed tomography, electroencephalogram, 29:137
- computed tomography, schizophrenia, 29:137
- computed tomography, Wisconsin Card Sort Test, 29:137
- desipramine, imipramine binding, 30:125
- desipramine, serotonin, 30:125
- desipramine, suicide, 30:125
- electroencephalogram, computed tomography, 29:137
- electroencephalogram, schizophrenia, 29:137
- electroencephalogram, Wisconsin Card Sort Test, 29:137
- evoked potentials, obsessive-compulsive disorder, 28:63
- evoked potentials, P300, 28:63
- head injury, cerebral blood flow, 29:313
- imipramine binding, desipramine, 30:125
- imipramine binding, serotonin, 30:125
- imipramine binding, suicide, 30:125
- magnetic resonance imaging, negative symptoms, 30:11
- magnetic resonance imaging, sagittal morphology, 30:11
- magnetic resonance imaging, schizophrenia, 30:11
- negative symptoms, magnetic resonance imaging, 30:11
- negative symptoms, sagittal morphology, 30:11
- negative symptoms, schizophrenia, 30:11
- obsessive-compulsive disorder, evoked potentials, 28:63
- obsessive-compulsive disorder, P300, 28:63
- P300, evoked potentials, 28:63
- P300, obsessive-compulsive disorder, 28:63
- parietal lobes, positron emission tomography, 28:119
- parietal lobes, schizophrenia, 28:119
- positron emission tomography, parietal lobes, 28:119
- positron emission tomography, schizophrenia, 28:119
- sagittal morphology, magnetic resonance imaging, 30:11
- sagittal morphology, negative symptoms, 30:11
- sagittal morphology, schizophrenia, 30:11
- schizophrenia, cerebral blood flow, 29:331
- schizophrenia, computed tomography, 29:137

Frontal lobe continued

- schizophrenia, electroencephalogram, 29:137
- schizophrenia, magnetic resonance imaging, 30:11
- schizophrenia, negative symptoms, 30:11
- schizophrenia, parietal lobes, 28:119
- schizophrenia, positron emission tomography, 28:119
- schizophrenia, sagittal morphology, 30:11
- schizophrenia, single photon emission computed tomography, 29:331
- schizophrenia, Wisconsin Card Sort Test, 29:137
- serotonin, desipramine, 30:125
- serotonin, imipramine binding, 30:125
- serotonin, suicide, 30:125
- single photon emission computed tomography, cerebral blood flow, 29:331
- single photon emission computed tomography, schizophrenia, 29:331
- suicide, desipramine, 30:125
- suicide, imipramine binding, 30:125
- suicide, serotonin, 30:125
- Wisconsin Card Sort Test, computed tomography, 29:137
- Wisconsin Card Sort Test, electroencephalogram, 29:137
- Wisconsin Card Sort Test, schizophrenia, 29:137

Gamma-aminobutyric acid

- corticotropin releasing hormone, gambling, 30:137
- corticotropin releasing hormone, 3-methoxy-4-hydroxyphenylglycol, 30:137
- corticotropin releasing hormone, neuropeptides, 30:137
- corticotropin releasing hormone, norepinephrine, 30:137
- gambling, corticotropin releasing hormone, 30:137
- gambling, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gambling, neuropeptides, 30:137
- gambling, norepinephrine, 30:137
- 3-methoxy-4-hydroxyphenylglycol, corticotropin releasing hormone, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gambling, 30:137
- 3-methoxy-4-hydroxyphenylglycol, neuropeptides, 30:137
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 30:137

Gamma-aminobutyric acid continued

- neuropeptides, corticotropin releasing hormone, 30:137
- neuropeptides, gambling, 30:137
- neuropeptides, norepinephrine, 30:137
- norepinephrine, corticotropin releasing hormone, 30:137
- norepinephrine, gambling, 30:137
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 30:137
- norepinephrine, neuropeptides, 30:137

Gambling

- corticotropin releasing hormone, gamma-aminobutyric acid, 30:137
- corticotropin releasing hormone, 3-methoxy-4-hydroxyphenylglycol, 30:137
- corticotropin releasing hormone, neuropeptides, 30:137
- corticotropin releasing hormone, norepinephrine, 30:137
- gamma-aminobutyric acid, corticotropin releasing hormone, 30:137
- gamma-aminobutyric acid, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gamma-aminobutyric acid, neuropeptides, 30:137
- gamma-aminobutyric acid, norepinephrine, 30:137
- 3-methoxy-4-hydroxyphenylglycol, corticotropin releasing hormone, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gamma-aminobutyric acid, 30:137
- 3-methoxy-4-hydroxyphenylglycol, neuropeptides, 30:137
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 30:137
- neuropeptides, corticotropin releasing hormone, 30:137
- neuropeptides, gamma-aminobutyric acid, 30:137
- neuropeptides, 3-methoxy-4-hydroxyphenylglycol, 30:137
- neuropeptides, norepinephrine, 30:137
- norepinephrine, corticotropin releasing hormone, 30:137
- norepinephrine, gamma-aminobutyric acid, 30:137
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 30:137
- norepinephrine, neuropeptides, 30:137

Gender

- Alzheimer's disease, cortisol, 29:169

Gender continued

- Alzheimer's disease, dexamethasone suppression test, 29:169
- borderline personality, 27:111
- cerebral blood flow, sex role orientation, 27:55
- cortisol, Alzheimer's disease, 29:169
- cortisol, dexamethasone suppression test, 29:169
- dexamethasone suppression test, Alzheimer's disease, 29:169
- dexamethasone suppression test, cortisol, 29:169
- genetics, heterogeneity, 28:243
- genetics, schizophrenia, 28:243
- heterogeneity, genetics, 28:243
- heterogeneity, schizophrenia, 28:243
- schizophrenia, genetics, 28:243
- schizophrenia, heterogeneity, 28:243
- sex role orientation, cerebral blood flow, 27:55

Generalized anxiety disorder

- affective disorders, norepinephrine, 30:253
- affective disorders, time sampling, 30:253
- blood pressure, cortisol, 27:173
- blood pressure, heart rate, 27:173
- blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173
- blood pressure, norepinephrine, 27:173
- blood pressure, yohimbine, 27:173
- cortisol, blood pressure, 27:173
- cortisol, heart rate, 27:173
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:173
- cortisol, norepinephrine, 27:173
- cortisol, yohimbine, 27:173
- heart rate, blood pressure, 27:173
- heart rate, cortisol, 27:173
- heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173
- heart rate, norepinephrine, 27:173
- heart rate, yohimbine, 27:173
- 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:173
- 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:173
- 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173
- norepinephrine, affective disorders, 30:253
- norepinephrine, blood pressure, 27:173
- norepinephrine, cortisol, 27:173

Generalized anxiety disorder continued

- norepinephrine, heart rate, 27:173
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:173
- norepinephrine, time sampling, 30:253
- norepinephrine, yohimbine, 27:173
- time sampling, affective disorders, 30:253
- time sampling, norepinephrine, 30:253
- yohimbine, blood pressure, 27:173
- yohimbine, cortisol, 27:173
- yohimbine, heart rate, 27:173
- yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173
- yohimbine, norepinephrine, 27:173

Genetics

- alcoholism, cocaine, 29:113
- alcoholism, comorbidity, 29:113
- cocaine, alcoholism, 29:113
- cocaine, comorbidity, 29:113
- comorbidity, alcoholism, 29:113
- comorbidity, cocaine, 29:113
- dermatoglyphics, schizophrenia, 29:37
- dermatoglyphics, twins, 29:37
- gender, heterogeneity, 28:243
- gender, schizophrenia, 28:243
- heterogeneity, gender, 28:243
- heterogeneity, schizophrenia, 28:243
- imipramine binding, platelet, 27:287
- imipramine binding, rats, 27:287
- perinatal complications, schizophrenia, 27:233
- schizophrenia, dermatoglyphics, 29:37
- schizophrenia, gender, 28:243
- schizophrenia, heterogeneity, 28:243
- schizophrenia, perinatal complications, 27:233
- schizophrenia, twins, 29:37
- substance abuse, comorbidity, 29:113
- twins, dermatoglyphics, 29:37
- twins, schizophrenia, 29:37

Geriatric depression

- affective disorder, antidepressants, 28:1
- affective disorder, maintenance pharmacotherapy, 27:225
- affective disorder, nortriptyline, 27:225, 28:1
- affective disorder, phenelzine, 28:1
- affective disorder, sleep, 27:13
- affective disorder, subtype, 27:13
- affective disorder, survival analysis, 27:225
- antidepressants, affective disorder, 28:1
- antidepressants, nortriptyline, 28:1
- antidepressants, phenelzine, 28:1
- maintenance pharmacotherapy, affective disorder, 27:225

Geriatric depression continued

- maintenance pharmacotherapy, nortriptyline, 27:225
- maintenance pharmacotherapy, survival analysis, 27:225
- nortriptyline, affective disorder, 27:225, 28:1
- nortriptyline, antidepressants, 28:1
- nortriptyline, phenelzine, 28:1
- nortriptyline, survival analysis, 27:225
- phenelzine, affective disorder, 28:1
- phenelzine, nortriptyline, 28:1
- sleep, affective disorder, 27:13
- sleep, subtype, 27:13
- subtype, affective disorder, 27:13
- subtype, sleep, 27:13
- survival analysis, affective disorder, 27:225
- survival analysis, maintenance pharmacotherapy, 27:225
- survival analysis, nortriptyline, 27:225

Gilles de la Tourette syndrome

- EEG mapping, normal comparison, 29:427
- normal comparison, EEG mapping, 29:427

Glucose

- affective disorder, children, 29:215
- children, affective disorder, 29:215
- cholesterol, affective disorder, children, 29:215
- dexamethasone suppression test, affective disorder, children, 29:215
- diabetes mellitus, haloperidol, 29:17
- diabetes mellitus, schizophrenia, 29:17
- diabetes mellitus, tardive dyskinesia, 29:17
- haloperidol, diabetes mellitus, 29:17
- haloperidol, schizophrenia, 29:17
- haloperidol, tardive dyskinesia, 29:17
- potassium, affective disorder, children, 29:215
- schizophrenia, diabetes mellitus, 29:17
- schizophrenia, haloperidol, 29:17
- schizophrenia, tardive dyskinesia, 29:17
- sodium, affective disorder, children, 29:215
- tardive dyskinesia, diabetes mellitus, 29:17
- tardive dyskinesia, haloperidol, 29:17
- tardive dyskinesia, schizophrenia, 29:17

Gonadotropins. See Luteinizing hormone**Growth hormone**

- affective disorder, Alzheimer's disease, 27:277
- affective disorder, clonidine, 27:277, 29:199
- alcoholism, computed tomography, 28:89
- alcoholism, prolactin, 28:89
- alcoholism, thyroid stimulating hormone, 28:89

Growth hormone continued

- alcoholism, thyrotropin releasing hormone test, 28:89
- Alzheimer's disease, affective disorder, 27:277
- Alzheimer's disease, clonidine, 27:277
- clonidine, affective disorder, 27:277, 29:199
- clonidine, Alzheimer's disease, 27:277
- clonidine, 3-methoxy-4-hydroxyphenylglycol, 27:297
- clonidine, norepinephrine, 27:297
- clonidine, schizophrenia, 27:297
- clonidine, treatment response prediction, 27:297
- computed tomography, alcoholism, 28:89
- computed tomography, prolactin, 28:89
- computed tomography, thyroid stimulating hormone, 28:89
- computed tomography, thyrotropin releasing hormone test, 28:89
- cortisol, panic disorder, 28:351
- cortisol, prolactin, 28:351
- cortisol, syncope, 28:351
- 3-methoxy-4-hydroxyphenylglycol, clonidine, 27:297
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:297
- 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 27:297
- 3-methoxy-4-hydroxyphenylglycol, treatment response prediction, 27:297
- norepinephrine, clonidine, 27:297
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:297
- norepinephrine, schizophrenia, 27:297
- norepinephrine, treatment response prediction, 27:297
- panic disorder, cortisol, 28:351
- panic disorder, prolactin, 28:351
- panic disorder, syncope, 28:351
- prolactin, alcoholism, 28:89
- prolactin, computed tomography, 28:89
- prolactin, cortisol, 28:351
- prolactin, panic disorder, 28:351
- prolactin, syncope, 28:351
- prolactin, thyroid stimulating hormone, 28:89
- prolactin, thyrotropin releasing hormone test, 28:89
- schizophrenia, clonidine, 27:297
- schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 27:297
- schizophrenia, norepinephrine, 27:297
- schizophrenia, treatment response prediction, 27:297
- syncope, cortisol, 28:351

Growth hormone continued

- syncope, panic disorder, 28:351
- syncope, prolactin, 28:351
- thyroid stimulating hormone, alcoholism, 28:89
- thyroid stimulating hormone, computed tomography, 28:89
- thyroid stimulating hormone, prolactin, 28:89
- thyrotropin releasing hormone test, alcoholism, 28:89
- thyrotropin releasing hormone test, computed tomography, 28:89
- thyrotropin releasing hormone test, prolactin, 28:89
- treatment response prediction, clonidine, 27:297
- treatment response prediction, 3-methoxy-4-hydroxyphenylglycol, 27:297
- treatment response prediction, norepinephrine, 27:297
- treatment response prediction, schizophrenia, 27:297

Haloperidol

- blood pressure, cocaine, 27:117
- blood pressure, heart rate, 27:117
- blood pressure, subjective effects, 27:117
- blood pressure, substance abuse, 27:117
- Chinese patients, plasma levels, 30:45
- Chinese patients, schizophrenia, 30:45
- cocaine, blood pressure, 27:117
- cocaine, heart rate, 27:117
- cocaine, subjective effects, 27:117
- diabetes mellitus, glucose tolerance, 29:17
- diabetes mellitus, schizophrenia, 29:17
- diabetes mellitus, tardive dyskinesia, 29:17
- glucose tolerance, diabetes mellitus, 29:17
- glucose tolerance, schizophrenia, 29:17
- glucose tolerance, tardive dyskinesia, 29:17
- heart rate, blood pressure, 27:117
- heart rate, cocaine, 27:117
- heart rate, subjective effects, 27:117
- plasma levels, Chinese patients, 30:45
- plasma levels, schizophrenia, 30:45
- schizophrenia, Chinese patients, 30:45
- schizophrenia, diabetes mellitus, 29:17
- schizophrenia, glucose tolerance, 29:17
- schizophrenia, plasma levels, 30:45
- schizophrenia, tardive dyskinesia, 29:17
- subjective effects, blood pressure, 27:117
- subjective effects, cocaine, 27:117
- subjective effects, heart rate, 27:117
- tardive dyskinesia, diabetes mellitus, 29:17
- tardive dyskinesia, glucose tolerance, 29:17
- tardive dyskinesia, schizophrenia, 29:17

Hamilton rating scale for depression

- affective disorder, fluoxetine, 30:191
- affective disorder, imipramine, 30:191
- affective disorder, placebo washout, 30:191
- fluoxetine, affective disorder, 30:191
- fluoxetine, imipramine, 30:191
- fluoxetine, placebo washout, 30:191
- imipramine, affective disorder, 30:191
- imipramine, fluoxetine, 30:191
- imipramine, placebo washout, 30:191
- placebo washout, affective disorder, 30:191
- placebo washout, fluoxetine, 30:191
- placebo washout, imipramine, 30:191

Head injury

- cerebral blood flow, frontal lobe, 29:313
- frontal lobe, cerebral blood flow, 29:313

Headache

- anxiety, depressed mood, 30:95
- anxiety, migraine, 30:95
- anxiety, monoamine oxidase, 30:95
- anxiety, tribulin, 30:95
- depressed mood, migraine, 30:95
- depressed mood, monoamine oxidase, 30:95
- depressed mood, tribulin, 30:95
- migraine, anxiety, 30:95
- migraine, depressed mood, 30:95
- migraine, monoamine oxidase, 30:95
- migraine, tribulin, 30:95
- monoamine oxidase, anxiety, 30:95
- monoamine oxidase, depressed mood, 30:95
- monoamine oxidase, migraine, 30:95
- monoamine oxidase, platelet, 30:95
- monoamine oxidase, tribulin, 30:95
- tribulin, anxiety, 30:95
- tribulin, depressed mood, 30:95
- tribulin, migraine, 30:95
- tribulin, monoamine oxidase, 30:95

Heart rate

- blood pressure, cocaine, 27:117
- blood pressure, cortisol, 27:173
- blood pressure, eating disorders, 30:223
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, haloperidol, 27:117
- blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173
- blood pressure, norepinephrine, 27:173
- blood pressure, premenstrual dysphoria, 27:183
- blood pressure, stressors, 30:223
- blood pressure, subjective effects, 27:117
- blood pressure, Type A behavior, 30:223
- blood pressure, yohimbine, 27:173
- cocaine, blood pressure, 27:117

Heart rate continued

cocaine, haloperidol, 27:117
 cocaine, subjective effects, 27:117
 cortisol, blood pressure, 27:173
 cortisol, generalized anxiety disorder, 27:173
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:173
 cortisol, norepinephrine, 27:173
 cortisol, yohimbine, 27:173
 eating disorders, blood pressure, 30:223
 eating disorders, stressors, 30:223
 eating disorders, Type A behavior, 30:223
 generalized anxiety disorder, blood pressure, 27:173
 generalized anxiety disorder, cortisol, 27:173
 generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173
 generalized anxiety disorder, norepinephrine, 27:173
 generalized anxiety disorder, yohimbine, 27:173
 haloperidol, blood pressure, 27:117
 haloperidol, cocaine, 27:117
 haloperidol, subjective effects, 27:117
 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173
 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:173
 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:173
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173
 norepinephrine, blood pressure, 27:173
 norepinephrine, cortisol, 27:173
 norepinephrine, generalized anxiety disorder, 27:173
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:173
 norepinephrine, yohimbine, 27:173
 premenstrual dysphoria, blood pressure, 27:183
 stressors, blood pressure, 30:223
 stressors, eating disorders, 30:223
 stressors, Type A behavior, 30:223
 subjective effects, blood pressure, 27:117
 subjective effects, cocaine, 27:117
 subjective effects, haloperidol, 27:117
 Type A behavior, blood pressure, 30:223
 Type A behavior, eating disorders, 30:223
 Type A behavior, stressors, 30:223
 yohimbine, blood pressure, 27:173

Heart rate continued

yohimbine, cortisol, 27:173
 yohimbine, generalized anxiety disorder, 27:173
 yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173
 yohimbine, norepinephrine, 27:173

5-Hydroxyindolacetic acid

affective disorder, cyclic adenosine monophosphate, 30:181
 affective disorder, dihydroergocryptine binding, 30:181
 affective disorder, serotonin uptake, 30:181
 cyclic adenosine monophosphate, affective disorder, 30:181
 cyclic adenosine monophosphate, dihydroergocryptine binding, 30:181
 cyclic adenosine monophosphate, serotonin uptake, 30:181
 dihydroergocryptine binding, affective disorder, 30:181
 dihydroergocryptine binding, cyclic adenosine monophosphate, 30:181
 serotonin uptake, affective disorder, 30:181

Homovanillic acid

affective disorder, dexamethasone suppression test, 29:177
 dexamethasone suppression test, affective disorder, 29:177
 pharmacological treatment, schizophrenia, 28:97
 schizophrenia, pharmacological treatment, 28:97

Huntington's disease

caudate nucleus, single photon emission computed tomography, 29:337
 positron emission tomography, psychiatric symptoms, 29:361
 psychiatric symptoms, positron emission tomography, 29:361
 single photon emission computed tomography, caudate nucleus, 29:337

Hypnosis

autogenic training, cerebral blood flow, 29:317
 autogenic training, laterality, 29:317
 cerebral blood flow, autogenic training, 29:317
 cerebral blood flow, laterality, 29:317
 laterality, autogenic training, 29:317
 laterality, cerebral blood flow, 29:317

Hypoglycemia

blood-brain barrier, electroconvulsive seizure, 29:151

Hypoglycemia continued

- blood-brain barrier, rats, 29:151
- electroconvulsive seizure, blood-brain barrier, 29:151
- electroconvulsive seizure, rats, 29:151

Imipramine

- affective disorder, circannual rhythms, 29:87, 30:21
- affective disorder, dexamethasone suppression test, 29:87
- affective disorder, diagnostic specificity, 30:21
- affective disorder, fluoxetine, 30:191
- affective disorder, Hamilton Rating Scale for Depression, 30:191
- affective disorder, placebo washout, 30:191
- circannual rhythms, affective disorder, 29:87, 30:21
- circannual rhythms, dexamethasone suppression test, 29:87
- circannual variation, platelet, 30:21
- desipramine, frontal lobe, 30:125
- desipramine, serotonin, 30:125
- desipramine, suicide, 30:125
- dexamethasone suppression test, affective disorder, 29:87
- dexamethasone suppression test, circannual rhythms, 29:87
- diagnostic specificity, affective disorders, 30:21
- eating disorder, platelet binding, 30:21
- fluoxetine, affective disorder, 30:191
- fluoxetine, Hamilton Rating Scale for Depression, 30:191
- fluoxetine, placebo washout, 30:191
- frontal lobe, desipramine, 30:125
- frontal lobe, serotonin, 30:125
- frontal lobe, suicide, 30:125
- genetics, platelet binding, rats, 27:287
- Hamilton Rating Scale for Depression, affective disorder, 30:191
- Hamilton Rating Scale for Depression, fluoxetine, 30:191
- Hamilton Rating Scale for Depression, placebo washout, 30:191
- panic disorder, platelet binding, 30:21
- placebo washout, affective disorders, 30:191
- placebo washout, fluoxetine, 30:191
- placebo washout, Hamilton Rating Scale for Depression, 30:191
- schizophrenia, platelet binding, 30:21
- serotonin, desipramine, 30:125
- serotonin, frontal lobe, 30:125
- serotonin, suicide, 30:125

Imipramine continued

- suicide, desipramine, 30:125
- suicide, frontal lobe, 30:125
- suicide, platelet binding, 30:21
- suicide, serotonin, 30:125

Immune function

- affective disorder, mania, 29:235
- mania, affective disorder, 29:235

Impulsivity

- aggression, serotonin, 27:5
- Barratt Impulsivity Scale, platelet serotonin uptake, 27:5
- serotonin, aggression, 27:5

Indalpine

- clenbuterol, food restriction, rats, 27:149
- clomipramine, food restriction, rats, 27:149
- desipramine, food restriction, rats, 27:149
- food restriction, rats, 27:149
- nialamide, food restriction, rats, 27:149
- rats, food restriction, 27:149

Inositol

- lithium, red blood cell, 27:217
- red blood cell, lithium, 27:217

Lactate

- Acute Panic Inventory, affective disorder, 27:357
- Acute Panic Inventory, panic disorder, 29:207
- Acute Panic Inventory, somatic symptoms, 29:207
- affective disorder, Acute Panic Inventory, 27:357
- agoraphobia, panic disorder, 28:181
- agoraphobia, prolactin, 28:181
- blood gases, panic disorder, 28:171
- panic, Acute Panic Inventory, 27:357
- panic, affective disorder, 27:357
- panic disorder, agoraphobia, 28:181
- panic disorder, blood gases, 28:171
- panic disorder, prolactin, 28:181
- panic disorder, somatic symptoms, 29:207
- prolactin, agoraphobia, 28:181
- prolactin, panic disorder, 28:181
- somatic symptoms, Acute Panic Inventory, 29:207
- somatic symptoms, panic disorder, 29:207

Laterality

- affective disorder, attention, 29:65
- affective disorder, continuous performance test, 29:65
- affective disorder, schizophrenia, 29:65
- attention, affective disorder, 29:65
- attention, computed tomography, 29:267
- attention, continuous performance test, 29:65

Laterality continued

- attention, schizophrenia, 29:65, 29:267
- attention, ventricle-brain ratio, 29:267
- autogenic training, cerebral blood flow, 29:317
- autogenic training, hypnosis, 29:317
- cerebral blood flow, autogenic training, 29:317
- cerebral blood flow, hypnosis, 29:317
- cerebral blood flow, positron emission tomography, 27:325
- cerebral blood flow, schizophrenia, 27:325
- computed tomography, attention, 29:267
- computed tomography, schizophrenia, 29:247, 29:267
- computed tomography, ventricle-brain ratio, 29:267
- continuous performance test, affective disorder, 29:65
- continuous performance test, attention, 29:65
- continuous performance test, schizophrenia, 29:65
- hypnosis, autogenic training, 29:317
- hypnosis, cerebral blood flow, 29:317
- neuroleptics, parkinsonism, 30:275
- neuroleptics, schizophrenia, 30:275
- parkinsonism, neuroleptics, 30:275
- parkinsonism, schizophrenia, 30:275
- positron emission tomography, cerebral blood flow, 27:325
- positron emission tomography, schizophrenia, 27:325
- schizophrenia, affective disorder, 29:65
- schizophrenia, attention, 29:65, 29:267
- schizophrenia, cerebral blood flow, 27:325
- schizophrenia, computed tomography, 29:247, 29:267
- schizophrenia, continuous performance test, 29:65
- schizophrenia, neuroleptics, 30:275
- schizophrenia, parkinsonism, 30:275
- schizophrenia, positron emission tomography, 27:325
- schizophrenia, ventricle-brain ratio, 29:267
- ventricle-brain ratio, attention, 29:267
- ventricle-brain ratio, computed tomography, 29:267
- ventricle-brain ratio, schizophrenia, 29:267

Learned helplessness

- antidepressants, food intake, 27:149
- antidepressants, rats, 27:149
- antidepressants, triiodothyronine, 27:149
- food intake, antidepressants, 27:149
- food intake, rats, 27:149

Learned helplessness continued

- food intake, triiodothyronine, 27:149
- triiodothyronine, antidepressants, 27:149
- triiodothyronine, food intake, 27:149

Life events

- affective disorder, mania, 30:213
- affective disorder, stressors, 30:213
- DSM-III, Psychiatric Epidemiology Research Interview, 30:201
- mania, affective disorder, 30:213
- mania, stressors, 30:213
- Psychiatric Epidemiology Research Interview, 30:201, 30:213
- stressors, affective disorder, 30:213
- stressors, mania, 30:213

Light therapy

- affective disorder, seasonal affective disorder, 29:29
- seasonal affective disorder, affective disorder, 29:29

Linoleic acid

- essential fatty acids, tardive dyskinesia, 27:313
- tardive dyskinesia, essential fatty acids, 27:313

Lithium

- affective disorder, ankyrin, 27:267
- affective disorder, antidepressants, 28:73
- affective disorder, bipolar, 27:267
- affective disorder, clonidine binding in platelets, 28:73
- affective disorder, red blood cell membrane, 27:267
- affective disorder, schizophrenia, 28:73
- alcoholism, prolactin, 29:55
- alcoholism, red blood cells, 29:55
- ankyrin, affective disorder, 27:267
- ankyrin, bipolar, 27:267
- ankyrin, red blood cell membrane, 27:267
- antidepressants, affective disorder, 28:73
- antidepressants, clonidine binding in platelets, 28:73
- antidepressants, schizophrenia, 28:73
- bipolar affective disorder, 27:267
- bipolar subtype, ankyrin, 27:267
- bipolar subtype, red blood cell membrane, 27:267
- clonidine, affective disorder, 28:73
- clonidine binding in platelets, affective disorder, 28:73
- clonidine binding in platelets, antidepressants, 28:73
- clonidine binding in platelets, schizophrenia, 28:73
- clonidine, schizophrenia, 28:73

Lithium continued

- inositol-1-phosphatase, red blood cell, 27:217
- light, pupillary response, 30:305
- light, sheep, 30:305
- prolactin, alcoholism, 29:55
- prolactin, red blood cells, 29:55
- pupillary response, light, 30:305
- pupillary response, sheep, 30:305
- rats, seizures, 30:77
- rats, theophylline, 30:77
- red blood cell, inositol-1-phosphatase, 27:217
- red blood cell membrane, affective disorder, 27:267
- red blood cell membrane, ankyrin, 27:267
- red blood cell membrane, bipolar subtype, 27:267
- red blood cells, alcoholism, 29:55
- red blood cells, prolactin, 29:55
- schizophrenia, affective disorder, 28:73
- schizophrenia, antidepressants, 28:73
- schizophrenia, clonidine, 28:73
- schizophrenia, clonidine binding in platelets, 28:73
- seizures, rats, 30:77
- seizures, theophylline, 30:77
- sheep, light, 30:305
- sheep, pupillary response, 30:305
- theophylline, rats, 30:77
- theophylline, seizures, 30:77

Liver function

- alcoholism, cortisol, 30:217
- alcoholism, dexamethasone suppression test, 30:217
- cortisol, alcoholism, 30:217
- cortisol, dexamethasone suppression test, 30:217
- dexamethasone suppression test, alcoholism, 30:217
- dexamethasone suppression test, cortisol, 30:217

Locus ceruleus

- dopamine-beta-hydroxylase, paranoid subtype, 27:31
- dopamine-beta-hydroxylase, post-mortem study, 27:31
- dopamine-beta-hydroxylase, schizophrenia, 27:31
- paranoid subtype, dopamine-beta-hydroxylase, 27:31
- paranoid subtype, post-mortem study, 27:31
- paranoid subtype, schizophrenia, 27:31
- post-mortem study, dopamine-beta-hydroxylase, 27:31

Locus ceruleus continued

- post-mortem study, schizophrenia, 27:31
- schizophrenia, dopamine-beta-hydroxylase, 27:31
- schizophrenia, paranoid subtype, 27:31
- schizophrenia, post-mortem study, 27:31

Lupus Erythematosus

- computed tomography, magnetic resonance imaging, 29:367
- computed tomography, positron emission tomography, 29:367
- magnetic resonance imaging, computed tomography, 29:367
- positron emission tomography, magnetic resonance imaging, 29:367

Lutenizing hormone

- eating disorders, follicle stimulating hormone, 28:11
- eating disorders, gonadotropin releasing hormone, 28:11
- eating disorders, menstrual cycle, 28:11
- follicle stimulating hormone, eating disorders, 28:11
- gonadotropin releasing hormone, eating disorders, 28:11
- gonadotropin releasing hormone, menstrual cycle, 28:11
- menstrual cycle, eating disorders, 28:11
- menstrual cycle, gonadotropin releasing hormone, 28:11

Lymphocytes

- butaclamol, dopamine, 30:259
- butaclamol, spiperone binding, 30:259
- dopamine, butaclamol, 30:259
- dopamine, spiperone binding, 30:259
- spiperone binding, butaclamol, 30:259
- spiperone binding, dopamine, 30:259

Magnetic resonance imaging

- alcoholism, computed tomography, 29:277
- alcoholism, cerebrospinal fluid volumetry, 29:277
- Alzheimer's disease, cerebral blood flow, 29:447
- Borna disease, psychiatric patients, 29:281
- cerebral blood flow, Alzheimer's disease, 29:447
- cerebral blood flow, corpus callosum, 29:453
- cerebral blood flow, schizophrenia, 29:453
- cerebrospinal fluid flow, normal pressure hydrocephalus, 29:289
- cerebrospinal fluid volumetry, alcoholism, 29:277
- cerebrospinal fluid volumetry, computed tomography, 29:277

Magnetic resonance imaging continued

computed tomography, alcoholism, 29:277
 computed tomography, cerebrospinal fluid volumetry, 29:277
 computed tomography, diencephalic lesions, 29:285
 computed tomography, EEG focus, 29:459
 computed tomography, lupus erythematosus, 29:367
 computed tomography, positron emission tomography, 29:363, 29:367
 computed tomography, schizophrenia, 29:265
 computed tomography, seizures, 29:459
 computed tomography, single photon emission computed tomography, 29:459
 computed tomography, thalamic infarction, 29:363
 computed tomography, ventricle-brain ratio, 29:265
 corpus callosum, cerebral blood flow, 29:453
 corpus callosum, schizophrenia, 29:453
 diencephalic lesions, computed tomography, 29:285
 EEG focus, computed tomography, 29:459
 EEG focus, seizures, 29:459
 EEG focus, single photon emission computed tomography, 29:459
 frontal lobe size, negative symptoms, 30:11
 frontal lobe size, sagittal morphology, 30:11
 frontal lobe size, schizophrenia, 30:11
 lupus erythematosus, computed tomography, 29:367
 lupus erythematosus, positron emission tomography, 29:367
 multiple sclerosis, neuropsychology, 29:293
 multiple sclerosis, optic neuritis, 29:295
 negative symptoms, frontal lobe size, 30:11
 negative symptoms, sagittal morphology, 30:11
 negative symptoms, schizophrenia, 30:11
 neuropsychology, multiple sclerosis, 29:293
 normal pressure hydrocephalus, cerebrospinal fluid flow, 29:289
 optic neuritis, multiple sclerosis, 29:295
 pituitary tumors, 29:283
 positron emission tomography, computed tomography, 29:363, 29:367
 positron emission tomography, lupus erythematosus, 29:367

Magnetic resonance imaging continued

positron emission tomography, thalamic infarction, 29:363
 psychiatric patients, Borna disease, 29:281
 sagittal morphology, frontal lobe size, 30:11
 sagittal morphology, negative symptoms, 30:11
 sagittal morphology, schizophrenia, 30:11
 schizophrenia, cerebral blood flow, 29:453
 schizophrenia, computed tomography, 29:265
 schizophrenia, corpus callosum, 29:453
 schizophrenia, frontal lobe size, 30:11
 schizophrenia, negative symptoms, 30:11
 schizophrenia, sagittal morphology, 30:11
 schizophrenia, temporal lobe, 29:261
 schizophrenia, ventricle-brain ratio, 29:265
 seizures, computed tomography, 29:459
 seizures, EEG focus, 29:459
 seizures, single photon emission computed tomography, 29:459
 single photon emission computed tomography, computed tomography, 29:459
 single photon emission computed tomography, EEG focus, 29:459
 single photon emission computed tomography, seizures, 29:459
 subcaudate tractotomy lesions, 29:291
 temporal lobe, schizophrenia, 29:261
 thalamic infarction, computed tomography, 29:363
 thalamic infarction, positron emission tomography, 29:363
 ventricle-brain ratio, computed tomography, 29:265
 ventricle-brain ratio, schizophrenia, 29:265

Magnetoencephalography

auditory stimuli, evoked potentials, 29:369
 clinical applications, comparison with EEG, 29:375
 comparison with EEG, clinical applications, 29:375
 comparison with EEG, seizures, 29:377
 evoked potentials, auditory stimuli, 29:369
 seizures, comparison with EEG, 29:377

Melatonin

affective disorder, light, 27:351
 affective disorders, circadian rhythms, 28:263
 affective disorders, cortisol, 28:263
 affective disorders, norepinephrine, 28:263
 affective disorders, temperature, 28:263

Melatonin continued

- affective disorders, thyroid stimulating hormone, 28:263
- circadian rhythms, affective disorder, 28:263
- circadian rhythms, cortisol, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, temperature, 28:263
- circadian rhythms, thyroid stimulating hormone, 28:263
- cortisol, affective disorder, 28:263
- cortisol, circadian rhythms, 28:263
- cortisol, norepinephrine, 28:263
- cortisol, temperature, 28:263
- cortisol, thyroid stimulating hormone, 28:263
- light, affective disorder, 27:351
- norepinephrine, affective disorder, 28:263
- norepinephrine, circadian rhythms, 28:263
- norepinephrine, cortisol, 28:263
- norepinephrine, temperature, 28:263
- norepinephrine, thyroid stimulating hormone, 28:263
- temperature, affective disorder, 28:263
- temperature, circadian rhythms, 28:263
- temperature, cortisol, 28:263
- temperature, norepinephrine, 28:263
- temperature, thyroid stimulating hormone, 28:263
- thyroid stimulating hormone, affective disorder, 28:263
- thyroid stimulating hormone, circadian rhythms, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, norepinephrine, 28:263
- thyroid stimulating hormone, temperature, 28:263

Menstrual period

- activity, premenstrual syndrome, 30:285
- activity, sleep, 30:285
- activity, temperature, 30:285
- eating disorders, gonadotropin releasing hormone, 28:11
- eating disorders, luteinizing hormone, 28:11
- gonadotropin releasing hormone, eating disorders, 28:11
- gonadotropin releasing hormone, luteinizing hormone, 28:11
- luteinizing hormone, eating disorders, 28:11
- luteinizing hormone, gonadotropin releasing hormone, 28:11
- premenstrual syndrome, activity, 30:285

Menstrual period continued

- premenstrual syndrome, sleep, 30:285
- premenstrual syndrome, temperature, 30:285
- sleep, activity, 30:285
- sleep, premenstrual syndrome, 30:285
- sleep, temperature, 30:285
- temperature, activity, 30:285
- temperature, premenstrual syndrome, 30:285
- temperature, sleep, 30:285

Mental retardation

- age, social group formation, 30:31
- social group formation, age, 30:31

Mescaline

- psychosis, single photon emission computed tomography, 29:335
- single photon emission computed tomography, psychosis, 29:335

Metachromatic leukodystrophy

- arylsulfatase A, schizophrenia, 30:107
- schizophrenia, arylsulfatase A, 30:107

3-Methoxy-4-hydroxyphenylglycol

- attention deficit disorder, conduct disorder, 27:241
- adolescents, affective disorder, 27:101
- adolescents, cortisol, 27:101
- adolescents, norepinephrine, 27:101
- affective disorder, adolescents, 27:101
- affective disorder, cortisol, 27:101
- affective disorder, norepinephrine, 27:101
- affective disorders, age of onset, 30:103
- age of onset, affective disorders, 30:103
- alprazolam, diazepam, 30:53
- alprazolam, panic disorder, 30:53
- alprazolam, treatment response, 30:53
- blood pressure, cortisol, 27:173
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, heart rate, 27:173
- blood pressure, norepinephrine, 27:173
- blood pressure, yohimbine, 27:173
- clonidine, growth hormone, 27:297
- clonidine, norepinephrine, 27:297
- clonidine, schizophrenia, 27:297
- clonidine, treatment response prediction, 27:297
- cocaine, eye movements, 29:123
- conduct disorder, attention deficit disorder, 27:241
- cortisol, adolescents, 27:101
- cortisol, affective disorder, 27:101
- cortisol, blood pressure, 27:173
- cortisol, generalized anxiety disorder, 27:173

3-Methoxy-4-hydroxyphenylglycol

continued

cortisol, heart rate, 27:173
 cortisol, norepinephrine, 27:101, 27:173
 cortisol, yohimbine, 27:173
 corticotropin releasing hormone, gambling, 30:137
 corticotropin releasing hormone, gamma-aminobutyric acid, 30:137
 corticotropin releasing hormone, neuropeptides, 30:137
 corticotropin releasing hormone, norepinephrine, 30:137
 diazepam, alprazolam, 30:53
 diazepam, panic disorder, 30:53
 diazepam, treatment response, 30:53
 eye movements, cocaine, 29:123
 eye movements, substance abuse, 29:123
 gambling, corticotropin releasing hormone, 30:137
 gambling, gamma-aminobutyric acid, 30:137
 gambling, neuropeptides, 30:137
 gambling, norepinephrine, 30:137
 gamma-aminobutyric acid, corticotropin releasing hormone, 30:137
 gamma-aminobutyric acid, gambling, 30:137
 gamma-aminobutyric acid, neuropeptides, 30:137
 gamma-aminobutyric acid, norepinephrine, 30:137
 generalized anxiety disorder, blood pressure, 27:173
 generalized anxiety disorder, cortisol, 27:173
 generalized anxiety disorder, heart rate, 27:173
 generalized anxiety disorder, norepinephrine, 27:173
 generalized anxiety disorder, yohimbine, 27:173
 growth hormone, clonidine, 27:297
 growth hormone, norepinephrine, 27:297
 growth hormone, schizophrenia, 27:297
 growth hormone, treatment response prediction, 27:297
 heart rate, blood pressure, 27:173
 heart rate, cortisol, 27:173
 heart rate, generalized anxiety disorder, 27:173
 heart rate, norepinephrine, 27:173
 heart rate, yohimbine, 27:173
 neuropeptides, corticotropin releasing hormone, 30:137

3-Methoxy-4-hydroxyphenylglycol

continued

neuropeptides, gambling, 30:137
 neuropeptides, gamma-aminobutyric acid, 30:137
 neuropeptides, norepinephrine, 30:137
 norepinephrine, adolescents, 27:101
 norepinephrine, affective disorder, 27:101
 norepinephrine, blood pressure, 27:173
 norepinephrine, clonidine, 27:297
 norepinephrine, cortisol, 27:101, 27:173
 norepinephrine, corticotropin releasing hormone, 30:137
 norepinephrine, gambling, 30:137
 norepinephrine, gamma-aminobutyric acid, 30:137
 norepinephrine, generalized anxiety disorder, 27:173
 norepinephrine, growth hormone, 27:297
 norepinephrine, heart rate, 27:173
 norepinephrine, neuropeptides, 30:137
 norepinephrine, schizophrenia, 27:297
 norepinephrine, sleep deprivation, 30:155
 norepinephrine, treatment response prediction, 27:297
 norepinephrine, yohimbine, 27:173
 panic disorder, alprazolam, 30:53
 panic disorder, diazepam, 30:53
 panic disorder, treatment response, 30:53
 schizophrenia, clonidine, 27:297
 schizophrenia, growth hormone, 27:297
 schizophrenia, norepinephrine, 27:297
 schizophrenia, treatment response prediction, 27:297
 sleep deprivation, norepinephrine, 30:155
 substance abuse, cocaine, 29:123
 substance abuse, eye movements, 29:123
 treatment response, alprazolam, 30:53
 treatment response, diazepam, 30:53
 treatment response, panic disorder, 30:53
 treatment response prediction, clonidine, 27:297
 treatment response prediction, growth hormone, 27:297
 treatment response prediction, norepinephrine, 27:297
 treatment response prediction, schizophrenia, 27:297
 yohimbine, blood pressure, 27:173
 yohimbine, cortisol, 27:173
 yohimbine, generalized anxiety disorder, 27:173
 yohimbine, heart rate, 27:173
 yohimbine, norepinephrine, 27:173

Metoclopramide

- prolactin, sleep, 29:161
- prolactin, thyrotropin releasing hormone, 29:161
- prolactin, tryptophan, 29:161
- prolactin, weight loss, 29:161
- sleep, prolactin, 29:161
- sleep, thyrotropin releasing hormone, 29:161
- sleep, tryptophan, 29:161
- sleep, weight loss, 29:161
- thyrotropin releasing hormone, prolactin, 29:161
- thyrotropin releasing hormone, sleep, 29:161
- thyrotropin releasing hormone, tryptophan, 29:161
- thyrotropin releasing hormone, weight loss, 29:161
- tryptophan, prolactin, 29:161
- tryptophan, sleep, 29:161
- tryptophan, thyrotropin releasing hormone, 29:161
- tryptophan, weight loss, 29:161
- weight loss, prolactin, 29:161
- weight loss, sleep, 29:161
- weight loss, thyrotropin releasing hormone, 29:161
- weight loss, tryptophan, 29:161

Mexican-Americans

- affective disorder, Center for Epidemiologic Studies Depression Scale, 27:137
- Center for Epidemiologic Studies Depression Scale, affective disorder, 27:137

Migraine. See Headache**Minnesota Multiphasic Personality Inventory**

- Brief Psychiatric Rating Scale, schizoaffective disorder, 28:135
- Brief Psychiatric Rating Scale, schizophrenia, 28:135
- monoamine oxidase, personality, 27:81
- monoamine oxidase, Personality Research Form, 27:81
- monoamine oxidase, platelet, 27:81
- monoamine oxidase, Sensation Seeking Scale, 27:81
- personality, monoamine oxidase, 27:81
- personality, Personality Research Form, 27:81
- Personality Research Form, monoamine oxidase, 27:81

Minnesota Multiphasic Personality Inventory continued

- Personality Research Form, personality, 27:81
- Personality Research Form, Sensation Seeking Scale, 27:81
- personality, Sensation Seeking Scale, 27:81
- schizoaffective disorder, Brief Psychiatric Rating Scale, 28:135
- schizoaffective disorder, schizophrenia, 28:135
- schizophrenia, Brief Psychiatric Rating Scale, 28:135
- schizophrenia, schizoaffective disorder, 28:135
- Sensation Seeking Scale, monoamine oxidase, 27:81
- Sensation Seeking Scale, personality, 27:81
- Sensation Seeking Scale, Personality Research Form, 27:81

Mitral valve prolapse

- body size, panic disorder, 28:161
- body size, triiodothyronine, 28:161
- panic disorder, body size, 28:161
- panic disorder, triiodothyronine, 28:161
- triiodothyronine, body size, 28:161
- triiodothyronine, panic disorder, 28:161

Monoamine oxidase

- affective disorder, antisocial personality disorder, 30:265
- affective disorder, borderline personality disorder, 30:265
- affective disorder, personality disorder, 30:265
- antisocial personality disorder, affective disorder, 30:265
- antisocial personality disorder, borderline personality disorder, 30:265
- antisocial personality disorder, personality disorder, 30:265
- anxiety, depressed mood, 30:95
- anxiety, headache, 30:95
- anxiety, migraine, 30:95
- anxiety, platelet, 30:95
- anxiety, tribulin, 30:95
- borderline personality disorder, affective disorder, 30:265
- borderline personality disorder, antisocial personality disorder, 30:265
- depressed mood, anxiety, 30:95
- depressed mood, headache, 30:95
- depressed mood, migraine, 30:95

Monoamine oxidase continued

depressed mood, tribulin, 30:95
 headache, anxiety, 30:95
 headache, depressed mood, 30:95
 headache, tribulin, 30:95
 migraine, anxiety, 30:95
 migraine, depressed mood, 30:95
 migraine, tribulin, 30:95

Minnesota Multiphasic Personality
 Inventory, Personality Research Form,
 27:81

Minnesota Multiphasic Personality
 Inventory, Sensation Seeking Scale,
 27:81

personality disorder, affective disorder,
 30:265

personality disorder, antisocial personality
 disorder, 30:265

personality disorder, borderline, 30:265

Personality Research Form, Minnesota
 Multiphasic Personality Inventory, 27:81

Personality Research Form, Sensation
 Seeking Scale, 27:81

Sensation Seeking Scale, Minnesota
 Multiphasic Personality Inventory, 27:81

Sensation Seeking Scale, Personality
 Research Form, 27:81

tribulin, anxiety, 30:95

tribulin, depressed mood, 30:95

tribulin, headache, 30:95

tribulin, migraine, 30:95

Multiple sclerosis

magnetic resonance imaging,
 neuropsychology, 29:293

magnetic resonance imaging, optic neuritis,
 29:295

neuropsychology, magnetic resonance
 imaging, 29:293

optic neuritis, magnetic resonance imaging,
 29:295

Neuroleptics

affective symptoms, schizophrenia, 28:315
 affective symptoms, tardive dyskinesia,
 28:315

akathisia, propranolol, 27:1

anticonvulsants, plasma concentration,
 28:153

Chinese patients, plasma levels, 30:45

choline, red blood cells, 29:45

choline, schizophrenia, 29:45

choline, tardive dyskinesia, 29:45

electroencephalography, schizophrenia,
 29:395

eye movements, schizophrenia, 28:307

high dose, schizophrenia, 30:1

Neuroleptics continued

high dose, treatment response, 30:1

laterality, parkinsonism, 30:275

laterality, schizophrenia, 30:275

parkinsonism, laterality, 30:275

parkinsonism, schizophrenia, 30:275

plasma concentration, anticonvulsants,
 28:153

plasma levels, Chinese patients, 30:45

propranolol, akathisia, 27:1

red blood cells, choline, 29:45

red blood cells, schizophrenia, 29:45

red blood cells, tardive dyskinesia, 29:45

schizophrenia, affective symptoms, 28:315

schizophrenia, choline, 29:45

schizophrenia, electroencephalography,
 29:395

schizophrenia, eye movements, 28:307

schizophrenia, high dose, 30:1

schizophrenia, laterality, 30:275

schizophrenia, parkinsonism, 30:275

schizophrenia, red blood cells, 29:275

schizophrenia, tardive dyskinesia, 28:315,
 29:45

schizophrenia, treatment response, 30:1
 tardive dyskinesia, affective symptoms,
 28:315

tardive dyskinesia, choline, 29:45

tardive dyskinesia, red blood cells, 29:45

tardive dyskinesia, schizophrenia, 28:315,
 29:45

treatment response, high dose, 30:1

treatment response, schizophrenia, 30:1

Neurological Evaluation Scale

schizophrenia, validity data, 27:335

validity data, schizophrenia, 27:335

Neuropeptides

adrenocorticotrophic hormone, gambling,
 30:137

corticotropin releasing hormone,
 gambling, 30:137

corticotropin releasing hormone,
 gamma-aminobutyric acid, 30:137

corticotropin releasing hormone,
 3-methoxy-4-hydroxyphenylglycol,
 30:137

corticotropin releasing hormone,
 norepinephrine, 30:137

gambling, corticotropin releasing
 hormone, 30:137

gambling, gamma-aminobutyric acid,
 30:137

gambling, 3-methoxy-4-hydroxyphenyl-
 glycol, 30:137

gambling, norepinephrine, 30:137

Neuropeptides continued

- gamma-aminobutyric acid, corticotropin releasing hormone, 30:137
- gamma-aminobutyric acid, gambling, 30:137
- gamma-aminobutyric acid, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gamma-aminobutyric acid, norepinephrine, 30:137
- growth hormone releasing hormone, gambling, 30:137
- 3-methoxy-4-hydroxyphenylglycol, corticotropin releasing hormone, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gambling, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gamma-aminobutyric acid, 30:137
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 30:137
- neuropeptide Y, gambling, 30:137
- norepinephrine, corticotropin releasing hormone, 30:137
- norepinephrine, gambling, 30:137
- norepinephrine, gamma-aminobutyric acid, 30:137
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 30:137
- somatostatin, gambling, 30:137

Nialamide

- clenbuterol, food restriction, rats, 27:149
- clomipramine, food restriction, rats, 27:149
- desipramine, food restriction, rats, 27:149
- food restriction, rats, 27:149
- indalpine, food restriction, rats, 27:149
- rats, food restriction, 27:149

Norepinephrine

- attention deficit disorder, catecholamines, 27:241
- attention deficit disorder, conduct disorder, 27:241
- attention deficit disorder, dopamine-beta-hydroxylase, 27:241
- adolescents, affective disorder, 27:101
- adolescents, cortisol, 27:101
- adolescents, 3-methoxy-4-hydroxyphenylglycol, 27:101
- affective disorder, adolescents, 27:101
- affective disorder, circadian rhythms, 28:263
- affective disorder, cortisol, 27:101, 28:263, 29:187
- affective disorder, dexamethasone suppression test, 29:187
- affective disorder, dopamine, 29:187

Norepinephrine continued

- affective disorder, epinephrine, 29:187
- affective disorder, generalized anxiety disorder, 30:253
- affective disorder, melatonin, 28:263
- affective disorder, 3-methoxy-4-hydroxyphenylglycol, 27:101
- affective disorder, temperature, 28:263
- affective disorder, thyroid stimulating hormone, 28:263
- affective disorder, time sampling, 30:253
- blood pressure, cortisol, 27:173
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, heart rate, 27:173
- blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173
- blood pressure, yohimbine, 27:173
- catecholamines, attention deficit disorder, 27:241
- catecholamines, conduct disorder, 27:241
- catecholamines, dopamine-beta-hydroxylase, 27:241
- circadian rhythms, affective disorder, 28:263
- circadian rhythms, cortisol, 28:263
- circadian rhythms, melatonin, 28:263
- circadian rhythms, temperature, 28:263
- circadian rhythms, thyroid stimulating hormone, 28:263
- clonidine, growth hormone, 27:297
- clonidine, 3-methoxy-4-hydroxyphenylglycol, 27:297
- clonidine, schizophrenia, 27:297
- clonidine, treatment response prediction, 27:297
- conduct disorder, attention deficit disorder, 27:241
- conduct disorder, catecholamines, 27:241
- conduct disorder, dopamine-beta-hydroxylase, 27:241
- cortisol, adolescents, 27:101
- cortisol, affective disorder, 27:101, 28:163, 29:187
- cortisol, blood pressure, 27:173
- cortisol, circadian rhythms, 28:263
- cortisol, dexamethasone suppression test, 29:187
- cortisol, dopamine, 29:187
- cortisol, epinephrine, 29:187
- cortisol, generalized anxiety disorder, 27:173
- cortisol, heart rate, 27:173
- cortisol, melatonin, 28:263
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:101, 27:173

Norepinephrine continued

cortisol, temperature, 28:263
 cortisol, thyroid stimulating hormone, 28:263
 cortisol, yohimbine, 27:173
 corticotropin releasing hormone, gambling, 30:137
 corticotropin releasing hormone, gamma-aminobutyric acid, 30:137
 corticotropin releasing hormone, 3-methoxy-4-hydroxyphenylglycol, 30:137
 corticotropin releasing hormone, neuropeptides, 30:137
 dexamethasone suppression test, affective disorder, 29:187
 dexamethasone suppression test, cortisol, 29:187
 dexamethasone suppression test, dopamine, 29:187
 dexamethasone suppression test, epinephrine, 29:187
 dopamine, affective disorder, 29:187
 dopamine-beta-hydroxylase, attention deficit disorder, 27:241
 dopamine-beta-hydroxylase, catecholamines, 27:241
 dopamine-beta-hydroxylase, conduct disorder, 27:241
 dopamine, cortisol, 29:187
 dopamine, dexamethasone suppression test, 29:187
 dopamine, epinephrine, 29:187
 epinephrine, affective disorder, 29:187
 epinephrine, cortisol, 29:187
 epinephrine, dexamethasone suppression test, 29:187
 epinephrine, dopamine, 29:187
 gambling, corticotropin releasing hormone, 30:137
 gambling, gamma-aminobutyric acid, 30:137
 gambling, 3-methoxy-4-hydroxyphenylglycol, 30:137
 gambling, neuropeptides, 30:137
 gamma-aminobutyric acid, corticotropin releasing hormone, 30:137
 gamma-aminobutyric acid, gambling, 30:137
 gamma-aminobutyric acid, 3-methoxy-4-hydroxyphenylglycol, 30:137
 gamma-aminobutyric acid, neuropeptides, 30:137

Norepinephrine continued

generalized anxiety disorder, affective disorder, 30:253
 generalized anxiety disorder, blood pressure, 27:173
 generalized anxiety disorder, cortisol, 27:173
 generalized anxiety disorder, heart rate, 27:173
 generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173
 generalized anxiety disorder, time sampling, 30:253
 generalized anxiety disorder, yohimbine, 27:173
 growth hormone, clonidine, 27:297
 growth hormone, 3-methoxy-4-hydroxyphenylglycol, 27:297
 growth hormone, schizophrenia, 27:297
 growth hormone, treatment response prediction, 27:297
 heart rate, blood pressure, 27:173
 heart rate, cortisol, 27:173
 heart rate, generalized anxiety disorder, 27:173
 heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173
 heart rate, yohimbine, 27:173
 melatonin, affective disorder, 28:263
 melatonin, circadian rhythms, 28:263
 melatonin, cortisol, 28:263
 melatonin, temperature, 28:263
 melatonin, thyroid stimulating hormone, 28:263
 3-methoxy-4-hydroxyphenylglycol, adolescents, 27:101
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 27:101
 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173
 3-methoxy-4-hydroxyphenylglycol, clonidine, 27:297
 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:101, 27:173
 3-methoxy-4-hydroxyphenylglycol, corticotropin releasing hormone, 30:137
 3-methoxy-4-hydroxyphenylglycol, gambling, 30:137
 3-methoxy-4-hydroxyphenylglycol, gamma-aminobutyric acid, 30:137
 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173
 3-methoxy-4-hydroxyphenylglycol, growth hormone, 27:297

Norepinephrine continued

- 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173
- 3-methoxy-4-hydroxyphenylglycol, neuropeptides, 30:137
- 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 27:297
- 3-methoxy-4-hydroxyphenylglycol, sleep deprivation, 30:155
- 3-methoxy-4-hydroxyphenylglycol, treatment response prediction, 27:297
- 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173
- neuropeptides, corticotropin releasing hormone, 30:137
- neuropeptides, gambling, 30:137
- neuropeptides, gamma-aminobutyric acid, 30:137
- neuropeptides, 3-methoxy-4-hydroxyphenylglycol, 30:137
- schizophrenia, clonidine, 27:297
- schizophrenia, growth hormone, 27:297
- schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 27:297
- schizophrenia, treatment response prediction, 27:297
- sleep deprivation, 3-methoxy-4-hydroxyphenylglycol, 30:155
- temperature, affective disorder, 28:263
- temperature, circadian rhythms, 28:263
- temperature, cortisol, 28:263
- temperature, melatonin, 28:263
- temperature, thyroid stimulating hormone, 28:263
- thyroid stimulating hormone, affective disorder, 28:263
- thyroid stimulating hormone, circadian rhythms, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, melatonin, 28:263
- thyroid stimulating hormone, temperature, 28:263
- time sampling, affective disorder, 30:253
- time sampling, generalized anxiety disorder, 30:253
- treatment response prediction, clonidine, 27:297
- treatment response prediction, growth hormone, 27:297
- treatment response prediction, 3-methoxy-4-hydroxyphenylglycol, 27:297
- treatment response prediction, schizophrenia, 27:297

Norepinephrine continued

- yohimbine, blood pressure, 27:173
- yohimbine, cortisol, 27:173
- yohimbine, generalized anxiety disorder, 27:173
- yohimbine, heart rate, 27:173
- yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173

Nortriptyline

- affective disorder, antidepressants, 28:1
- affective disorder, geriatric depression, 27:225, 28:1
- affective disorder, maintenance pharmacotherapy, 27:225
- affective disorder, phenelzine, 28:1
- affective disorder, survival analysis, 27:225
- antidepressants, affective disorder, 28:1
- antidepressants, geriatric depression, 28:1
- antidepressants, phenelzine, 28:1
- geriatric depression, affective disorder, 27:225, 28:1
- geriatric depression, antidepressants, 28:1
- geriatric depression, maintenance pharmacotherapy, 27:225
- geriatric depression, phenelzine, 28:1
- geriatric depression, survival analysis, 27:225
- maintenance pharmacotherapy, affective disorder, 27:225
- maintenance pharmacotherapy, geriatric depression, 27:225
- maintenance pharmacotherapy, survival analysis, 27:225
- phenelzine, affective disorder, 28:1
- phenelzine, antidepressants, 28:1
- phenelzine, geriatric depression, 28:1
- survival analysis, affective disorder, 27:225
- survival analysis, geriatric depression, 27:225
- survival analysis, maintenance pharmacotherapy, 27:225

Nuclear magnetic resonance. See Magnetic resonance imaging

Obsessive-compulsive disorder

- anxiety, depressed mood, 27:65
- anxiety, pseudocholinesterase, 27:65
- cortisol, dexamethasone suppression test, 30:243
- depressed mood, anxiety, 27:65
- depressed mood, pseudocholinesterase, 27:65
- dexamethasone suppression test, cortisol, 30:243
- evoked potentials, frontal lobe, 28:63
- evoked potentials, P300, 28:63
- frontal lobe, evoked potentials, 28:63

Obsessive-compulsive disorder continued

frontal lobe, P300, 28:63
 P300, evoked potentials, 28:63
 P300, frontal lobe, 28:63
 pseudocholinesterase, anxiety, 27:65
 pseudocholinesterase, depressed mood, 27:65

Osteoporosis

cortisol, eating disorders, 29:105
 cortisol, estradiol, 29:105
 eating disorders, cortisol, 29:105
 eating disorders, estradiol, 29:105
 estradiol, eating disorders, 29:105

Panic disorder

Acute Panic Inventory, affective disorder, 27:357
 Acute Panic Inventory, carbon dioxide inhalation, 27:183
 Acute Panic Inventory, lactate, 27:357, 29:207
 Acute Panic Inventory, premenstrual dysphoria, 27:183
 Acute Panic Inventory, somatic symptoms, 29:207
 adenosine, caffeine, 30:231
 adenosine, posttraumatic stress disorder, 30:231
 adenosine, taste test, 30:231
 affective disorder, Acute Panic Inventory, 27:357
 affective disorder, lactate, 27:357
 agoraphobia, lactate, 28:181
 agoraphobia, prolactin, 28:181
 alprazolam, diazepam, 30:53
 alprazolam, 3-methoxy-4-hydroxy-phenylglycol, 30:53
 alprazolam, treatment response, 30:53
 anxiety, fenfluramine, 28:295
 anxiety, serotonin, 28:295
 blood gases, lactate, 28:171
 body size, mitral valve prolapse, 28:161
 body size, triiodothyronine, 28:161
 caffeine, adenosine, 30:231
 caffeine, posttraumatic stress disorder, 30:231
 caffeine, taste test, 30:231
 carbon dioxide inhalation, Acute Panic Inventory, 27:183
 carbon dioxide inhalation, premenstrual dysphoria, 27:183
 cortisol, dehydroepiandrosterone, 28:345
 cortisol, dexamethasone suppression test, 30:243
 cortisol, growth hormone, 28:351
 cortisol, prolactin, 28:351

Panic disorder continued

cortisol, syncope, 28:351
 dehydroepiandrosterone, cortisol, 28:345
 dexamethasone suppression test, cortisol, 30:243
 diazepam, alprazolam, 30:53
 diazepam, 3-methoxy-4-hydroxy-phenylglycol, 30:53
 diazepam, treatment response, 30:53
 fenfluramine, anxiety, 28:295
 fenfluramine, serotonin, 28:295
 growth hormone, cortisol, 28:351
 growth hormone, prolactin, 28:351
 growth hormone, syncope, 28:351
 imipramine binding, platelet, 30:21
 lactate, Acute Panic Inventory, 27:357, 29:207
 lactate, affective disorder, 27:357
 lactate, agoraphobia, 28:181
 lactate, blood gases, 28:171
 lactate, prolactin, 28:181
 lactate, somatic symptoms, 29:207
 3-methoxy-4-hydroxyphenylglycol, alprazolam, 30:53
 3-methoxy-4-hydroxyphenylglycol, diazepam, 30:53
 3-methoxy-4-hydroxyphenylglycol, treatment response, 30:53
 mitral valve prolapse, body size, 28:161
 mitral valve prolapse, triiodothyronine, 28:161
 posttraumatic stress disorder, adenosine, 30:231
 posttraumatic stress disorder, caffeine, 30:231
 posttraumatic stress disorder, taste test, 30:231
 premenstrual dysphoria, Acute Panic Inventory, 27:183
 premenstrual dysphoria, carbon dioxide inhalation, 27:183
 prolactin, agoraphobia, 28:181
 prolactin, cortisol, 28:351
 prolactin, growth hormone, 28:351
 prolactin, lactate, 28:181
 prolactin, syncope, 28:351
 serotonin, anxiety, 28:295
 serotonin, fenfluramine, 28:295
 serotonin uptake, platelet, 30:63
 somatic symptoms, Acute Panic Inventory, 29:207
 somatic symptoms, lactate, 29:207
 syncope, cortisol, 28:351
 syncope, growth hormone, 28:351
 syncope, prolactin, 28:351

Panic disorder continued

- taste test, adenosine, 30:231
- taste test, caffeine, 30:231
- taste test, posttraumatic stress disorder, 30:231
- treatment response, alprazolam, 30:53
- treatment response, diazepam, 30:53
- treatment response, 3-methoxy-4-hydroxy phenylglycol, 30:53
- triiodothyronine, body size, 28:161
- triiodothyronine, mitral valve prolapse, 28:161

Parietal lobe

- frontal lobes, positron emission tomography, 28:119
- frontal lobes, schizophrenia, 28:119
- positron emission tomography, frontal lobes, 28:119
- positron emission tomography, schizophrenia, 8:119
- schizophrenia, frontal lobes, 28:119
- schizophrenia, positron emission tomography, 28:119

Parkinson's disease

- laterality, neuroleptics, 30:275
- laterality, schizophrenia, 30:275
- neuroleptics, laterality, 30:275
- neuroleptics, schizophrenia, 30:275
- schizophrenia, laterality, 30:275
- schizophrenia, neuroleptics, 30:275

Perceptual Aberration-Magical Ideation Scale

- attention, college students, 27:207
- attention, Physical Anhedonia Scale, 27:207
- attention, psychosis proneness, 27:207
- attention, risk factors, 27:207
- college students, attention, 27:207
- college students, Physical Anhedonia Scale, 27:207
- college students, psychosis proneness, 27:207
- college students, risk factors, 27:207
- Physical Anhedonia Scale, attention, 27:207
- Physical Anhedonia Scale, college students, 27:207
- Physical Anhedonia Scale, psychosis proneness, 27:207
- Physical Anhedonia Scale, risk factors, 27:207
- psychosis proneness, attention, 27:207
- psychosis proneness, college students, 27:207

Perceptual Aberration-Magical Ideation Scale continued

- psychosis proneness, Physical Anhedonia Scale, 27:207
- psychosis proneness, risk factors, 27:207
- risk factors, attention, 27:207
- risk factors, college students, 27:207
- risk factors, Physical Anhedonia Scale, 27:207
- risk factors, psychosis proneness, 27:207

Perinatal complications

- genetics, schizophrenia, 27:233
- schizophrenia, genetics, 27:233

Personality disorder

- affective disorder, antisocial personality disorder, 30:265
- affective disorder, borderline personality disorder, 30:265
- affective disorder, monoamine oxidase, platelet, 30:265
- antisocial personality disorder, affective disorder, 30:265
- antisocial personality disorder, borderline personality disorder, 30:265
- antisocial personality disorder, monoamine oxidase, platelet, 30:265
- borderline personality disorder, affective disorder, 30:265
- borderline personality disorder, antisocial personality disorder, 30:265
- borderline personality disorder, monoamine oxidase, platelet, 30:265
- diagnostic criteria, self-defeating personality disorder, 30:145
- Minnesota Multiphasic Personality Inventory, monoamine oxidase, platelet, 27:81
- Minnesota Multiphasic Personality Inventory, Personality Research Form, 27:81
- Minnesota Multiphasic Personality Inventory, Sensation Seeking Scale, 27:81
- monoamine oxidase, affective disorder, 30:265
- monoamine oxidase, antisocial personality disorder, 30:265
- monoamine oxidase, borderline personality disorder, 30:265
- monoamine oxidase, Minnesota Multiphasic Personality Inventory, 27:81
- monoamine oxidase, personality, 27:81
- monoamine oxidase, Personality Research Form, 27:81
- monoamine oxidase, platelet, 27:81, 30:265
- monoamine oxidase, Sensation Seeking Scale, 27:81

Perceptual Aberration-Magical Ideation Scale continued

- personality, monoamine oxidase, 27:81
- Personality Research Form, Minnesota Multiphasic Personality Inventory, 27:81
- Personality Research Form, monoamine oxidase, 27:81
- Personality Research Form, Sensation Seeking Scale, 27:81
- personality, Sensation Seeking Scale, 27:81
- self-defeating personality disorder, diagnostic criteria, 30:145
- Sensation Seeking Scale, Minnesota Multiphasic Personality Inventory, 27:81
- Sensation Seeking Scale, monoamine oxidase, 27:81
- Sensation Seeking Scale, Personality Research Form, 27:81

Phenelzine

- affective disorder, antidepressants, 28:1
- affective disorder, geriatric depression, 28:1
- affective disorder, nortriptyline, 28:1
- antidepressants, affective disorder, 28:1
- antidepressants, geriatric depression, 28:1
- antidepressants, nortriptyline, 28:1
- geriatric depression, affective disorder, 28:1
- geriatric depression, antidepressants, 28:1
- geriatric depression, nortriptyline, 28:1
- nortriptyline, affective disorder, 28:1
- nortriptyline, antidepressants, 28:1
- nortriptyline, geriatric depression, 28:1

Phenylacetic acid

- hostility, schizophrenia, 30:111
- paranoid subtype, hostility, 30:111
- paranoid subtype, schizophrenia, 30:111
- schizophrenia, hostility, 30:111
- schizophrenia, paranoid subtype, 30:111

Phenylethanolamine-N-methyltransferase

- dopamine-beta-hydroxylase, locus ceruleus, 27:31
- schizophrenia, post-mortem study, 27:31

Phobic disorders

- simple phobia, subtypes, 28:25
- subtypes, simple phobia, 28:25

Phosphatidylserine

- Alzheimer's disease, EEG mapping, 29:411
- EEG mapping, Alzheimer's disease, 29:411
- EEG mapping, normal volunteers, 29:417

Phosphatidylserine continued

- normal volunteers, EEG mapping, 29:417

Physical Anhedonia Scale

- attention, college students, 27:207
- attention, Perceptual Aberration-Magical Ideation Scale, 27:207
- attention, psychosis proneness, 27:207
- attention, risk factors, 27:207
- college students, attention, 27:207
- college students, Perceptual Aberration-Magical Ideation Scale, 27:207
- college students, psychosis proneness, 27:207
- college students, risk factors, 27:207
- Perceptual Aberration-Magical Ideation Scale, attention, 27:207
- Perceptual Aberration-Magical Ideation Scale, college students, 27:207
- Perceptual Aberration-Magical Ideation Scale, psychosis, 27:207
- Perceptual Aberration-Magical Ideation Scale, risk factors, 27:207
- psychosis proneness, attention, 27:207
- psychosis proneness, college students, 27:207
- psychosis proneness, Perceptual Aberration-Magical Ideation, 27:207
- psychosis proneness, risk factors, 27:207
- risk factors, attention, 27:207
- risk factors, college students, 27:207
- risk factors, Perceptual Aberration-Magical Ideation Scale, 27:207
- risk factors, psychosis proneness, 27:207

Pittsburgh Sleep Quality Index

- affective disorders, sleep, 28:193
- sleep, affective disorders, 28:193

Pituitary

- magnetic resonance imaging, psychiatric symptoms, 29:283
- Placebo withdrawal affective disorder, fluoxetine, 30:191
- affective disorder, Hamilton Rating Scale for Depression, 30:191
- affective disorder, imipramine, 30:191
- fluoxetine, affective disorder, 30:191
- fluoxetine, Hamilton Rating Scale for Depression, 30:191
- Hamilton Rating Scale for Depression, affective disorder, 30:191
- Hamilton Rating Scale for Depression, fluoxetine, 30:191
- Hamilton Rating Scale for Depression, imipramine, 30:191
- imipramine, affective disorder, 30:191

Pituitary continued

imipramine, Hamilton Rating Scale for Depression, 30:191

Positron emission tomography

Alzheimer's disease, computed tomography, 29:359
 Alzheimer's disease, deoxyglucose, 29:351
 Alzheimer's disease, white matter, 29:359
 bromospiperone, dopamine receptors, 29:357
 bromospiperone, schizophrenia, 29:357
 cerebral blood flow, laterality, 27:325
 cerebral blood flow, schizophrenia, 27:325
 computed tomography, Alzheimer's disease, 29:359
 computed tomography, lupus erythematosus, 29:367
 computed tomography, magnetic resonance imaging, 29:363, 29:367
 computed tomography, thalamic infarction, 29:363
 computed tomography, white matter, 29:359
 dementia, deoxyglucose, 29:353
 deoxyglucose, Alzheimer's disease, 29:351
 deoxyglucose, dementia, 29:353
 dopamine receptors, bromospiperone, 29:357
 dopamine receptors, schizophrenia, 29:357
 frontal lobes, parietal lobes, 28:119
 frontal lobes, schizophrenia, 28:119
 Huntington's chorea, psychiatric symptoms, 29:361
 laterality, cerebral blood flow, 27:325
 laterality, schizophrenia, 27:325
 lupus erythematosus, computed tomography, 29:367
 lupus erythematosus, magnetic resonance imaging, 29:367
 magnetic resonance imaging, computed tomography, 29:363, 29:367
 magnetic resonance imaging, lupus erythematosus, 29:367
 magnetic resonance imaging, thalamic infarction, 29:363
 parietal lobes, frontal lobes, 28:119
 parietal lobes, schizophrenia, 28:119
 psychiatric symptoms, Huntington's chorea, 29:361

Positron emission tomography continued

schizophrenia, bromospiperone, 29:357
 schizophrenia, cerebral blood flow, 27:325
 schizophrenia, dopamine receptors, 29:357
 schizophrenia, frontal lobes, 28:119
 schizophrenia, laterality, 27:325
 schizophrenia, parietal lobes, 28:119
 thalamic infarction, computed tomography, 29:363
 thalamic infarction, magnetic resonance imaging, 29:363
 white matter, Alzheimer's disease, 29:359
 white matter, computed tomography, 29:359

Posttraumatic stress disorder

adenosine, caffeine, 30:231
 adenosine, panic disorder, 30:231
 adenosine, taste test, 30:231
 akathisia, beta blocker, 27:1
 akathisia, schizophrenia, 27:1
 beta blocker, akathisia, 27:1
 beta blocker, schizophrenia, 27:1
 caffeine, adenosine, 30:231
 caffeine, panic disorder, 30:231
 caffeine, taste test, 30:231
 panic disorder, adenosine, 30:231
 panic disorder, caffeine, 30:231
 panic disorder, taste test, 30:231
 schizophrenia, akathisia, 27:1
 schizophrenia, beta blocker, 27:1
 taste test, adenosine, 30:231
 taste test, caffeine, 30:231
 taste test, panic disorder, 30:231

Potassium

affective disorder, children,
 children, affective disorder, 29:215

Premenstrual dysphoria

activity, menstrual cycle, 30:285
 activity, sleep, 30:285
 activity, temperature, 30:285
 Acute Panic Inventory, carbon dioxide inhalation, 27:183
 Acute Panic Inventory, panic, 27:183
 blood pressure, heart rate, 27:183
 carbon dioxide inhalation, Acute Panic Inventory, 27:183
 carbon dioxide inhalation, panic, 27:183
 heart rate, blood pressure, 27:183
 menstrual cycle, activity, 30:285
 menstrual cycle, sleep, 30:285
 menstrual cycle, temperature, 30:285
 panic, Acute Panic Inventory, 27:183
 panic, carbon dioxide inhalation, 27:183
 sleep, activity, 30:285

Premenstrual dysphoria continued

- sleep, menstrual cycle, 30:285
- sleep, temperature, 30:285
- temperature, activity, 30:285
- temperature, menstrual cycle, 30:285
- temperature, sleep, 30:285

Prolactin

- age, chlorophenylpiperazine, 29:1
- age, cortisol, 29:1
- age, serotonin, 29:1
- agoraphobia, lactate, 28:181
- agoraphobia, panic disorder, 28:181
- alcoholism, computed tomography, 28:89
- alcoholism, growth hormone, 28:89
- alcoholism, lithium, 29:55
- alcoholism, red blood cells, 29:55
- alcoholism, thyroid stimulating hormone, 28:89
- alcoholism, thyrotropin releasing hormone test, 28:89
- chlorophenylpiperazine, age, 29:1
- chlorophenylpiperazine, cortisol, 29:1
- chlorophenylpiperazine, serotonin, 29:1
- computed tomography, alcoholism, 28:89
- computed tomography, growth hormone, 28:89
- computed tomography, thyroid stimulating hormone, 28:89
- computed tomography, thyrotropin releasing hormone test, 28:89
- cortisol, age, 29:1
- cortisol, chlorophenylpiperazine, 29:1
- cortisol, growth hormone, 28:351
- cortisol, panic disorder, 28:351
- cortisol, serotonin, 29:1
- cortisol, syncope, 28:351
- growth hormone, alcoholism, 28:89
- growth hormone, computed tomography, 28:89
- growth hormone, cortisol, 28:351
- growth hormone, panic disorder, 28:351
- growth hormone, syncope, 28:351
- growth hormone, thyroid stimulating hormone, 28:89
- growth hormone, thyrotropin releasing hormone test, 28:89
- lactate, agoraphobia, 28:181
- lactate, panic disorder, 28:181
- lithium, alcoholism, 29:55
- lithium, red blood cells, 29:55
- metoclopramide, sleep, 29:161
- metoclopramide, thyrotropin releasing hormone, 29:161
- metoclopramide, tryptophan, 29:161
- metoclopramide, weight loss, 29:161

Prolactin continued

- panic disorder, agoraphobia, 28:181
- panic disorder, cortisol, 28:351
- panic disorder, growth hormone, 28:351
- panic disorder, lactate, 28:181
- panic disorder, syncope, 28:351
- red blood cells, alcoholism, 29:55
- red blood cells, lithium, 29:55
- serotonin, age, 29:1
- serotonin, chlorophenylpiperazine, 29:1
- serotonin, cortisol, 29:1
- sleep, metoclopramide, 29:161
- sleep, thyrotropin releasing hormone, 29:161
- sleep, tryptophan, 29:161
- sleep, weight loss, 29:161
- syncope, cortisol, 28:351
- syncope, growth hormone, 28:351
- syncope, panic disorder, 28:351
- thyroid stimulating hormone, alcoholism, 28:89
- thyroid stimulating hormone, computed tomography, 28:89
- thyroid stimulating hormone, growth hormone, 28:89
- releasing hormone, metoclopramide, 29:161
- thyrotropin releasing hormone, sleep, 29:161
- thyrotropin releasing hormone test, alcoholism, 28:89
- thyrotropin releasing hormone test, computed tomography, 28:89
- thyrotropin releasing hormone test, growth hormone, 28:89
- thyrotropin releasing hormone, weight loss, 29:161
- tryptophan, metoclopramide, 29:161
- tryptophan, sleep, 29:161
- tryptophan, thyrotropin releasing hormone, 29:161
- tryptophan, weight loss, 29:161
- weight loss, metoclopramide, 29:161
- weight loss, sleep, 29:161
- weight loss, thyrotropin releasing hormone, 29:161
- weight loss, tryptophan, 29:161

Propranolol

- akathisia, neuroleptic side effect, 27:1
- neuroleptic side effect, akathisia, 27:1

Prostaglandins

- affective disorder, cortisol, 30:181
- affective disorder, cyclic adenosine monophosphate, 30:181
- affective disorder, dihydroergocryptine, 30:181

Prolactin continued

- cortisol, affective disorders, 30:181
- cortisol, cyclic adenosine monophosphate, 30:181
- cortisol, dihydroergocryptine, 30:181
- cyclic adenosine monophosphate, affective disorder, 30:181
- cyclic adenosine monophosphate, cortisol, 30:181
- cyclic adenosine monophosphate, dihydroergocryptine, 30:181
- dihydroergocryptine, affective disorder, 30:181
- dihydroergocryptine, cyclic adenosine monophosphate, 30:181
- dihydroergocryptine, cortisol, 30:181

Pseudocholinesterase

- anxiety, depressed mood, 27:65
- anxiety, obsessive-compulsive disorder, 27:65
- depressed mood, anxiety, 27:65
- depressed mood, obsessive-compulsive disorder, 27:65
- obsessive-compulsive disorder, anxiety, 27:65
- obsessive-compulsive disorder, depressed mood, 27:65

Psychiatric Epidemiology Research Interview

- affective disorder, life events, 30:213
- DSM-III, life events, 30:201
- life events, affective disorder, 30:213
- life events, DSM-III, 30:201

Pupillary response

- light, lithium, 30:305
- light, sheep, 30:305
- lithium, light, 30:305
- lithium, sheep, 30:305
- sheep, light, 30:305

Pyritinol

- Alzheimer's disease, cerebral blood flow, 29:303
- cerebral blood flow, Alzheimer's disease, 29:303
- cognitive function, EEG mapping, 29:387
- EEG mapping, cognitive function, 29:387
- EEG mapping, evoked potentials, 29:413
- EEG mapping, P300, 29:413
- evoked potentials, EEG mapping, 29:413
- evoked potentials, P300, 29:413
- P300, EEG mapping, 29:413
- P300, evoked potentials, 29:413

Pyruvate

- acetazolamide, schizophrenia, 28:279
- acetazolamide, thiamine, 28:279

Pyruvate continued

- schizophrenia, acetazolamide, 28:279
- schizophrenia, thiamine, 28:279
- thiamine, acetazolamide, 28:279
- thiamine, schizophrenia, 28:279

Red blood cells

- affective disorder, ankyrin, 27:267
- affective disorder, bipolar subtype, 27:267
- affective disorder, lithium, 27:267
- alcoholism, lithium, 29:55
- alcoholism, prolactin, 29:55
- ankyrin, affective disorder, 27:267
- ankyrin, bipolar subtype, 27:267
- ankyrin, lithium, 27:267
- bipolar subtype, affective disorder, 27:267
- bipolar subtype, ankyrin, 27:267
- bipolar subtype, lithium, 27:267
- choline, neuroleptics, 29:45
- choline, schizophrenia, 29:45
- choline, tardive dyskinesia, 29:45
- inositol-1-phosphatase, lithium, 27:217
- lithium, affective disorder, 27:267
- lithium, alcoholism, 29:55
- lithium, ankyrin, 27:267
- lithium, bipolar subtype, 27:267
- lithium, inositol-1-phosphatase, 27:217
- lithium, prolactin, 29:55
- neuroleptics, choline, 29:45
- neuroleptics, schizophrenia, 29:45
- neuroleptics, tardive dyskinesia, 29:45
- prolactin, alcoholism, 29:55
- prolactin, lithium, 29:55
- schizophrenia, choline, 29:45
- schizophrenia, neuroleptics, 29:45
- schizophrenia, tardive dyskinesia, 29:45
- tardive dyskinesia, choline, 29:45
- tardive dyskinesia, neuroleptics, 29:45
- tardive dyskinesia, schizophrenia, 29:45

Rapid eye movement (REM). See also Sleep

- affective disorder, relatives of unipolars, 27:127
- affective disorder, sleep, 27:127
- relatives of unipolars, affective disorder, 27:127
- relatives of unipolars, sleep, 27:127
- sleep, affective disorder, 27:127
- sleep, relatives of unipolars, 27:127

Rett syndrome

- EEG mapping, theta activity, 29:425
- theta activity, EEG mapping, 29:425

Risk factors

- attention, college students, 27:207
- attention, Perceptual Aberration-Magical Ideation Scale, 27:207

Risk factors continued

- attention, Physical Anhedonia Scale, 27:207
- attention, psychosis proneness, 27:207
- college students, attention, 27:207
- college students, Physical Anhedonia Scale, 27:207
- college students, psychosis proneness, 27:207
- Perceptual Aberration-Magical Ideation Scale, attention, 27:207
- Physical Anhedonia Scale, attention, 27:207
- Physical Anhedonia Scale, college students, 27:207
- Physical Anhedonia Scale, Perceptual Aberration-Magical Ideation Scale, 27:207
- Physical Anhedonia Scale, psychosis proneness, 27:207
- psychosis proneness, attention, 27:207
- psychosis proneness, college students, 27:207
- psychosis proneness, Physical Anhedonia Scale, 27:207

Scale for the Assessment of Negative Symptoms

- affective flattening, schizophrenia, 27:199
- affective flattening, videotaped interviews, 27:199
- cortisol, schizophrenia, 30:69
- EEG topography, schizophrenia, 29:137
- electromechanical measures, schizophrenia, 28:145
- electromechanical measures, tardive dyskinesia, 28:145
- REM, schizophrenia, 27:359
- REM, sleep, 27:359
- schizophrenia, affective flattening, 27:199
- schizophrenia, cortisol, 30:69
- schizophrenia, EEG topography, 29:137
- schizophrenia, electromechanical measures, 28:145
- schizophrenia, REM, 27:359
- schizophrenia, sleep, 27:359
- schizophrenia, tardive dyskinesia, 28:145
- schizophrenia, videotaped interviews, 27:199
- sleep, REM, 27:359
- sleep, schizophrenia, 27:359
- tardive dyskinesia, electromechanical measures, 28:145
- tardive dyskinesia, schizophrenia, 28:145
- videotaped interviews, affective flattening, 27:199
- videotaped interviews, schizophrenia, 27:199

Schedule for the Deficit Syndrome

- negative symptoms, schizophrenia, 30:119
- schizophrenia, negative symptoms, 30:119

Schizoaffective disorder

- Brief Psychiatric Rating Scale, schizophrenia, 28:135
- Minnesota Multiphasic Personality Inventory, schizophrenia, 28:135
- schizophrenia, Brief Psychiatric Rating Scale, 28:135
- schizophrenia, Minnesota Multiphasic Personality Inventory, 28:135

Schizophrenia

- acetazolamide, pyruvate dehydrogenase, 28:279
- acetazolamide, thiamine, 28:279
- affective disorder, antidepressants, 28:73
- affective disorder, attention, 29:65
- affective disorder, clonidine binding in platelets, 28:73
- affective disorder, continuous performance test, 29:65
- affective disorder, laterality, 29:65
- affective disorder, lithium, 28:73
- affective flattening, Scale for the Assessment of Negative Symptoms, 27:199
- affective flattening, videotaped interviews, 27:199
- affective symptoms, neuroleptics, 28:315
- affective symptoms, tardive dyskinesia, 28:315
- akathisia, beta blocker, 27:1
- akathisia, posttraumatic stress disorder, 27:1
- alpha, EEG, 30:313
- alpha, photic driving, 30:313
- alpha, thalamus, 30:313
- antidepressants, affective disorder, 28:73
- antidepressants, clonidine binding in platelets, 28:73
- antidepressants, lithium, 28:73
- arachnoid cyst, EEG mapping, 29:421
- arachnoid cyst, evoked potentials, 29:421
- arachnoid cyst, P300, 29:421
- arylsulfatase A, metachromatic leucodystrophy, 30:107
- attention, affective disorder, 29:65
- attention, clinical stabilization, 28:31
- attention, computed tomography, 29:267
- attention, continuous performance test, 29:65
- attention, eye movements, 28:31
- attention, laterality, 29:65, 29:267
- attention, ventricle-brain ratio, 29:267
- beta blocker, akathisia, 27:1
- beta blocker, posttraumatic stress disorder, 27:1

Schizophrenia continued

- Brief Psychiatric Rating Scale, schizoaffective disorder, 28:135
- bromospiperone, dopamine receptors, 29:357
- bromospiperone, positron emission tomography, 29:357
- cerebral blood flow, corpus callosum, 29:453
- cerebral blood flow, frontal lobe reduction, 29:331
- cerebral blood flow, laterality, 27:325
- cerebral blood flow, magnetic resonance imaging, 29:453
- cerebral blood flow, positron emission tomography, 27:325
- cerebral blood flow, single photon emission computed tomography, 29:331
- Chinese patients, haloperidol, 30:45
- Chinese patients, plasma levels, 30:45
- choline, neuroleptics, 29:45
- choline, red blood cells, 29:45
- choline, tardive dyskinesia, 29:45
- clinical stabilization, attention, 28:31
- clinical stabilization, eye movements, 28:31
- clonidine, affective disorder, 28:73
- clonidine, antidepressants, 28:73
- clonidine binding in platelets, affective disorder, 28:73
- clonidine binding in platelets, antidepressants, 28:73
- clonidine binding in platelets, lithium, 28:73
- clonidine, growth hormone, 27:297
- clonidine, lithium, 28:73
- clonidine, 3-methoxy-4-hydroxyphenylglycol, 27:297
- clonidine, norepinephrine, 27:297
- clonidine, treatment response prediction, 27:297
- computed tomography, attention, 29:267
- computed tomography, electroencephalogram, 29:137
- computed tomography, frontal lobe, 29:137
- computed tomography, laterality, 29:247, 29:267
- computed tomography, limbic system, 29:255
- computed tomography, magnetic resonance imaging, 29:265
- computed tomography, ventricle-brain ratio, 29:257, 29:265, 29:267
- computed tomography, Wisconsin Card Sort Test, 29:137
- continuous performance test, affective disorder, 29:65
- continuous performance test, attention, 29:65
- continuous performance test, laterality, 29:65

Schizophrenia continued

- corpus callosum, cerebral blood flow, 29:453
- corpus callosum, magnetic resonance imaging, 29:453
- cortisol, dexamethasone suppression test, 30:69
- cortisol, negative symptoms, 30:69
- cortisol, Scale for the Assessment of Negative Symptoms, 30:69
- dementia, EEG mapping, 29:391
- dementia, evoked potentials, 29:391
- dementia, P300, 29:391
- dermatoglyphics, genetics, 29:37
- dermatoglyphics, twins, 29:37
- dexamethasone suppression test, cortisol, 30:69
- dexamethasone suppression test, negative symptoms, 30:69
- diabetes mellitus, glucose tolerance, 29:17
- diabetes mellitus, haloperidol, 29:17
- diabetes mellitus, tardive dyskinesia, 29:17
- dopamine-beta-hydroxylase, locus ceruleus, 27:31
- dopamine-beta-hydroxylase, paranoid subtype, 27:31
- dopamine-beta-hydroxylase, post-mortem study, 27:31
- dopamine receptors, bromospiperone, 29:357
- dopamine receptors, positron emission tomography, 29:357
- EEG, alpha, 30:313
- EEG mapping, arachnoid cyst, 29:421
- EEG mapping, dementia, 29:391
- EEG mapping, evoked potentials, 29:391, 29:421
- EEG mapping, P300, 29:391, 29:421
- EEG mapping, temporal lobe beta, 29:419
- EEG, photic driving, 30:313
- EEG, thalamus, 30:313
- EEG topography, Scale for the Assessment of Negative Symptoms, 29:137
- electroencephalogram, computed tomography, 29:137
- electroencephalogram, frontal lobe, 29:137
- electroencephalogram, neuroleptics, 29:395
- electroencephalogram, Wisconsin Card Sort Test, 29:137
- electromechanical measures, tardive dyskinesia, 28:145
- evoked potentials, arachnoid cyst, 29:421
- evoked potentials, dementia, 29:391

Schizophrenia continued

- evoked potentials, EEG mapping, 29:391, 29:421
- evoked potentials, P300, 29:391, 29:421
- evoked potentials, tardive dyskinesia, 28:117
- eye movements, attention, 28:31
- eye movements, clinical stabilization, 28:31
- eye movements, neuroleptics, 28:307
- frontal lobe, computed tomography, 29:137
- frontal lobe, electroencephalogram, 29:137
- frontal lobe reduction, cerebral blood flow, 29:331
- frontal lobe reduction, single photon emission computed tomography, 29:331
- frontal lobe size, magnetic resonance imaging, 30:11
- frontal lobe size, negative symptoms, 30:11
- frontal lobe size, sagittal morphology, 30:11
- frontal lobe, Wisconsin Card Sort Test, 29:137
- frontal lobes, parietal lobes, 28:119
- frontal lobes, positron emission tomography, 28:119
- gender, 28:243
- gender, genetics, 28:243
- gender, heterogeneity, 28:243
- genetics, 28:243
- genetics, dermatoglyphics, 29:37
- genetics, gender, 28:243
- genetics, heterogeneity, 28:243
- genetics, perinatal complications, 27:233
- genetics, twins, 29:37
- glucose tolerance, diabetes mellitus, 29:17
- glucose tolerance, haloperidol, 29:17
- glucose tolerance, tardive dyskinesia, 29:17
- growth hormone, clonidine, 27:297
- growth hormone, 3-methoxy-4-hydroxyphenylglycol, 27:297
- growth hormone, norepinephrine, 27:297
- growth hormone, treatment response prediction, 27:297
- haloperidol, Chinese patients, 30:45
- haloperidol, diabetes mellitus, 29:17
- haloperidol, glucose tolerance, 29:17
- haloperidol, plasma levels, 30:45
- haloperidol, tardive dyskinesia, 29:17
- heterogeneity, 28:243
- heterogeneity, gender, 28:243
- heterogeneity, genetics, 28:243
- high dose, neuroleptics, 30:1
- high dose, treatment response, 30:1

Schizophrenia continued

- homovanillic acid, pharmacological treatment, 28:97
- hostility, paranoid subtype, 30:111
- hostility, phenylacetic acid, 30:111
- imipramine binding, platelet, 30:21
- laterality, affective disorder, 29:65
- laterality, attention, 29:65, 29:267
- laterality, cerebral blood flow, 27:325
- laterality, computed tomography, 29:247, 29:267
- laterality, continuous performance test, 29:65
- laterality, neuroleptics, 30:275
- laterality, parkinsonism, 30:275
- laterality, positron emission tomography, 27:325
- laterality, ventricle-brain ratio, 29:267
- limbic system, computed tomography, 29:255
- lithium, affective disorder, 28:73
- lithium, antidepressants, 28:73
- lithium, clonidine, 28:73
- lithium, clonidine binding in platelets, 28:73
- locus ceruleus, dopamine-beta-hydroxylase, 27:31
- locus ceruleus, paranoid subtype, 27:31
- locus ceruleus, post-mortem study, 27:31
- magnetic resonance imaging, cerebral blood flow, 29:453
- magnetic resonance imaging, computed tomography, 29:265
- magnetic resonance imaging, corpus callosum, 29:453
- magnetic resonance imaging, frontal lobe size, 30:11
- magnetic resonance imaging, negative symptoms, 30:11
- magnetic resonance imaging, sagittal morphology, 30:11
- magnetic resonance imaging, temporal lobe, 29:261
- magnetic resonance imaging, ventricle-brain ratio, 29:265
- metachromatic leucodystrophy, arylsulfatase A, 30:107
- 3-methoxy-4-hydroxyphenylglycol, clonidine, 27:297
- 3-methoxy-4-hydroxyphenylglycol, growth hormone, 27:297
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:297
- 3-methoxy-4-hydroxyphenylglycol, treatment response prediction, 27:297

Schizophrenia continued

- Minnesota Multiphasic Personality Inventory, schizoaffective disorder, 28:135
- negative symptoms, cortisol, 30:69
- negative symptoms, dexamethasone suppression test, 30:69
- negative symptoms, frontal lobe size, 30:11
- negative symptoms, magnetic resonance imaging, 30:11
- negative symptoms, saggital morphology, 30:11
- negative symptoms, Schedule for the Deficit Syndrome, 30:119
- neuroleptics, affective symptoms, 28:315
- neuroleptics, choline, 29:45
- neuroleptics, electroencephalography, 29:395
- neuroleptics, eye movements, 28:307
- neuroleptics, high dose, 30:1
- neuroleptics, laterality, 30:275
- neuroleptics, parkinsonism, 30:275
- neuroleptics, red blood cells, 29:45
- neuroleptics, tardive dyskinesia, 28:315, 29:45
- neuroleptics, treatment response, 30:1
- Neurological Evaluation Scale, validity data, 27:335
- norepinephrine, clonidine, 27:297
- norepinephrine, growth hormone, 27:297
- norepinephrine, 3-methoxy-4-hydroxy-phenylglycol, 27:297
- norepinephrine, treatment response prediction, 27:297
- P300, arachnoid cyst, 29:421
- P300, dementia, 29:391
- P300, EEG mapping, 29:391, 29:421
- P300, evoked potentials, 29:391, 29:421
- paranoid subtype, dopamine-beta-hydroxylase, 27:31
- paranoid subtype, hostility, 30:111
- paranoid subtype, locus ceruleus, 27:31
- paranoid subtype, phenylacetic acid, 30:111
- paranoid subtype, post-mortem study, 27:31
- parietal lobes, frontal lobes, 28:119
- parietal lobes, positron emission tomography, 28:119
- parkinsonism, laterality, 30:275
- parkinsonism, neuroleptics, 30:275
- perinatal complications, genetics, 27:233
- pharmacological treatment, homovanillic acid, 28:97
- phenylacetic acid, hostility, 30:111

Schizophrenia continued

- phenylacetic acid, paranoid subtype, 30:111
- phenylethanolamine-N-methyltransferase, post-mortem study, 27:31
- photic driving, alpha, 30:313
- photic driving, EEG, 30:313
- photic driving, thalamus, 30:313
- plasma levels, Chinese patients, 30:45
- plasma levels, haloperidol, 30:45
- platelet, imipramine binding, 30:21
- positron emission tomography, bromospiperone, 29:357
- positron emission tomography, cerebral blood flow, 27:325
- positron emission tomography, dopamine receptors, 29:357
- positron emission tomography, frontal lobes, 28:119
- positron emission tomography, laterality, 27:325
- positron emission tomography, parietal lobes, 28:119
- post-mortem study, dopamine-beta-hydroxylase, 27:31
- post-mortem study, locus ceruleus, 27:31
- post-mortem study, paranoid subtype, 27:31
- post-mortem study, phenylethanolamine-N-methyltransferase, 27:31
- posttraumatic stress disorder, akathisia, 27:1
- posttraumatic stress disorder, beta blocker, 27:1
- pyruvate dehydrogenase, acetazolamide, 28:279
- pyruvate dehydrogenase, thiamine, 28:279
- red blood cells, choline, 29:45
- red blood cells, neuroleptics, 29:45
- red blood cells, tardive dyskinesia, 29:45
- REM, Scale for the Assessment of Negative Symptoms, 27:359
- REM, sleep, 27:359
- saggital morphology, frontal lobe size, 30:11
- saggital morphology, magnetic resonance imaging, 30:11
- saggital morphology, negative symptoms, 30:11
- Scale for the Assessment of Negative Symptoms, affective flattening, 27:199
- Scale for the Assessment of Negative Symptoms, cortisol, 30:69
- Scale for the Assessment of Negative Symptoms, EEG topography, 29:137

Schizophrenia continued

- Scale for the Assessment of Negative Symptoms, REM, 27:359
- Scale for the Assessment of Negative Symptoms, sleep, 27:359
- Scale for the Assessment of Negative Symptoms, tardive dyskinesia, 28:315
- Scale for the Assessment of Negative Symptoms, videotaped interviews, 27:199
- Schedule for the Deficit Syndrome, negative symptoms, 30:119
- schizoaffective disorder, Brief Psychiatric Rating Scale, 28:135
- schizoaffective disorder, Minnesota Multiphasic Personality Inventory, 28:135
- sleep, REM, 27:359
- sleep, Scale for the Assessment of Negative Symptoms, 27:359
- single photon emission computed tomography, cerebral blood flow, 29:331
- single photon emission computed tomography, frontal lobe reduction, 29:331
- tardive dyskinesia, affective symptoms, 28:315
- tardive dyskinesia, choline, 29:45
- tardive dyskinesia, diabetes mellitus, 29:17
- tardive dyskinesia, electromechanical measures, 28:145
- tardive dyskinesia, evoked potentials, 28:117
- tardive dyskinesia, glucose tolerance, 29:17
- tardive dyskinesia, haloperidol, 29:17
- tardive dyskinesia, neuroleptics, 28:315, 29:45
- tardive dyskinesia, red blood cells, 29:45
- tardive dyskinesia, Scale for the Assessment of Negative Symptoms, 28:145
- temporal lobe beta, EEG mapping, 29:419
- temporal lobe, magnetic resonance imaging, 29:261
- thalamus, alpha, 30:313
- thalamus, EEG, 30:313
- thalamus, photic driving, 30:313
- thiamine, acetazolamide, 28:279
- thiamine, pyruvate dehydrogenase, 28:279
- treatment response, high dose, 30:1

Schizophrenia continued

- treatment response, neuroleptics, 30:1
- treatment response prediction, clonidine, 27:297
- treatment response prediction, growth hormone, 27:297
- treatment response prediction, 3-methoxy-4-hydroxyphenylglycol, 27:297
- treatment response prediction, norepinephrine, 27:297
- twins, dermatoglyphics, 29:37
- twins, genetics, 29:37
- validity data, Neurological Evaluation Scale, 27:335
- ventricle-brain ratio, attention, 29:267
- ventricle-brain ratio, computed tomography, 29:257, 29:265, 29:267
- ventricle-brain ratio, laterality, 29:267
- ventricle-brain ratio, magnetic resonance imaging, 29:265
- videotaped interviews, affective flattening, 27:199
- videotaped interviews, Scale for the Assessment of Negative Symptoms, 27:199
- Wisconsin Card Sort Test, computed tomography, 29:137
- Wisconsin Card Sort Test, electroencephalogram, 29:137
- Wisconsin Card Sort Test, frontal lobe, 29:137

Seasonal affective disorder

- affective disorder, cluster analysis, 28:227
- affective disorder, light therapy, 29:29
- affective disorder, statistics, 28:227
- affective disorder, temperature, 28:323
- cluster analysis, affective disorder, 28:227
- cluster analysis, statistics, 28:227
- light therapy, affective disorder, 29:29
- statistics, affective disorder, 28:227
- statistics, cluster analysis, 28:227
- temperature, affective disorder, 28:323

Seizures

- comparison with EEG, magnetoencephalography, 29:377
- computed tomography, EEG focus, 29:459
- computed tomography, magnetic resonance imaging, 29:459
- computed tomography, single photon emission computed tomography, 29:459
- EEG focus, computed tomography, 29:459
- EEG focus, magnetic resonance imaging, 29:459
- EEG focus, single photon emission computed tomography, 29:459

Seizures continued

- lithium, rats, 30:77
- lithium, theophylline, 30:77
- magnetic resonance imaging, computed tomography, 29:459
- magnetic resonance imaging, EEG focus, 29:459
- magnetic resonance imaging, single photon emission computed tomography, 29:459
- magnetoencephalography, comparison with EEG, 29:377
- rats, lithium, 30:77
- rats, theophylline, 30:77
- single photon emission computed tomography, computed tomography, 29:459
- single photon emission computed tomography, EEG focus, 29:459
- single photon emission computed tomography, magnetic resonance imaging, 29:459
- theophylline, lithium, 30:77
- theophylline, rats, 30:77

Sensation Seeking Scale

- Minnesota Multiphasic Personality Inventory, monoamine oxidase, 27:81
- Minnesota Multiphasic Personality Inventory, Personality Research Form, 27:81
- monoamine oxidase, Minnesota Multiphasic Personality Inventory, 27:81
- monoamine oxidase, Personality Research Form, 27:81
- monoamine oxidase, platelet, 27:81
- personality, monoamine oxidase, 27:81
- Personality Research Form, Minnesota Multiphasic Personality Inventory, 27:81
- Personality Research Form, monoamine oxidase, 27:81

Serotonin

- affective disorders, cyclic adenosine monophosphate, 30:181
- affective disorders, dihydroergocryptine binding, 30:181
- affective disorders, 5-hydroxyindolacetic acid, 30:181
- age, chlorophenylpiperazine, 29:1
- age, cortisol, 29:1
- age, prolactin, 29:1
- aggression, impulsivity, 27:5
- anxiety, fenfluramine, 28:295
- anxiety, panic disorder, 28:295
- cyclic adenosine monophosphate, affective disorder, 30:181

Serotonin continued

- cyclic adenosine monophosphate, dihydroergocryptine binding, 30:181
- cyclic adenosine monophosphate, 5-hydroxyindolacetic acid, 30:181
- chlorophenylpiperazine, age, 29:1
- chlorophenylpiperazine, cortisol, 29:1
- chlorophenylpiperazine, prolactin, 29:1
- circannual rhythm, platelet uptake, 27:5
- cortisol, age, 29:1
- cortisol, chlorophenylpiperazine, 29:1
- cortisol, prolactin, 29:1
- desipramine, frontal lobe, 30:125
- desipramine, imipramine binding, 30:125
- desipramine, suicide, 30:125
- dihydroergocryptine binding, affective disorder, 30:181
- dihydroergocryptine binding, cyclic adenosine monophosphate, 30:181
- dihydroergocryptine binding, 5-hydroxyindolacetic acid, 30:181
- fenfluramine, anxiety, 28:295
- fenfluramine, panic disorder, 28:295
- frontal lobe, desipramine, 30:125
- frontal lobe, imipramine binding, 30:125
- frontal lobe, suicide, 30:125
- 5-hydroxyindolacetic acid, affective disorders, 30:181
- 5-hydroxyindolacetic acid, cyclic adenosine monophosphate, 30:181
- 5-hydroxyindolacetic acid, dihydroergocryptine binding, 30:181
- imipramine binding, desipramine, 30:125
- imipramine binding, frontal lobe, 30:125
- imipramine binding, suicide, 30:125
- impulsivity, aggression, 27:5
- panic disorder, anxiety, 28:295
- panic disorder, fenfluramine, 28:295
- platelet, aggression, 27:5
- platelet, panic disorder, 30:63
- platelet uptake, circannual rhythm, 27:5
- prolactin, age, 29:1
- prolactin, chlorophenylpiperazine, 29:1
- prolactin, cortisol, 29:1
- suicide, desipramine, 30:125
- suicide, frontal lobe, 30:125
- suicide, imipramine binding, 30:125

Sleep deprivation

- activity, menstrual cycle, 30:285
- activity, premenstrual syndrome, 30:285
- activity, temperature, 30:285
- affective disorder, bipolar depression, 27:23
- affective disorder, circadian rhythm, 27:23

Sleep deprivation continued

- affective disorder, clomipramine, 28:47, 30:165
- affective disorder, geriatric depression, 27:13
- affective disorder, interview behavior, 28:47
- affective disorder, naps, 27:253
- affective disorder, Pittsburgh Sleep Quality Index, 28:193
- affective disorder, relatives of unipolars, 27:127
- affective disorder, REM latency, 27:127
- affective disorder, subtype, 27:13
- affective disorder, temperature, 27:23
- affective disorder, thyroid stimulating hormone, 29:231
- affective disorder, triiodothyronine, 29:231
- bipolar depression, affective disorder, 27:23
- bipolar depression, circadian rhythms, 27:23
- bipolar depression, temperature, 27:23
- circadian rhythms, affective disorder, 27:23
- circadian rhythms, bipolar depression, 27:23
- circadian rhythms, temperature, 27:23
- clomipramine, affective disorder, 28:47, 30:165
- clomipramine, interview behavior, 28:47
- EEG mapping, K complex, 29:435
- geriatric depression, affective disorder, 27:13
- geriatric depression, subtype, 27:13
- interview behavior, affective disorder, 28:47
- interview behavior, clomipramine, 28:47
- K complex, EEG mapping, 29:435
- menstrual cycle, activity, 30:285
- menstrual cycle, premenstrual syndrome, 30:285
- menstrual cycle, temperature, 30:285
- metoclopramide, prolactin, 29:161
- metoclopramide, thyrotropin releasing hormone, 29:161
- metoclopramide, tryptophan, 29:161
- metoclopramide, weight loss, 29:161
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 30:155
- naps, affective disorder, 27:253
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 30:155

Sleep Deprivation continued

- Pittsburgh Sleep Quality Index, affective disorder, 28:193
- premenstrual syndrome, activity, 30:285
- premenstrual syndrome, menstrual cycle, 30:285
- premenstrual syndrome, temperature, 30:285
- prolactin, metoclopramide, 29:161
- prolactin, thyrotropin releasing hormone, 29:161
- prolactin, tryptophan, 29:161
- prolactin, weight loss, 29:161
- relatives of unipolars, affective disorder, 27:127
- relatives of unipolars, REM latency, 27:127
- REM latency, affective disorder, 27:127
- REM latency, relatives of unipolars, 27:127
- REM, Scale for the Assessment of Negative Symptoms, 27:359
- REM, schizophrenia, 27:359
- Scale for the Assessment of Negative Symptoms, REM, 27:359
- Scale for the Assessment of Negative Symptoms, schizophrenia, 27:359
- schizophrenia, REM, 27:359
- schizophrenia, Scale for the Assessment of Negative Symptoms, 27:359
- subtype, affective disorder, 27:13
- subtype, geriatric depression, 27:13
- temperature, activity, 30:285
- temperature, affective disorder, 27:23
- temperature, bipolar depression, 27:23
- temperature, circadian rhythms, 27:23
- temperature, menstrual cycle, 30:285
- temperature, premenstrual syndrome, 30:285
- thyroid stimulating hormone, affective disorder, 29:231
- thyroid stimulating hormone, triiodothyronine, 29:231
- thyrotropin releasing hormone, metoclopramide, 29:161
- thyrotropin releasing hormone, prolactin, 29:161
- thyrotropin releasing hormone, tryptophan, 29:161
- thyrotropin releasing hormone, weight loss, 29:161
- triiodothyronine, affective disorder, 29:231
- triiodothyronine, thyroid stimulating hormone, 29:231

Sleep deprivation continued

- tryptophan, metoclopramide, 29:161
- tryptophan, prolactin, 29:161
- tryptophan, thyrotropin releasing hormone, 29:161
- tryptophan, weight loss, 29:161
- weight loss, metoclopramide, 29:161
- weight loss, prolactin, 29:161
- weight loss, thyrotropin releasing hormone, 29:161
- weight loss, tryptophan, 29:161

Social group size

- age, mental retardation, 30:31
- mental retardation, ethology, 30:31

Sodium

- affective disorder, children, 29:215
- children, affective disorder, 29:215

Single photon emission computed tomography

- affective disorder, cerebral blood flow, 29:323, 29:331
- Alzheimer's disease, cerebral blood flow, 29:347
- Alzheimer's disease, computed tomography, 29:445
- Alzheimer's disease, dementia, 29:445
- Alzheimer's disease, EEG mapping, 29:449
- brain death, children, 29:343
- brain tumors, cerebral blood flow, 29:341
- caudate nucleus, Huntington's chorea, 29:337
- cerebral blood flow, affective disorder, 29:323, 29:331
- cerebral blood flow, Alzheimer's disease, 29:347
- cerebral blood flow, brain tumors, 29:341
- cerebral blood flow, dementia, 29:327
- cerebral blood flow, frontal lobe reduction, 29:331
- cerebral blood flow, schizophrenia, 29:331
- cerebral ischemia, computed tomography, 29:457
- children, brain death, 29:343
- computed tomography, Alzheimer's disease, 29:445
- computed tomography, cerebral ischemia, 29:457
- computed tomography, dementia, 29:445
- computed tomography, EEG focus, 29:459
- computed tomography, magnetic resonance imaging, 29:459
- computed tomography, seizures, 29:459
- dementia, Alzheimer's disease, 29:445
- dementia, cerebral blood flow, 29:327
- dementia, computed tomography, 29:445

Single photon emission computed tomography continued

- EEG focus, computed tomography, 29:459
- EEG focus, magnetic resonance imaging, 29:459
- EEG focus, seizures, 29:459
- EEG mapping, Alzheimer's disease, 29:449
- frontal lobe reduction, cerebral blood flow, 29:331
- frontal lobe reduction, schizophrenia, 29:331
- Huntington's chorea, caudate nucleus, 29:337
- magnetic resonance imaging, computed tomography, 29:459
- magnetic resonance imaging, EEG focus, 29:459
- magnetic resonance imaging, seizures, 29:459
- mescaline, psychosis, 29:335
- psychosis, mescaline, 29:335
- schizophrenia, cerebral blood flow, 29:331
- schizophrenia, frontal lobe reduction, 29:331
- seizures, computed tomography, 29:459
- seizures, EEG focus, 29:459
- seizures, magnetic resonance imaging, 29:459

Spiperone

- butaclamol, dopamine, 30:259
- butaclamol, lymphocytes, 30:259
- dopamine, butaclamol, 30:259
- dopamine, lymphocytes, 30:259
- lymphocytes, butaclamol, 30:259
- lymphocytes, dopamine, 30:258

Statistics

- affective disorder, cluster analysis, 28:227
- affective disorder, seasonal affective disorder, 28:227
- binary data, correlated data, 28:41
- binary data, matched pair data, 28:41
- cluster analysis, affective disorder, 28:227
- cluster analysis, seasonal affective disorder, 28:227
- correlated data, binary data, 28:41
- correlated data, matched pair data, 28:41
- matched pair data, binary data, 28:41
- matched pair data, correlated data, 28:41
- seasonal affective disorder, affective disorder, 28:227
- seasonal affective disorder, cluster analysis, 28:227

Stressors

- affective disorder, life events, 30:213
- affective disorder, mania, 30:213

Stressors continued

- Axis IV, diagnostic criteria, 30:201
- Axis IV, DSM-III, 30:201
- blood pressure, eating disorders, 30:223
- blood pressure, heart rate, 30:223
- blood pressure, Type A behavior, 30:223
- diagnostic criteria, Axis IV, 30:201
- diagnostic criteria, DSM-III, 30:201
- DSM-III, Axis IV, 30:201
- DSM-III, diagnostic criteria, 30:201
- eating disorders, blood pressure, 30:223
- eating disorders, heart rate, 30:223
- eating disorders, Type A behavior, 30:223
- heart rate, blood pressure, 30:223
- heart rate, eating disorders, 30:223
- heart rate, Type A behavior, 30:223
- life events, affective disorder, 30:213
- life events, mania, 30:213
- mania, affective disorder, 30:213
- mania, life events, 30:213
- Type A behavior, blood pressure, 30:223
- Type A behavior, eating disorders, 30:223
- Type A behavior, heart rate, 30:223

Stroke

- computed tomography, embolic mechanisms, 29:273
- embolic mechanisms, computed tomography, 29:273

Substance abuse

- affective disorder, cocaine, 28:105, 28:335
- affective disorder, comorbidity, 28:105, 28:335
- alcoholism, cocaine, 29:113
- alcoholism, comorbidity, 29:113
- alcoholism, genetics, 29:113
- amantadine, bromocriptine, 29:11
- amantadine, cocaine, 29:11
- amantadine, withdrawal, 29:11
- blood pressure, cocaine, 27:117
- blood pressure, haloperidol, 27:117
- blood pressure, heart rate, 27:117
- blood pressure, subjective effects, 27:117
- bromocriptine, amantadine, 29:11
- bromocriptine, cocaine, 29:11
- bromocriptine, withdrawal, 29:11
- cocaine, affective disorder, 28:105, 28:335
- cocaine, alcoholism, 29:113
- cocaine, amantadine, 29:11
- cocaine, blood pressure, 27:117
- cocaine, bromocriptine, 29:11
- cocaine, comorbidity, 28:105, 28:335, 29:113
- cocaine, eye movements, 29:123
- cocaine, genetics, 29:113
- cocaine, haloperidol, 27:117

Substance abuse continued

- cocaine, heart rate, 27:117
- cocaine, 3-methoxy-4-hydroxyphenylglycol, 29:123
- cocaine, subjective effects, 27:117
- cocaine, withdrawal, 29:11
- comorbidity, affective disorder, 28:105, 28:335
- comorbidity, alcoholism, 29:113
- comorbidity, cocaine, 28:105, 28:335, 29:113
- comorbidity, genetics, 29:113
- eye movements, cocaine, 29:123
- eye movements, 3-methoxy-4-hydroxyphenylglycol, 29:123
- genetics, alcoholism, 29:113
- genetics, cocaine, 29:113
- genetics, comorbidity, 29:113
- haloperidol, blood pressure, 27:117
- haloperidol, cocaine, 27:117
- haloperidol, heart rate, 27:117
- haloperidol, subjective effects, 27:117
- heart rate, blood pressure, 27:117
- heart rate, cocaine, 27:117
- heart rate, haloperidol, 27:117
- heart rate, subjective effects, 27:117
- 3-methoxy-4-hydroxyphenylglycol, cocaine, 29:123
- 3-methoxy-4-hydroxyphenylglycol, eye movements, 29:123
- subjective effects, blood pressure, 27:117
- subjective effects, cocaine, 27:117
- subjective effects, haloperidol, 27:117
- subjective effects, heart rate, 27:117
- withdrawal, amantadine, 29:11
- withdrawal, bromocriptine, 29:11
- withdrawal, cocaine, 29:11

Suicide

- Albert Einstein College of Medicine Suicide Intent Scale, affective disorder, 27:71
- affective disorder, Albert Einstein College of Medicine Suicide Intent Scale, 27:71
- depressed mood, impulsivity, 27:71
- depressed mood, seriousness of attempt, 27:71
- desipramine, frontal lobe, 30:125
- desipramine, imipramine binding, 30:125
- desipramine, serotonin, 30:125
- frontal lobe, desipramine, 30:125
- frontal lobe, imipramine binding, 30:125
- frontal lobe, serotonin, 30:125
- imipramine binding, desipramine, 30:125
- imipramine binding, frontal lobe, 30:125
- imipramine binding, platelet, 30:21

Suicide continued

- imipramine binding, serotonin, 30:125
- impulsivity, depressed mood, 27:71
- impulsivity, seriousness of attempt, 27:71
- risk factors, violence, 28:215
- seriousness of attempt, depressed mood, 27:71
- seriousness of attempt, impulsivity, 27:71
- serotonin, desipramine, 30:125
- serotonin, frontal lobe, 30:125
- serotonin, imipramine binding, 30:125
- violence, risk factors, 28:215

Syncope

- cortisol, growth hormone, 28:351
- cortisol, panic disorder, 28:351
- cortisol, prolactin, 28:351
- growth hormone, panic disorder, 28:351
- growth hormone, prolactin, 28:351
- panic disorder, cortisol, 28:351
- panic disorder, growth hormone, 28:351
- panic disorder, prolactin, 28:351
- prolactin, panic disorder, 28:351

Tardive dyskinesia

- Abnormal Involuntary Movement Scale, electromechanical measures, 27:193
- Abnormal Involuntary Movement Scale, observer ratings, 27:193
- affective symptoms, neuroleptics, 28:315
- affective symptoms, schizophrenia, 28:315
- choline, neuroleptics, 29:45
- choline, red blood cells, 29:45
- choline, schizophrenia, 29:45
- diabetes mellitus, glucose tolerance, 29:17
- diabetes mellitus, haloperidol, 29:17
- diabetes mellitus, schizophrenia, 29:17
- electromechanical measures, Abnormal Involuntary Movement Scale, 27:193
- electromechanical measures, observer ratings, 27:193
- electromechanical measures, Scale for the Assessment of Negative Symptoms, 28:145
- electromechanical measures, schizophrenia, 28:145
- essential fatty acids, linoleic acid, 27:313
- evoked potentials, schizophrenia, 28:117
- glucose tolerance, diabetes mellitus, 29:17
- glucose tolerance, haloperidol, 29:17
- glucose tolerance, schizophrenia, 29:17
- haloperidol, diabetes mellitus, 29:17
- haloperidol, glucose tolerance, 29:17
- haloperidol, schizophrenia, 29:17
- linoleic acid, essential fatty acids, 27:313
- neuroleptics, affective symptoms, 28:315
- neuroleptics, choline, 29:45
- neuroleptics, red blood cells, 29:45

Tardive dyskinesia continued

- neuroleptics, schizophrenia, 28:315, 29:45
- observer ratings, Abnormal Involuntary Movement Scale, 27:193
- observer ratings, electromechanical measures, 27:193
- red blood cells, choline, 29:45
- red blood cells, neuroleptics, 29:45
- red blood cells, schizophrenia, 29:45
- Scale for the Assessment of Negative Symptoms, electromechanical measures, 28:145
- Scale for the Assessment of Negative Symptoms, schizophrenia, 28:145
- schizophrenia, affective symptoms, 28:315
- schizophrenia, choline, 29:45
- schizophrenia, diabetes mellitus, 29:17
- schizophrenia, electromechanical measures, 28:145
- schizophrenia, evoked potentials, 28:117
- schizophrenia, glucose tolerance, 29:17
- schizophrenia, haloperidol, 29:17
- schizophrenia, neuroleptics, 28:315, 29:45
- schizophrenia, red blood cells, 29:45
- schizophrenia, Scale for the Assessment of Negative Symptoms, 28:145

Temperature

- activity, menstrual cycle, 30:285
- activity, premenstrual syndrome, 30:285
- activity, sleep, 30:285
- affective disorder, bipolar depression, 27:23
- affective disorder, circadian rhythms, 27:23, 28:263
- affective disorder, cortisol, 28:263
- affective disorder, melatonin, 28:263
- affective disorder, norepinephrine, 28:263
- affective disorder, seasonal affective disorder, 28:323
- affective disorder, sleep, 27:23
- affective disorder, thyroid stimulating hormone, 28:263
- bipolar depression, affective disorder, 27:23
- bipolar depression, circadian rhythms, 27:23
- bipolar depression, sleep, 27:23
- circadian rhythms, affective disorder, 27:23, 28:263
- circadian rhythms, bipolar depression, 27:23
- circadian rhythms, cortisol, 28:263
- circadian rhythms, melatonin, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, sleep, 27:23

Temperature continued

- circadian rhythms, thyroid stimulating hormone, 28:263
- cortisol, affective disorder, 28:263
- cortisol, circadian rhythms, 28:263
- cortisol, melatonin, 28:263
- cortisol, norepinephrine, 28:263
- cortisol, thyroid stimulating hormone, 28:263
- melatonin, affective disorder, 28:263
- melatonin, circadian rhythms, 28:263
- melatonin, cortisol, 28:263
- melatonin, norepinephrine, 28:263
- melatonin, thyroid stimulating hormone, 28:263
- menstrual cycle, activity, 30:285
- menstrual cycle, premenstrual syndrome, 30:285
- menstrual cycle, sleep, 30:285
- norepinephrine, affective disorder, 28:263
- norepinephrine, circadian rhythms, 28:263
- norepinephrine, cortisol, 28:263
- norepinephrine, melatonin, 28:263
- norepinephrine, thyroid stimulating hormone, 28:263
- premenstrual syndrome, activity, 30:285
- premenstrual syndrome, menstrual cycle, 30:285
- premenstrual syndrome, sleep, 30:285
- seasonal affective disorder, affective disorder, 28:323
- sleep, activity, 30:285
- sleep, affective disorder, 27:23
- sleep, bipolar depression, 27:23
- sleep, circadian rhythms, 27:23
- sleep, menstrual cycle, 30:285
- sleep, premenstrual syndrome, 30:285
- thyroid stimulating hormone, affective disorder, 28:263
- thyroid stimulating hormone, circadian rhythms, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, melatonin, 28:263
- thyroid stimulating hormone, norepinephrine, 28:263

Theophylline

- lithium, rats, 30:77
- lithium, seizures, 30:77
- rats, lithium, 30:77
- rats, seizures, 30:77
- seizures, lithium, 30:77
- seizures, rats, 30:77

Thiamine

- acetazolamide, pyruvate dehydrogenase, 28:279
- acetazolamide, schizophrenia, 28:279
- pyruvate dehydrogenase, acetazolamide, 28:279
- pyruvate dehydrogenase, schizophrenia, 28:279
- schizophrenia, acetazolamide, 28:279
- schizophrenia, pyruvate dehydrogenase, 28:279

Thyroid stimulating hormone

- affective disorder, circadian rhythms, 28:263
- affective disorder, cortisol, 28:263
- affective disorder, melatonin, 28:263
- affective disorder, norepinephrine, 28:263
- affective disorder, sleep deprivation, 29:231
- affective disorder, temperature, 28:263
- affective disorder, triiodothyronine, 29:231
- alcoholism, computed tomography, 28:89
- alcoholism, growth hormone, 28:89
- alcoholism, prolactin, 28:89
- alcoholism, thyrotropin releasing hormone test, 28:89
- circadian rhythms, affective disorder, 28:263
- circadian rhythms, cortisol, 28:263
- circadian rhythms, melatonin, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, temperature, 28:263
- computed tomography, alcoholism, 28:89
- computed tomography, growth hormone, 28:89
- computed tomography, prolactin, 28:89
- computed tomography, thyrotropin releasing hormone test, 28:89
- cortisol, affective disorder, 28:263
- cortisol, circadian rhythms, 28:263
- cortisol, melatonin, 28:263
- cortisol, norepinephrine, 28:263
- cortisol, temperature, 28:263
- growth hormone, alcoholism, 28:89
- growth hormone, computed tomography, 28:89
- growth hormone, prolactin, 28:89
- growth hormone, thyrotropin releasing hormone test, 28:89
- melatonin, affective disorder, 28:263
- melatonin, circadian rhythms, 28:263
- melatonin, cortisol, 28:263
- melatonin, norepinephrine, 28:263

Thyroid Stimulating Hormone continued

melatonin, temperature, 28:263
 norepinephrine, affective disorder, 28:263
 norepinephrine, circadian rhythms, 28:263
 norepinephrine, cortisol, 28:263
 norepinephrine, melatonin, 28:263
 norepinephrine, temperature, 28:263
 prolactin, alcoholism, 28:89
 prolactin, computed tomography, 28:89
 prolactin, growth hormone, 28:89
 prolactin, thyrotropin releasing hormone test, 28:89
 sleep deprivation, affective disorder, 29:231
 sleep deprivation, triiodothyronine, 29:231
 temperature, affective disorder, 28:263
 temperature, circadian rhythms, 28:263
 temperature, cortisol, 28:263
 temperature, melatonin, 28:263
 temperature, norepinephrine, 28:263
 thyrotropin releasing hormone test, alcoholism, 28:89
 thyrotropin releasing hormone test, computed tomography, 28:89
 thyrotropin releasing hormone test, growth hormone, 28:89
 thyrotropin releasing hormone test, prolactin, 28:89
 triiodothyronine, affective disorder, 29:231
 triiodothyronine, sleep deprivation, 29:231

Thyrotropin releasing hormone

alcoholism, computed tomography, 28:89
 alcoholism, growth hormone, 28:89
 alcoholism, prolactin, 28:89
 alcoholism, thyroid stimulating hormone, 28:89
 computed tomography, alcoholism, 28:89
 computed tomography, growth hormone, 28:89
 computed tomography, prolactin, 28:89
 computed tomography, thyroid stimulating hormone, 28:89
 growth hormone, alcoholism, 28:89
 growth hormone, computed tomography, 28:89
 growth hormone, prolactin, 28:89
 growth hormone, thyroid stimulating hormone, 28:89
 metoclopramide, prolactin, 29:161
 metoclopramide, sleep, 29:161
 metoclopramide, tryptophan, 29:161
 metoclopramide, weight loss, 29:161
 prolactin, alcoholism, 28:89

Thyrotropin releasing hormone continued

prolactin, computed tomography, 28:89
 prolactin, growth hormone, 28:89
 prolactin, metoclopramide, 29:161
 prolactin, sleep, 29:161
 prolactin, thyroid stimulating hormone, 28:89
 prolactin, tryptophan, 29:161
 prolactin, weight loss, 29:161
 sleep, metoclopramide, 29:161
 sleep, prolactin, 29:161
 sleep, tryptophan, 29:161
 sleep, weight loss, 29:161
 thyroid stimulating hormone, alcoholism, 28:89
 thyroid stimulating hormone, computed tomography, 28:89
 thyroid stimulating hormone, growth hormone, 28:89
 thyroid stimulating hormone, prolactin, 28:89
 tryptophan, metoclopramide, 29:161
 tryptophan, prolactin, 29:161
 tryptophan, sleep, 29:161
 tryptophan, weight loss, 29:161
 weight loss, metoclopramide, 29:161
 weight loss, prolactin, 29:161
 weight loss, sleep, 29:161
 weight loss, tryptophan, 29:161

Tribulin

anxiety, depressed mood, 30:95
 anxiety, headache, 30:95
 anxiety, migraine, 30:95
 anxiety, monoamine oxidase, 30:95
 depressed mood, anxiety, 30:95
 depressed mood, headache, 30:95
 depressed mood, migraine, 30:95
 depressed mood, monoamine oxidase, 30:95
 headache, anxiety, 30:95
 headache, depressed mood, 30:95
 headache, monoamine oxidase, 30:95
 migraine, anxiety, 30:95
 migraine, depressed mood, 30:95
 migraine, monoamine oxidase, 30:95
 monoamine oxidase, anxiety, 30:95
 monoamine oxidase, depressed mood, 30:95
 monoamine oxidase, headache, 30:95
 monoamine oxidase, migraine, 30:95
 monoamine oxidase, platelet, 30:95

Triiodothyronine

affective disorder, sleep deprivation, 29:231

Triiodothyronine continued

- affective disorder, thyroid stimulating hormone, 29:231
- antidepressants, food intake, 27:149
- antidepressants, learned helplessness, 27:149
- antidepressants, rats, 27:149
- beta-hydroxybutyric acid, computed tomography, 27:39
- beta-hydroxybutyric acid, cortisol, 27:39
- beta-hydroxybutyric acid, eating disorders, 27:39
- beta-hydroxybutyric acid, ventricle-brain ratio, 27:39
- body size, mitral valve prolapse, 28:161
- body size, panic disorder, 28:161
- computed tomography, beta-hydroxybutyric acid, 27:39
- computed tomography, cortisol, 27:39
- computed tomography, eating disorders, 27:39
- computed tomography, ventricle-brain ratio, 27:39
- cortisol, beta-hydroxybutyric acid, 27:39
- cortisol, computed tomography, 27:39
- cortisol, eating disorders, 27:39
- cortisol, ventricle-brain ratio, 27:39
- eating disorders, beta-hydroxybutyric acid, 27:39
- eating disorders, computed tomography, 27:39
- eating disorders, cortisol, 27:39
- eating disorders, ventricle-brain ratio, 27:39
- food intake, antidepressants, 27:149
- food intake, learned helplessness, 27:149
- food intake, rats, 27:149
- learned helplessness, antidepressants, 27:149
- learned helplessness, food intake, 27:149
- learned helplessness, rats, 27:149
- mitral valve prolapse, body size, 28:161
- mitral valve prolapse, panic disorder, 28:161
- panic disorder, body size, 28:161
- panic disorder, mitral valve prolapse, 28:161
- rats, antidepressants, 27:149
- rats, food intake, 27:149
- rats, learned helplessness, 27:149
- sleep deprivation, affective disorder, 29:231
- sleep deprivation, thyroid stimulating hormone, 29:231

Triiodothyronine continued

- thyroid stimulating hormone, affective disorder, 29:231
- thyroid stimulating hormone, sleep deprivation, 29:231
- ventricle-brain ratio, beta-hydroxybutyric acid, 27:39
- ventricle-brain ratio, computed tomography, 27:39
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, eating disorders, 27:39

Tryptophan

- metoclopramide, prolactin, 29:161
- metoclopramide, sleep, 29:161
- metoclopramide, thyrotropin releasing hormone, 29:161
- metoclopramide, weight loss, 29:161
- prolactin, metoclopramide, 29:161
- prolactin, sleep, 29:161
- prolactin, thyrotropin releasing hormone, 29:161
- prolactin, weight loss, 29:161
- sleep, metoclopramide, 29:161
- sleep, prolactin, 29:161
- sleep, thyrotropin releasing hormone, 29:161
- sleep, weight loss, 29:161
- thyrotropin releasing hormone, metoclopramide, 29:161
- thyrotropin releasing hormone, prolactin, 29:161
- thyrotropin releasing hormone, sleep, 29:161
- thyrotropin releasing hormone, weight loss, 29:161
- weight loss, metoclopramide, 29:161
- weight loss, prolactin, 29:161
- weight loss, sleep, 29:161
- weight loss, thyrotropin releasing hormone, 29:161

Type A and B personality

- blood pressure, eating disorders, 30:223
- blood pressure, stressors, 30:223
- eating disorders, blood pressure, 30:223
- eating disorders, heart rate, 30:223
- eating disorders, stressors, 30:223
- heart rate, eating disorders, 30:223
- heart rate, stressors, 30:223
- stressors, eating disorders, 30:223

Ventricle-brain ratio

- affective disorders, computed tomography, 29:271
- affective disorders, symptomatology, 29:271

Ventricle-brain ratio continued

attention, computed tomography, 29:267
 attention, laterality, 29:267
 attention, schizophrenia, 29:267
 beta-hydroxybutyric acid, computed tomography, 27:39
 beta-hydroxybutyric acid, cortisol, 27:39
 beta-hydroxybutyric acid, eating disorders, 27:39
 beta-hydroxybutyric acid, triiodothyronine, 27:39
 computed tomography, affective disorders, 29:271
 computed tomography, attention, 29:267
 computed tomography, beta-hydroxybutyric acid, 27:39
 computed tomography, cortisol, 27:39
 computed tomography, eating disorders, 27:39
 computed tomography, laterality, 29:267
 computed tomography, magnetic resonance imaging, 29:265
 computed tomography, schizophrenia, 29:257, 29:265, 29:267
 computed tomography, symptomatology, 29:271
 computed tomography, triiodothyronine, 27:39
 cortisol, beta-hydroxybutyric acid, 27:39
 cortisol, computed tomography, 27:39
 cortisol, eating disorders, 27:39
 cortisol, triiodothyronine, 27:39
 eating disorders, beta-hydroxybutyric acid, 27:39
 eating disorders, computed tomography, 27:39
 eating disorders, cortisol, 27:39
 eating disorders, triiodothyronine, 27:39
 laterality, attention, 29:267
 laterality, computed tomography, 29:267
 laterality, schizophrenia, 29:267
 magnetic resonance imaging, computed tomography, 29:265
 magnetic resonance imaging, schizophrenia, 29:265
 schizophrenia, attention, 29:267
 schizophrenia, computed tomography, 29:257, 29:265, 29:267
 schizophrenia, laterality, 29:267
 schizophrenia, magnetic resonance imaging, 29:265
 symptomatology, affective disorder, 29:271
 symptomatology, computed tomography, 29:271

Ventricle-brain ratio continued

triiodothyronine, beta-hydroxybutyric acid, 27:39
 triiodothyronine, computed tomography, 27:39
 triiodothyronine, cortisol, 27:39
 triiodothyronine, eating disorders, 27:39

Violence

risk factors, suicide, 28:215
 suicide, risk factors, 28:215
 Visual analogue scale
 affective disorder, circadian rhythms, 27:89
 affective disorder, global vigor and affect, 27:89
 circadian rhythms, affective disorder, 27:89
 circadian rhythms, global vigor and affect, 27:89
 global vigor and affect, affective disorder, 27:89
 global vigor and affect, circadian rhythms, 27:89

Wisconsin Card Sort Test

computed tomography, electroencephalogram, 29:137
 computed tomography, frontal lobe, 29:137
 computed tomography, schizophrenia, 29:137
 electroencephalogram, frontal lobe, 29:137
 electroencephalogram, schizophrenia, 29:137
 frontal lobe, computed tomography, 29:137
 frontal lobe, electroencephalogram, 29:137
 frontal lobe, schizophrenia, 29:137
 schizophrenia, frontal lobe, 29:137

Weight loss

metoclopramide, prolactin, 29:161
 metoclopramide, sleep, 29:161
 metoclopramide, thyrotropin releasing hormone, 29:161
 metoclopramide, tryptophan, 29:161
 prolactin, sleep, 29:161
 prolactin, thyrotropin releasing hormone, 29:161
 prolactin, tryptophan, 29:161
 sleep, metoclopramide, 29:161
 sleep, prolactin, 29:161
 sleep, thyrotropin releasing hormone, 29:161
 sleep, tryptophan, 29:161
 thyrotropin releasing hormone, metoclopramide, 29:161
 thyrotropin releasing hormone, prolactin, 29:161

Weight loss continued

- thyrotropin releasing hormone, sleep, 29:161
- thyrotropin releasing hormone, tryptophan, 29:161
- tryptophan, prolactin, 29:161
- tryptophan, sleep, 29:161
- tryptophan, thyrotropin releasing hormone, 29:161

Yohimbine

- blood pressure, cortisol, 27:173
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, heart rate, 27:173
- blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173
- blood pressure, norepinephrine, 27:173
- cortisol, blood pressure, 27:173
- cortisol, generalized anxiety disorder, 27:173
- cortisol, heart rate, 27:173
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:173
- cortisol, norepinephrine, 27:173
- generalized anxiety disorder, blood pressure, 27:173
- generalized anxiety disorder, cortisol, 27:173

Yohimbine continued

- generalized anxiety disorder, heart rate, 27:173
- generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173
- generalized anxiety disorder, norepinephrine, 27:173
- heart rate, cortisol, 27:173
- heart rate, generalized anxiety disorder, 27:173
- heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173
- heart rate, norepinephrine, 27:173
- 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:173
- 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173
- 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:173
- norepinephrine, generalized anxiety disorder, 27:173
- norepinephrine, heart rate, 27:173
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:173

